data_1q9p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1q9p _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.43 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER . . . . . 0 CA--C 1.528 0.113 0 CA-C-O 120.718 0.294 . . . . 0.0 110.469 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.43 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.409 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.4 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.613 ' O ' ' CD2' ' A' ' 53' ' ' PHE . 72.0 t80 . . . . . 0 N--CA 1.468 0.468 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.419 ' N ' ' CG2' ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.603 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.603 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 1.7 m120 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.401 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt . . . . . 0 C--O 1.232 0.154 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.591 ' N ' ' CD2' ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 35' ' ' GLU . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.678 ' H ' ' CD2' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.444 ' HG3' HH11 ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.523 HH11 ' HG2' ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.444 ' CG2' ' O ' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.594 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.558 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.538 ' HG2' HH11 ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.565 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.565 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt . . . . . 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.717 0.294 . . . . 0.0 110.819 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.489 ' HG1' ' H ' ' A' ' 82' ' ' VAL . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.489 ' H ' ' HG1' ' A' ' 80' ' ' THR . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.419 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.921 0.391 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD2' ' HZ3' ' A' ' 14' ' ' LYS . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.511 ' CD1' ' N ' ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.708 ' H ' HD21 ' A' ' 83' ' ' ASN . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.504 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.441 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.441 ' OD2' ' NZ ' ' A' ' 43' ' ' LYS . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 66' ' ' ILE . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 82' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.426 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.708 HD21 ' H ' ' A' ' 34' ' ' GLU . 9.6 m120 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.564 ' CD1' ' N ' ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.854 0.359 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 20' ' ' LYS . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.592 ' CD1' ' N ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.526 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.404 ' O ' ' OG1' ' A' ' 12' ' ' THR . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.442 ' OD1' ' C ' ' A' ' 29' ' ' ASP . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.433 ' H ' ' CD1' ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.45 ' CD1' ' N ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.648 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm . . . . . 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.462 0.13 0 CA-C-O 120.762 0.315 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.542 ' CD1' ' N ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.418 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 80' ' ' THR . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.43 ' H ' ' C ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt . . . . . 0 N--CA 1.458 -0.068 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.46 HG22 HD11 ' A' ' 15' ' ' ILE . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.693 ' H ' ' ND2' ' A' ' 83' ' ' ASN . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.644 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.642 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 . . . . . 0 C--O 1.231 0.105 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 45' ' ' LYS . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.435 HD11 HG23 ' A' ' 72' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.693 ' ND2' ' H ' ' A' ' 34' ' ' GLU . 4.8 m120 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.461 ' O ' ' CG2' ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.461 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.591 ' CD2' ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.735 0.302 . . . . 0.0 110.334 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.744 ' HZ2' HD22 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.712 ' HG1' ' H ' ' A' ' 86' ' ' GLY . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.58 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.58 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.424 HG22 HD11 ' A' ' 47' ' ' ILE . 34.8 mm . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' ARG . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.478 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.744 HD22 ' HZ2' ' A' ' 20' ' ' LYS . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.712 ' H ' ' HG1' ' A' ' 31' ' ' THR . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.508 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.572 ' H ' ' CG ' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.508 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.726 0.298 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.587 ' CG2' ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 37' ' ' SER . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.764 0.316 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.482 ' OH ' ' O ' ' A' ' 38' ' ' LEU . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.734 ' CG2' ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.734 ' H ' ' CG2' ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.429 ' CB ' HE22 ' A' ' 92' ' ' GLN . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.538 ' HG1' ' N ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.538 ' N ' ' HG1' ' A' ' 80' ' ' THR . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.577 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.587 ' H ' ' CG2' ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.477 ' CD2' ' N ' ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.505 ' N ' ' CG2' ' A' ' 91' ' ' THR . 1.6 tt0 . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.877 0.37 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.424 ' C ' ' H ' ' A' ' 17' ' ' GLY . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 15' ' ' ILE . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.6 pt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.736 0.303 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.435 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.641 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.426 ' CD1' ' N ' ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.413 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 37.3 tp . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.58 ' CD1' ' N ' ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.526 ' CG2' HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.604 ' HZ3' HH21 ' A' ' 57' ' ' ARG . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.604 HH21 ' HZ3' ' A' ' 55' ' ' LYS . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.433 ' OD2' ' NZ ' ' A' ' 43' ' ' LYS . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.515 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.438 ' O ' ' CG1' ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.406 HD12 ' H ' ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.459 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.459 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.513 ' O ' ' O ' ' A' ' 25' ' ' ASP . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.526 HH21 ' CG2' ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt . . . . . 0 C--O 1.232 0.151 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.639 ' NH2' ' NZ ' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.639 ' NZ ' ' NH2' ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.501 ' HZ3' ' NE2' ' A' ' 58' ' ' GLN . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.501 ' NE2' ' HZ3' ' A' ' 45' ' ' LYS . 48.2 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.461 HD11 HG21 ' A' ' 63' ' ' ILE . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' CD1' ' H ' ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.426 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.886 0.374 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.489 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.487 ' HZ3' ' ND2' ' A' ' 83' ' ' ASN . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.415 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.552 ' HG1' ' CD2' ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 C--O 1.231 0.116 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.5 HH11 ' HG2' ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.454 HD12 HG21 ' A' ' 62' ' ' ILE . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.487 ' ND2' ' HZ3' ' A' ' 20' ' ' LYS . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.552 ' CD2' ' HG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt . . . . . 0 C--O 1.232 0.138 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.628 ' N ' ' CD2' ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.557 ' HG1' ' H ' ' A' ' 86' ' ' GLY . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.438 ' O ' ' OG ' ' A' ' 37' ' ' SER . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 36' ' ' MET . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.451 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.3 pt . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.566 HE21 ' CG2' ' A' ' 74' ' ' THR . 60.7 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.566 ' CG2' HE21 ' A' ' 58' ' ' GLN . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.445 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 85' ' ' ILE . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.557 ' H ' ' HG1' ' A' ' 31' ' ' THR . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' N ' ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? . . . . . 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 N--CA 1.461 0.1 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.406 ' C ' ' H ' ' A' ' 17' ' ' GLY . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 15' ' ' ILE . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.406 ' H ' ' HG3' ' A' ' 20' ' ' LYS . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.6 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.627 HH11 ' NE2' ' A' ' 61' ' ' GLN . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 8.9 t80 . . . . . 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.556 ' HG2' HH11 ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.5 ' CG ' ' HG1' ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.627 ' NE2' HH11 ' A' ' 41' ' ' ARG . 86.1 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.468 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.5 ' HG1' ' CG ' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.444 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . 0.609 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.609 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.914 0.388 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.581 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.669 ' C ' ' H ' ' A' ' 26' ' ' THR . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.669 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.494 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.428 HG22 HD11 ' A' ' 33' ' ' ILE . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.664 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 . . . . . 0 CA--C 1.521 -0.167 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.4 HE21 HG23 ' A' ' 74' ' ' THR . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.661 ' H ' ' CD1' ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.726 ' CG2' ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.726 ' H ' ' CG2' ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.4 HG23 HE21 ' A' ' 58' ' ' GLN . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.586 ' CD1' ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.494 ' O ' ' OG1' ' A' ' 31' ' ' THR . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.488 ' O ' ' OG1' ' A' ' 91' ' ' THR . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.488 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.55 ' CD1' ' N ' ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.571 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 10.9 tp . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.688 0.28 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.409 ' O ' ' N ' ' A' ' 69' ' ' HIS . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.429 HD12 HG22 ' A' ' 72' ' ' ILE . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.454 ' O ' ' OG1' ' A' ' 91' ' ' THR . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.869 0.366 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.604 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.483 ' CG2' ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 84' ' ' ILE . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.67 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.67 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.741 0.305 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.472 ' O ' ' CG2' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.454 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 32' ' ' VAL . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.483 ' H ' ' CG2' ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.655 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.58 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.441 ' CD ' ' N ' ' A' ' 38' ' ' LEU . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 C--O 1.231 0.08 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.433 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.41 HG22 HD12 ' A' ' 72' ' ' ILE . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.443 ' CD1' ' N ' ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' A' ' 81' ' ' PRO . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 120.894 0.378 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.442 HD13 HG21 ' A' ' 13' ' ' ILE . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.57 ' NZ ' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.57 ' CG2' ' NZ ' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.476 ' H ' HD21 ' A' ' 83' ' ' ASN . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.438 ' CE ' ' HZ3' ' A' ' 55' ' ' LYS . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt . . . . . 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . 0.624 ' O ' ' CG ' ' A' ' 53' ' ' PHE . 3.5 t80 . . . . . 0 C--O 1.232 0.182 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.438 ' HZ3' ' CE ' ' A' ' 46' ' ' MET . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.402 HG21 HD12 ' A' ' 62' ' ' ILE . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.471 ' HG1' ' H ' ' A' ' 82' ' ' VAL . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.471 ' H ' ' HG1' ' A' ' 80' ' ' THR . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.476 HD21 ' H ' ' A' ' 34' ' ' GLU . 3.2 m120 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.4 ' CD2' ' C ' ' A' ' 90' ' ' LEU . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 . . . . . 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.827 0.346 . . . . 0.0 110.248 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.588 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.477 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ARG . . . . . 0.473 HH11 ' HG2' ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 56' ' ' VAL . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.721 0.296 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' O ' ' A' ' 45' ' ' LYS . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.522 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.588 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.445 HD13 ' H ' ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 57' ' ' ARG . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.477 ' O ' ' OG1' ' A' ' 31' ' ' THR . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.5 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 109.687 -0.928 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -60.0 -31.88 70.34 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.405 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 92.1 mt -51.73 -39.54 24.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.113 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.477 ' O ' ' O ' ' A' ' 1' ' ' PRO . 52.6 m -120.77 135.78 55.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.087 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.479 ' N ' ' CD2' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -95.27 126.69 40.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.646 -179.713 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.518 ' O ' ' O ' ' A' ' 7' ' ' LYS . 99.3 m95 -57.98 -38.95 77.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.322 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' O ' ' O ' ' A' ' 6' ' ' TRP . 24.1 tttp 55.87 140.63 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.845 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.697 ' H ' ' CD ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -59.25 153.98 44.2 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.212 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -42.36 151.47 0.21 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.398 2.065 . . . . 0.0 112.32 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER -59.82 -166.54 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.469 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.43 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.409 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.4 tt -126.13 133.6 68.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -132.66 -103.09 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.66 -126.42 34.97 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 70.3 mt -117.73 123.63 71.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.863 0.363 . . . . 0.0 110.279 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.69 20.45 73.96 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -136.82 159.3 24.52 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 -179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.613 ' O ' ' CD2' ' A' ' 53' ' ' PHE . 72.0 t80 168.26 54.15 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.875 0.397 . . . . 0.0 110.16 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.419 ' N ' ' CG2' ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.603 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.603 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 1.7 m120 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.401 ' N ' ' CD1' ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 55.3 tt0 -58.5 -36.1 73.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 26.7 mt -65.7 -31.03 51.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.377 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.4 -167.29 42.86 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.476 179.992 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.919 0 N-CA-C 109.53 -0.988 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.4 mt-30 -118.71 151.36 38.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.532 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -58.93 -24.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.119 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.9 t -132.75 156.1 47.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.365 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.84 155.09 20.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.685 -179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -58.17 151.11 19.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.361 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.9 mttm 62.67 46.4 5.38 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.518 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.485 ' CB ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -42.03 -63.62 0.84 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.033 -179.929 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 12.3 Cg_endo -57.3 144.82 90.05 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.488 2.125 . . . . 0.0 112.565 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt -84.79 172.23 11.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.157 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.591 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 35' ' ' GLU . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.678 ' H ' ' CD2' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.444 HH11 ' HG3' ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt -123.12 130.18 74.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.92 -105.74 1.8 Allowed Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.3 -109.93 2.91 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.2 tt -56.74 -23.93 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.784 0.326 . . . . 0.0 110.471 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 126.12 24.3 1.49 Allowed Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -92.1 51.63 2.82 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 -54.74 91.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.523 ' HG2' HH11 ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.444 ' O ' ' CG2' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.6 ' C ' ' H ' ' A' ' 94' ' ' GLY . 4.2 tp60 -86.56 141.53 28.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 64.6 mt 61.66 -39.5 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 O-C-N 123.209 0.318 . . . . 0.0 111.284 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.6 ' H ' ' C ' ' A' ' 92' ' ' GLN . . . 95.15 6.46 60.15 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.534 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.555 179.915 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo . . . . . 0 N--CA 1.481 0.744 0 N-CA-C 109.802 -0.884 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -58.64 -37.27 75.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.673 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 67.9 mt -118.84 134.14 63.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.759 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.3 m -76.32 137.18 39.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.031 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -99.36 141.51 32.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.954 0.407 . . . . 0.0 111.114 -179.359 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -101.5 144.75 29.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.032 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 42.3 mttt -57.19 -62.61 1.64 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.99 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.64 149.98 40.21 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.578 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.81 148.35 70.91 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.447 2.098 . . . . 0.0 111.929 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt -89.72 147.15 24.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.594 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.558 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.538 ' HG2' HH11 ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.565 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.565 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt -131.58 152.82 37.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.18 -172.15 52.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 156.33 -47.68 0.48 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.8 mt -56.59 -41.13 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.704 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.2 -78.97 0.74 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.07 129.92 6.48 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -109.75 132.66 53.94 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.819 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.489 ' HG1' ' H ' ' A' ' 82' ' ' VAL . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.489 ' H ' ' HG1' ' A' ' 80' ' ' THR . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.419 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -62.99 -39.17 93.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 25.9 mt -70.1 -28.77 37.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.594 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 93.75 5.32 63.02 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo . . . . . 0 N--CA 1.484 0.915 0 N-CA-C 109.579 -0.97 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -112.34 152.35 28.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.166 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 74.6 mt -114.59 129.81 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.935 0.398 . . . . 0.0 111.06 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -129.35 166.8 18.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.157 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.666 ' CD2' ' H ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -74.2 129.76 38.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.78 0.324 . . . . 0.0 110.362 179.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -95.53 118.43 32.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.689 -179.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -102.95 -73.12 0.67 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.642 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.647 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -44.54 -52.47 17.52 Favored Pre-proline 0 N--CA 1.463 0.188 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.744 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.503 ' O ' ' O ' ' A' ' 8' ' ' ARG . 86.1 Cg_exo -44.83 -178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.543 2.162 . . . . 0.0 112.37 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp -71.54 134.16 46.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.861 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.489 ' CD2' ' HZ3' ' A' ' 14' ' ' LYS . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.511 ' N ' ' CD1' ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.708 ' H ' HD21 ' A' ' 83' ' ' ASN . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.504 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.441 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt -113.66 119.86 62.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.01 -170.74 19.3 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 67.97 -172.88 32.44 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.59 -28.05 41.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.971 0.415 . . . . 0.0 110.175 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.39 -36.91 92.25 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -171.57 -174.52 39.26 Favored Glycine 0 CA--C 1.526 0.75 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.45 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 -172.68 34.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.441 ' OD2' ' NZ ' ' A' ' 43' ' ' LYS . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 66' ' ' ILE . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 82' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.426 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.708 HD21 ' H ' ' A' ' 34' ' ' GLU . 9.6 m120 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.564 ' N ' ' CD1' ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.2 tt0 -56.23 -38.11 70.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 35.6 mt -70.59 -23.88 24.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.434 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.84 3.41 58.16 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.531 179.915 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 N--CA 1.485 0.985 0 N-CA-C 109.498 -1.001 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -102.35 140.84 36.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.452 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 30.8 mm -113.06 132.53 61.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.438 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.4 p -63.62 -36.97 85.56 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.861 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.9 116.21 28.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.936 0.398 . . . . 0.0 110.83 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 71.3 t-105 -118.92 142.27 47.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.07 179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.57 115.25 10.53 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.331 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.648 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -88.34 -39.51 0.47 Allowed Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.958 179.865 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.648 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 38.5 Cg_exo -55.22 146.42 60.4 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 C-N-CA 122.533 2.155 . . . . 0.0 112.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mp -88.1 153.51 21.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.596 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 20' ' ' LYS . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.592 ' CD1' ' N ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.526 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.404 ' O ' ' OG1' ' A' ' 12' ' ' THR . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.442 ' OD1' ' C ' ' A' ' 29' ' ' ASP . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.433 ' H ' ' CD1' ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.45 ' CD1' ' N ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.648 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm -89.44 150.83 3.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.81 27.65 0.65 Allowed Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -66.57 -45.56 83.97 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.591 -0.603 . . . . 0.0 111.591 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.428 HD12 HG23 ' A' ' 50' ' ' ILE . 88.6 mt -61.16 -41.37 89.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.66 0.267 . . . . 0.0 111.365 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 162.42 -68.23 0.23 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.644 -0.983 . . . . 0.0 110.644 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -77.4 168.36 54.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -108.39 124.08 49.83 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.064 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.542 ' CD1' ' N ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.418 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 80' ' ' THR . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.43 ' H ' ' C ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -61.28 -45.54 94.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 14.0 tt -66.17 -28.76 44.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.955 -0.298 . . . . 0.0 110.866 -179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.415 ' O ' ' OXT' ' A' ' 95' ' ' ALA . . . -84.79 -176.03 50.82 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.415 ' OXT' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.548 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.417 ' H2 ' ' H ' ' A' ' 2' ' ' GLN . 6.6 Cg_exo . . . . . 0 N--CA 1.483 0.889 0 N-CA-C 109.488 -1.005 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.417 ' H ' ' H2 ' ' A' ' 1' ' ' PRO . 55.0 tp60 -56.32 -35.86 68.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.83 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.8 pt -117.54 149.44 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 110.704 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.7 m -63.03 -40.17 96.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.564 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.574 ' CD2' ' H ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -80.09 -179.17 6.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.946 0.403 . . . . 0.0 111.022 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' TRP . 39.5 m0 -90.04 138.18 31.73 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.955 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -58.66 -40.02 82.29 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.135 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.77 133.75 48.46 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.692 -179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.36 159.43 46.76 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.422 2.081 . . . . 0.0 112.061 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt -79.98 149.96 30.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.109 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.46 HG22 HD11 ' A' ' 15' ' ' ILE . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.693 ' H ' ' ND2' ' A' ' 83' ' ' ASN . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.644 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.642 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt -130.12 158.27 42.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.27 176.83 27.84 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 92.3 -63.22 2.38 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 72.3 mt -117.47 130.77 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 110.681 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.32 7.45 72.85 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.02 138.47 0.13 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -48.37 105.19 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.238 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 45' ' ' LYS . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.435 HD11 HG23 ' A' ' 72' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.693 ' ND2' ' H ' ' A' ' 34' ' ' GLU . 4.8 m120 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.461 ' O ' ' CG2' ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.461 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -59.61 -40.25 86.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 73.0 mt -87.05 -34.09 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.668 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.68 -165.7 38.81 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.591 -179.929 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 109.549 -0.981 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -58.59 -35.01 71.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.411 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.443 HG22 HD13 ' A' ' 3' ' ' ILE . 85.5 mt -59.51 -35.56 59.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.282 179.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.0 m -73.37 136.48 44.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.468 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.59 164.63 11.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.581 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -65.59 116.32 6.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -113.96 146.0 40.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.622 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.65 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -70.33 170.92 8.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.063 179.609 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.49 145.32 22.32 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.319 2.012 . . . . 0.0 112.178 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.591 ' CD2' ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? -85.99 154.04 21.73 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.334 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.744 ' HZ2' HD22 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.712 ' HG1' ' H ' ' A' ' 86' ' ' GLY . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.58 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.58 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.424 HG22 HD11 ' A' ' 47' ' ' ILE . 34.8 mm -115.84 131.15 69.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.67 -47.78 0.26 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.19 -36.53 62.11 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.499 -0.381 . . . . 0.0 112.416 -178.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 69.4 mt -118.89 132.86 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.641 -0.423 . . . . 0.0 111.952 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 69.09 26.23 74.83 Favored Glycine 0 CA--C 1.525 0.665 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.887 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.55 -153.84 52.68 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -101.05 123.36 45.1 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.537 ' O ' ' CG2' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' A' ' 57' ' ' ARG . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.478 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.744 HD22 ' HZ2' ' A' ' 20' ' ' LYS . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.712 ' H ' ' HG1' ' A' ' 31' ' ' THR . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.508 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.572 ' H ' ' CG ' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.508 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -56.05 -39.42 71.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 75.4 mt -95.37 -75.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.525 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.71 -161.1 36.36 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.577 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo . . . . . 0 N--CA 1.485 0.971 0 N-CA-C 109.556 -0.978 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -58.91 -35.14 72.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 73.0 mt -117.17 138.12 48.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.459 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 27.3 m -107.85 136.01 48.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.575 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.77 149.09 35.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.345 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 93.9 m95 -61.09 143.4 55.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.433 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 16.7 ttmm -57.32 -40.92 78.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -91.22 112.41 53.8 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -78.29 -57.8 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.278 0 C-N-CA 122.012 1.808 . . . . 0.0 112.131 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp -90.46 133.01 35.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.482 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.587 ' CG2' ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.513 ' N ' ' OG ' ' A' ' 37' ' ' SER . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt -127.86 138.79 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.28 18.73 2.87 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.818 -0.705 . . . . 0.0 111.512 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -59.31 -41.32 96.82 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 79.6 mt -63.53 -40.14 87.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.706 0.289 . . . . 0.0 110.985 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.68 -63.34 0.35 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.44 53.97 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.59 123.24 48.63 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.579 -0.449 . . . . 0.0 110.851 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 52.4 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.482 ' OH ' ' O ' ' A' ' 38' ' ' LEU . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.734 ' CG2' ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.734 ' H ' ' CG2' ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.429 ' CB ' HE22 ' A' ' 92' ' ' GLN . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.538 ' HG1' ' N ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.538 ' N ' ' HG1' ' A' ' 80' ' ' THR . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.577 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.587 ' H ' ' CG2' ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.477 ' CD2' ' N ' ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.505 ' N ' ' CG2' ' A' ' 91' ' ' THR . 1.6 tt0 -63.78 -173.51 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.42 ' H ' ' HG2' ' A' ' 92' ' ' GLN . 78.9 mt 60.83 57.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.509 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -56.05 -33.78 61.24 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.555 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 109.674 -0.933 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -108.85 150.96 26.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.418 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.417 ' O ' ' C ' ' A' ' 4' ' ' THR . 28.7 pt -123.78 157.52 30.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.874 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.417 ' C ' ' O ' ' A' ' 3' ' ' ILE . 4.0 m 37.08 54.69 1.25 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.921 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -88.57 129.06 35.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.466 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -133.7 -52.52 0.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.5 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.5 ttmm -121.47 138.63 54.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.254 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -61.4 129.1 90.74 Favored Pre-proline 0 CA--C 1.534 0.337 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.039 -179.941 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.34 -22.53 25.11 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 122.015 1.81 . . . . 0.0 112.036 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp -90.54 126.98 36.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.377 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.424 ' C ' ' H ' ' A' ' 17' ' ' GLY . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 15' ' ' ILE . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.6 pt -122.38 -170.15 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 138.95 -41.86 1.31 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.0 -73.5 0.13 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 71.3 mt -112.34 141.52 27.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.696 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.58 21.91 45.73 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.479 -1.049 . . . . 0.0 110.479 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.22 -171.2 38.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -109.94 135.78 50.25 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.719 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.435 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.641 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.426 ' CD1' ' N ' ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.413 ' CG2' ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -53.82 -39.48 65.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 21.0 mm -85.11 -31.46 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.02 179.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.78 -167.21 38.21 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.568 -179.939 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo . . . . . 0 N--CA 1.482 0.819 0 N-CA-C 109.538 -0.985 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -114.08 149.59 35.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.808 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.29 153.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.622 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.2 p -110.02 -5.54 15.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.062 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -68.16 -30.52 69.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.843 0.354 . . . . 0.0 110.416 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -55.17 -26.69 40.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.712 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -62.29 -37.4 85.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.731 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.61 ' O ' ' N ' ' A' ' 10' ' ' LEU . 6.0 mpt_? -46.45 -61.66 2.48 Favored Pre-proline 0 N--CA 1.465 0.281 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.254 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.434 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 50.0 Cg_exo -37.58 -17.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.891 2.394 . . . . 0.0 112.764 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 8' ' ' ARG . 37.3 tp -84.25 130.7 34.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.58 ' CD1' ' N ' ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.526 ' CG2' HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' CG2' ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt -129.89 142.46 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.55 105.78 2.86 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.35 172.84 35.14 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.3 mm -60.58 -47.39 93.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.378 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.07 -36.28 92.69 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 165.04 -125.89 1.42 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -110.57 130.12 55.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.604 ' HZ3' HH21 ' A' ' 57' ' ' ARG . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.604 HH21 ' HZ3' ' A' ' 55' ' ' LYS . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.433 ' OD2' ' NZ ' ' A' ' 43' ' ' LYS . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.515 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.407 ' CG ' ' O ' ' A' ' 93' ' ' ILE . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.438 ' O ' ' CG1' ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.406 HD12 ' H ' ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.459 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.459 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.513 ' O ' ' O ' ' A' ' 25' ' ' ASP . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.526 HH21 ' CG2' ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -96.54 131.62 42.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.407 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 18.7 tt -170.66 -3.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.386 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.77 -165.78 40.56 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.636 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.489 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.6 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 109.535 -0.987 . . . . 0.0 109.535 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -59.89 -37.64 79.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.406 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.82 -32.38 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.173 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 1' ' ' PRO . 33.1 m -108.64 138.59 44.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.959 0.409 . . . . 0.0 110.978 -179.356 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 pp -95.65 1.14 53.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.809 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -102.85 132.66 48.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.013 0.435 . . . . 0.0 110.928 -179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -140.84 133.47 28.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.903 179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.1 mtp180 -62.56 148.28 90.94 Favored Pre-proline 0 C--N 1.328 -0.332 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.95 146.09 81.68 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.44 2.093 . . . . 0.0 112.243 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -87.14 149.09 24.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.069 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.639 ' NH2' ' NZ ' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.639 ' NZ ' ' NH2' ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.501 ' HZ3' ' NE2' ' A' ' 58' ' ' GLN . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt -116.52 123.97 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.15 -154.07 8.43 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.04 -124.5 11.45 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 65.2 mt -115.54 130.05 70.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.821 0.343 . . . . 0.0 110.44 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.54 0.52 62.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.36 161.47 32.14 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.499 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 177.67 37.71 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.501 ' NE2' ' HZ3' ' A' ' 45' ' ' LYS . 48.2 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.461 HD11 HG21 ' A' ' 63' ' ' ILE . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' CD1' ' H ' ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.426 ' CG1' ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.426 ' N ' ' CG1' ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -64.57 -49.39 71.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.9 tt -68.22 -27.73 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.852 0.358 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.2 -164.14 38.24 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.569 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.484 0.931 0 N-CA-C 109.623 -0.953 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -110.53 145.89 36.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.382 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.5 pt -70.79 -11.65 15.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.0 p -101.1 24.7 9.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.561 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 pp -52.27 -36.18 52.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.773 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 5.3 m-90 -54.84 -36.93 65.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.859 0.361 . . . . 0.0 110.364 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -103.87 145.74 29.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.494 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -89.85 115.8 64.8 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.903 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -46.52 141.59 10.63 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.795 1.663 . . . . 0.0 112.024 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -89.67 135.21 33.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.218 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.489 ' N ' ' CD1' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.487 ' HZ3' ' ND2' ' A' ' 83' ' ' ASN . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.415 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.552 ' HG1' ' CD2' ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt -133.19 148.09 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 148.63 18.19 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.16 -81.2 0.11 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -117.04 134.85 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.821 0.343 . . . . 0.0 110.221 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.01 31.91 46.46 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.64 -129.98 25.34 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -109.99 132.73 53.89 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.5 HH11 ' HG2' ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.454 HD12 HG21 ' A' ' 62' ' ' ILE . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.487 ' ND2' ' HZ3' ' A' ' 20' ' ' LYS . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.552 ' CD2' ' HG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 -104.73 118.97 37.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 17.7 tt -173.55 -23.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.774 0.321 . . . . 0.0 110.296 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -56.17 -34.75 63.01 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.572 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 N--CA 1.481 0.763 0 N-CA-C 109.593 -0.964 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -86.65 148.63 25.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.486 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.0 tt -121.53 136.98 56.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.749 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.4 p -89.82 162.16 15.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.575 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.653 ' CD1' ' H ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -95.51 160.73 14.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.809 179.791 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 30.3 p90 -108.62 133.85 52.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.64 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -138.08 139.51 39.55 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.331 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -54.75 145.88 38.97 Favored Pre-proline 0 C--N 1.328 -0.369 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.216 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.94 145.1 78.96 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.321 2.014 . . . . 0.0 112.13 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt -88.42 146.12 25.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.163 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.628 ' N ' ' CD2' ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.557 ' HG1' ' H ' ' A' ' 86' ' ' GLY . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.438 ' O ' ' OG ' ' A' ' 37' ' ' SER . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 36' ' ' MET . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.451 ' O ' ' OH ' ' A' ' 59' ' ' TYR . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.3 pt -154.96 142.25 12.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.72 -79.72 0.03 OUTLIER Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 103.64 -34.47 5.75 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.159 -0.776 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 56.2 mt -117.81 126.51 74.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 71.95 16.3 76.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.81 156.06 32.48 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -54.58 140.9 33.46 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.566 HE21 ' CG2' ' A' ' 74' ' ' THR . 60.7 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.566 ' CG2' HE21 ' A' ' 58' ' ' GLN . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.445 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.445 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.417 HG22 HD13 ' A' ' 85' ' ' ILE . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.557 ' H ' ' HG1' ' A' ' 31' ' ' THR . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.582 ' CD2' ' N ' ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? -57.52 -43.58 84.41 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 9.9 tt -66.79 -25.58 35.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.81 -179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.07 -166.72 39.07 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.62 179.977 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.431 -1.027 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 90.8 mt-30 -114.13 149.57 35.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.33 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.87 -24.59 26.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.583 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.1 m -101.59 134.1 45.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.444 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.14 -24.57 13.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.76 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -57.09 -39.6 75.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.883 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 32.5 tttp -60.15 -38.1 82.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.613 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.7 mmt180 -81.78 122.56 80.36 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.634 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -77.61 172.53 15.64 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 C-N-CA 122.24 1.96 . . . . 0.0 112.297 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -72.88 158.93 34.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.406 ' C ' ' H ' ' A' ' 17' ' ' GLY . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 15' ' ' ILE . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.406 ' H ' ' HG3' ' A' ' 20' ' ' LYS . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.6 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.627 HH11 ' NE2' ' A' ' 61' ' ' GLN . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt -126.75 137.12 58.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.42 170.47 22.65 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.41 -125.67 2.12 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.5 mt -113.15 120.25 62.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.31 17.21 78.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.556 ' O ' ' CB ' ' A' ' 53' ' ' PHE . . . -116.3 -146.9 8.72 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.556 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 8.9 t80 92.52 56.94 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.556 ' HG2' HH11 ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.5 ' CG ' ' HG1' ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.627 ' NE2' HH11 ' A' ' 41' ' ' ARG . 86.1 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.468 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.5 ' HG1' ' CG ' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG1' ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.444 ' H ' ' CG1' ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.576 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . 0.609 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.609 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -123.47 96.24 4.9 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 20.3 tt -63.81 -21.1 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.41 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 101.31 5.11 52.86 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.507 179.85 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo . . . . . 0 N--CA 1.484 0.922 0 N-CA-C 109.583 -0.968 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -55.67 -36.47 67.13 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.309 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.0 tt -59.67 -23.82 27.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.521 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 67.1 m -105.62 132.91 51.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.714 -179.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -97.41 -12.27 22.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.716 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 6' ' ' TRP . 35.4 m0 -58.4 -32.07 68.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.481 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.1 tttm 62.18 -99.46 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.337 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 19.6 ptt180 -75.6 137.0 70.71 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.209 179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.28 -20.98 36.37 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.247 1.965 . . . . 0.0 112.43 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt -90.42 144.13 26.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.581 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.669 ' C ' ' H ' ' A' ' 26' ' ' THR . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.669 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.537 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.494 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.428 HG22 HD11 ' A' ' 33' ' ' ILE . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.664 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.27 175.4 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.7 -12.96 29.97 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -178.62 -175.59 45.82 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.77 -29.99 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.947 0.404 . . . . 0.0 110.195 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.68 -7.84 25.26 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 78.71 130.94 0.66 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -107.56 7.7 28.87 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.4 HE21 HG23 ' A' ' 74' ' ' THR . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.661 ' H ' ' CD1' ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.726 ' CG2' ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.726 ' H ' ' CG2' ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.4 HG23 HE21 ' A' ' 58' ' ' GLN . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.586 ' CD1' ' H ' ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.494 ' O ' ' OG1' ' A' ' 31' ' ' THR . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.488 ' O ' ' OG1' ' A' ' 91' ' ' THR . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.488 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 -100.25 125.75 46.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.519 ' CG2' ' O ' ' A' ' 93' ' ' ILE . 20.3 tt -159.03 64.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.803 0.335 . . . . 0.0 110.601 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.98 21.04 61.89 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.52 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.484 0.957 0 N-CA-C 109.736 -0.909 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -56.94 -37.81 72.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -117.66 135.11 59.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.892 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 41.1 p -123.23 158.73 30.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.277 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -131.25 123.51 28.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.63 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -61.41 -39.43 90.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.511 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.2 mttp -128.25 147.52 50.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.759 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.8 mtt180 -71.48 146.4 91.54 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.175 179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.16 -35.81 50.62 Favored 'Trans proline' 0 N--CA 1.495 1.58 0 C-N-CA 122.437 2.091 . . . . 0.0 112.706 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt -90.74 143.06 27.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 -179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.55 ' N ' ' CD1' ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.571 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.571 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 10.9 tp -137.42 154.34 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.51 -33.11 3.07 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.38 -165.51 35.65 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 78.5 mt -59.75 -33.99 54.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.676 0.274 . . . . 0.0 110.894 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.66 -32.05 38.78 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.16 156.37 9.75 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.4 129.32 55.79 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.663 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.409 ' O ' ' N ' ' A' ' 69' ' ' HIS . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.429 HD12 HG22 ' A' ' 72' ' ' ILE . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.454 ' O ' ' OG1' ' A' ' 91' ' ' THR . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.454 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -94.44 122.91 37.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 18.8 tt -174.32 -10.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.036 0.446 . . . . 0.0 110.389 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.423 ' O ' ' CB ' ' A' ' 95' ' ' ALA . . . -115.82 -43.32 0.68 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.423 ' CB ' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.6 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . 0.462 ' O ' ' O ' ' A' ' 2' ' ' GLN . 14.3 Cg_exo . . . . . 0 N--CA 1.484 0.945 0 N-CA-C 109.491 -1.004 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.462 ' O ' ' O ' ' A' ' 1' ' ' PRO . 46.5 tt0 43.65 97.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.651 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -114.12 128.95 70.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.186 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.9 p -115.91 -4.3 12.08 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 120.816 -0.353 . . . . 0.0 111.563 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.401 HD12 ' H ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -133.15 108.85 9.07 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.745 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.2 m-90 -64.51 -40.36 95.49 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -99.59 141.21 32.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.654 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.82 112.9 54.74 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.631 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -49.86 -12.9 0.45 Allowed 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.098 1.865 . . . . 0.0 112.111 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp -87.09 135.46 33.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.422 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.604 ' CD2' ' N ' ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.483 ' CG2' ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 84' ' ' ILE . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.67 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.67 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt -140.71 163.77 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.69 -22.24 30.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 50.82 -128.58 29.61 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.541 ' C ' ' H ' ' A' ' 52' ' ' GLY . 18.9 tt -61.33 -27.84 42.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.758 0.313 . . . . 0.0 110.907 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.32 17.81 1.37 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.541 ' H ' ' C ' ' A' ' 50' ' ' ILE . . . 100.22 148.95 23.16 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.17 126.19 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.184 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.472 ' O ' ' CG2' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.454 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 32' ' ' VAL . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.483 ' H ' ' CG2' ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.655 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 -96.97 118.46 33.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 11.1 tp -171.22 -23.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 110.381 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.538 ' O ' ' CB ' ' A' ' 95' ' ' ALA . . . -55.0 -33.47 57.27 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.538 ' CB ' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.5 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo . . . . . 0 N--CA 1.484 0.921 0 N-CA-C 109.554 -0.979 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -119.32 164.23 15.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.092 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.6 mm -98.79 144.52 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.953 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 m -59.94 138.29 57.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.682 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.44 ' H ' ' CD2' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -79.55 149.97 31.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.856 -179.564 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -88.87 131.94 34.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.548 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -105.12 -28.03 11.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.029 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 1.2 ttt180 -50.02 -48.43 78.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.291 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 32.5 Cg_exo -55.65 -17.52 17.84 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.411 2.074 . . . . 0.0 112.053 -179.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp -89.9 128.12 36.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.562 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.58 ' N ' ' CD2' ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.441 ' CD ' ' N ' ' A' ' 38' ' ' LEU . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.468 HD11 ' H ' ' A' ' 48' ' ' GLY . 0.3 OUTLIER -136.02 150.2 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.468 ' H ' HD11 ' A' ' 47' ' ' ILE . . . 134.71 -10.96 4.58 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.91 -169.17 40.97 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.6 tt -56.54 -31.23 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.92 0.39 . . . . 0.0 110.027 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.0 -1.14 30.16 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.04 120.06 0.01 OUTLIER Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -96.74 4.63 51.69 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.433 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.41 HG22 HD12 ' A' ' 72' ' ' ILE . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.443 ' CD1' ' N ' ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.491 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' A' ' 81' ' ' PRO . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 -97.82 127.08 43.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.8 tt -159.25 6.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.971 0.415 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -83.1 179.1 52.94 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.635 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo . . . . . 0 N--CA 1.482 0.826 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -58.86 -36.91 75.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.538 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.81 -26.92 39.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.4 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.4 m -87.89 137.45 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.809 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.77 141.97 46.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.35 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m-90 -62.12 137.7 58.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.876 0.37 . . . . 0.0 110.411 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.8 mttp -61.0 -37.9 84.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.856 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.1 mmt180 -91.27 111.1 46.97 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -80.18 157.49 23.15 Favored 'Trans proline' 0 N--CA 1.489 1.252 0 C-N-CA 122.159 1.906 . . . . 0.0 111.787 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt -87.02 136.05 33.06 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.378 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.442 HD13 HG21 ' A' ' 13' ' ' ILE . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.57 ' NZ ' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.57 ' CG2' ' NZ ' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.476 ' H ' HD21 ' A' ' 83' ' ' ASN . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.438 ' CE ' ' HZ3' ' A' ' 55' ' ' LYS . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt -129.45 143.83 39.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.74 171.41 37.41 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . -151.63 -111.7 0.51 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 80.7 mt -57.86 -37.38 60.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.886 0.374 . . . . 0.0 110.196 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -71.04 1.3 Allowed Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -84.15 -177.07 51.33 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.455 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . 0.624 ' O ' ' CG ' ' A' ' 53' ' ' PHE . 3.5 t80 163.76 77.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.438 ' HZ3' ' CE ' ' A' ' 46' ' ' MET . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.402 HG21 HD12 ' A' ' 62' ' ' ILE . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.471 ' HG1' ' H ' ' A' ' 82' ' ' VAL . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.471 ' H ' ' HG1' ' A' ' 80' ' ' THR . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.476 HD21 ' H ' ' A' ' 34' ' ' GLU . 3.2 m120 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.4 ' CD2' ' C ' ' A' ' 90' ' ' LEU . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -55.57 -35.41 65.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 13.4 tt -57.49 -25.28 23.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.756 -179.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.5 -165.88 37.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.684 -179.916 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.003 0 N-CA-C 109.667 -0.936 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 51.27 60.73 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.59 -24.73 26.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.677 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.8 p -80.22 160.44 25.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.537 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.89 43.84 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.641 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -105.34 129.25 53.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.438 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 56.1 tttp -99.25 -72.89 0.64 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.748 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -89.98 149.73 42.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.678 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -43.53 95.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 122.114 1.876 . . . . 0.0 111.659 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.6 128.37 36.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.248 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.588 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.477 ' OG1' ' O ' ' A' ' 84' ' ' ILE . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ARG . . . . . 0.473 HH11 ' HG2' ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 56' ' ' VAL . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt -138.57 166.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -152.58 27.92 0.85 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 120.396 -0.907 . . . . 0.0 112.123 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.28 -41.66 93.08 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.224 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.0 mm -65.57 -40.87 89.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.866 0.365 . . . . 0.0 110.939 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 156.08 -64.02 0.32 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.81 175.2 55.1 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 178.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -110.03 127.05 54.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 117.278 0.539 . . . . 0.0 111.179 -179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' N ' ' O ' ' A' ' 45' ' ' LYS . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.522 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.588 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.445 HD13 ' H ' ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' A' ' 57' ' ' ARG . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.477 ' O ' ' OG1' ' A' ' 31' ' ' THR . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 9.8 mt -67.63 -35.77 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 110.517 179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.12 -35.05 82.39 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.685 -179.889 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.407 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER . . . . . 0 CA--C 1.528 0.113 0 CA-C-O 120.718 0.294 . . . . 0.0 110.469 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.407 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.694 HD11 HG23 ' A' ' 64' ' ' ILE . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.422 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.412 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.423 HG22 ' O ' ' A' ' 54' ' ' ILE . 17.4 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.613 ' CD2' ' O ' ' A' ' 53' ' ' PHE . 72.0 t80 . . . . . 0 N--CA 1.468 0.468 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 47' ' ' ILE . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.409 HG12 ' HD3' ' A' ' 79' ' ' PRO . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.559 ' OD1' HG23 ' A' ' 74' ' ' THR . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.482 ' N ' HG22 ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.694 HG23 HD11 ' A' ' 15' ' ' ILE . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.824 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 60' ' ' ASP . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.409 ' HD3' HG12 ' A' ' 56' ' ' VAL . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.74 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.74 ' H ' HG12 ' A' ' 82' ' ' VAL . 4.3 m-20 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.514 ' O ' HG23 ' A' ' 31' ' ' THR . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.613 ' N ' HD12 ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.824 ' NE2' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tt0 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt . . . . . 0 C--O 1.232 0.154 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD13 ' A' ' 13' ' ' ILE . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.866 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.481 HG12 ' CG2' ' A' ' 84' ' ' ILE . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.546 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.813 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.46 HH11 ' HG3' ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.561 ' HG2' HH11 ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 76' ' ' LEU . 17.8 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.476 HG23 ' OD1' ' A' ' 60' ' ' ASP . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 58' ' ' GLN . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.442 ' C ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.481 ' CG2' HG12 ' A' ' 32' ' ' VAL . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.442 HD12 ' CD1' ' A' ' 24' ' ' LEU . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.615 ' O ' HG23 ' A' ' 91' ' ' THR . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.615 HG23 ' O ' ' A' ' 87' ' ' ARG . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.404 HG11 HD11 ' A' ' 24' ' ' LEU . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.479 HG12 HG23 ' A' ' 64' ' ' ILE . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.872 ' N ' HD22 ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.531 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' CG2' ' A' ' 84' ' ' ILE . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.429 HD11 HG11 ' A' ' 75' ' ' VAL . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.578 ' HG2' HH11 ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.597 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt . . . . . 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.717 0.294 . . . . 0.0 110.819 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.615 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.479 HG23 HG12 ' A' ' 15' ' ' ILE . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.615 HG23 ' OD1' ' A' ' 60' ' ' ASP . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.449 HG21 HD11 ' A' ' 64' ' ' ILE . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.574 ' H ' HG12 ' A' ' 82' ' ' VAL . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.46 ' CG2' HG12 ' A' ' 32' ' ' VAL . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.921 0.391 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.726 HG12 HG23 ' A' ' 64' ' ' ILE . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.648 HG12 HG21 ' A' ' 80' ' ' THR . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.571 ' O ' ' SD ' ' A' ' 36' ' ' MET . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.476 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.688 ' HB3' HD12 ' A' ' 76' ' ' LEU . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 70' ' ' LYS . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.726 HG23 HG12 ' A' ' 15' ' ' ILE . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.485 ' HB3' HD11 ' A' ' 63' ' ' ILE . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.402 ' HA ' HE22 ' A' ' 92' ' ' GLN . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.688 HD12 ' HB3' ' A' ' 58' ' ' GLN . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG12 ' A' ' 32' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 39.4 m-20 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.402 HE22 ' HA ' ' A' ' 71' ' ' ALA . 62.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.854 0.359 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.868 ' H ' HD13 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.762 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.538 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.461 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.585 HG13 HG13 ' A' ' 77' ' ' VAL . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.829 ' H ' HD12 ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.829 HD12 ' H ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.66 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm . . . . . 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.462 0.13 0 CA-C-O 120.762 0.315 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.929 HD13 ' H ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.49 ' CE1' HD13 ' A' ' 38' ' ' LEU . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 63' ' ' ILE . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 75' ' ' VAL . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.455 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.813 HG21 HD11 ' A' ' 64' ' ' ILE . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.585 HG13 HG13 ' A' ' 33' ' ' ILE . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 34' ' ' GLU . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.538 HD11 ' OD2' ' A' ' 25' ' ' ASP . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.455 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 7.1 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt . . . . . 0 N--CA 1.458 -0.068 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.818 HD12 ' N ' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.579 HG23 ' CG ' ' A' ' 83' ' ' ASN . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.584 ' C ' ' H ' ' A' ' 36' ' ' MET . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.41 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.584 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.921 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 . . . . . 0 C--O 1.231 0.105 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.522 ' CG2' HD11 ' A' ' 76' ' ' LEU . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.624 ' HB3' HD12 ' A' ' 76' ' ' LEU . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.694 HG22 HG12 ' A' ' 72' ' ' ILE . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.56 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.694 HG12 HG22 ' A' ' 63' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 58' ' ' GLN . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 33' ' ' ILE . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.433 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.579 ' CG ' HG23 ' A' ' 33' ' ' ILE . 16.7 m-20 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.811 ' O ' HG23 ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.811 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.654 HD22 ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.735 0.302 . . . . 0.0 110.334 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.423 HD11 ' HZ1' ' A' ' 20' ' ' LYS . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' HG23 ' A' ' 64' ' ' ILE . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.603 ' HZ2' HD21 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.401 ' OG1' ' ND2' ' A' ' 88' ' ' ASN . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.461 HG11 HG21 ' A' ' 80' ' ' THR . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.745 HG23 ' ND2' ' A' ' 83' ' ' ASN . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.523 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.8 mm . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.431 ' OE1' HD23 ' A' ' 76' ' ' LEU . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 63' ' ' ILE . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 75' ' ' VAL . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.402 HG22 HG12 ' A' ' 63' ' ' ILE . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.431 HD23 ' OE1' ' A' ' 58' ' ' GLN . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.63 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.745 ' ND2' HG23 ' A' ' 33' ' ' ILE . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.464 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.558 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.558 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.726 0.298 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 22' ' ' ALA . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.623 ' HG2' HD23 ' A' ' 19' ' ' LEU . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 15' ' ' ILE . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.623 HD23 ' HG2' ' A' ' 14' ' ' LYS . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.446 ' O ' HG23 ' A' ' 11' ' ' VAL . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . 1.021 HG22 ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.594 HD11 HD11 ' A' ' 38' ' ' LEU . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.407 ' H ' ' H ' ' A' ' 37' ' ' SER . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.594 HD11 HD11 ' A' ' 33' ' ' ILE . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.764 0.316 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.524 ' OD1' HG23 ' A' ' 74' ' ' THR . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 75' ' ' VAL . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.745 HG22 HG12 ' A' ' 72' ' ' ILE . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.741 HD11 HG11 ' A' ' 75' ' ' VAL . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.026 HG22 ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 1.026 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.745 HG12 HG22 ' A' ' 63' ' ' ILE . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.524 HG23 ' OD1' ' A' ' 60' ' ' ASP . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.741 HG11 HD11 ' A' ' 64' ' ' ILE . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.654 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.654 ' H ' HG12 ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 1.021 ' H ' HG22 ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.479 ' N ' HD22 ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.505 ' N ' ' CG2' ' A' ' 91' ' ' THR . 6.8 tt0 . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.877 0.37 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.442 ' HG2' HD23 ' A' ' 19' ' ' LEU . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.476 HG22 HG23 ' A' ' 64' ' ' ILE . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.442 HD23 ' HG2' ' A' ' 14' ' ' LYS . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.699 ' OD1' HD11 ' A' ' 84' ' ' ILE . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.406 ' HA2' ' NH1' ' A' ' 87' ' ' ARG . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.613 HG23 ' HA ' ' A' ' 85' ' ' ILE . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG2' HG23 ' A' ' 47' ' ' ILE . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.479 HG23 ' HG2' ' A' ' 45' ' ' LYS . 42.6 pt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.736 0.303 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.701 ' HB3' HD12 ' A' ' 76' ' ' LEU . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.53 HG12 HG22 ' A' ' 72' ' ' ILE . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.761 HD11 ' CG2' ' A' ' 75' ' ' VAL . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.552 HD11 HD23 ' A' ' 89' ' ' LEU . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 53.7 t-80 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.53 HG22 HG12 ' A' ' 63' ' ' ILE . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.761 ' CG2' HD11 ' A' ' 64' ' ' ILE . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.701 HD12 ' HB3' ' A' ' 58' ' ' GLN . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 80' ' ' THR . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.699 HD11 ' OD1' ' A' ' 25' ' ' ASP . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.613 ' HA ' HG23 ' A' ' 31' ' ' THR . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 37.3 tp . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.509 ' C ' HD12 ' A' ' 24' ' ' LEU . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.785 HG21 HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.599 ' N ' HG22 ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 85' ' ' ILE . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG12 ' HB2' ' A' ' 76' ' ' LEU . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.537 ' O ' HD12 ' A' ' 38' ' ' LEU . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 37' ' ' SER . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HG12 ' A' ' 75' ' ' VAL . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.548 HG12 HG22 ' A' ' 72' ' ' ILE . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.413 ' O ' HD13 ' A' ' 66' ' ' ILE . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.566 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.548 HG22 HG12 ' A' ' 63' ' ' ILE . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.523 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.752 HG12 ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.752 ' H ' HG12 ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.513 ' O ' ' O ' ' A' ' 25' ' ' ASP . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.785 HH21 HG21 ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt . . . . . 0 C--O 1.232 0.151 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 11' ' ' VAL . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.49 HG22 ' OE1' ' A' ' 21' ' ' GLU . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 13' ' ' ILE . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' HG22 ' A' ' 12' ' ' THR . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 23' ' ' LEU . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.401 HD12 ' HB ' ' A' ' 85' ' ' ILE . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.467 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 84' ' ' ILE . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.521 HD12 ' CG2' ' A' ' 75' ' ' VAL . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.775 HH21 ' HZ2' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.775 ' HZ2' HH21 ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' VAL . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.422 ' H ' ' HB3' ' A' ' 43' ' ' LYS . 18.1 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.757 ' OD1' HG23 ' A' ' 74' ' ' THR . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 59' ' ' TYR . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.757 HG23 ' OD1' ' A' ' 60' ' ' ASP . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.521 ' CG2' HD12 ' A' ' 33' ' ' ILE . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.549 ' N ' HG12 ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.502 ' O ' HG23 ' A' ' 31' ' ' THR . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.401 ' HB ' HD12 ' A' ' 24' ' ' LEU . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.467 ' H ' ' HA ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.886 0.374 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.419 ' HG3' ' N ' ' A' ' 21' ' ' GLU . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.499 ' CD2' HD11 ' A' ' 85' ' ' ILE . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.662 ' OG1' HD23 ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.436 ' O ' HD13 ' A' ' 38' ' ' LEU . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 C--O 1.231 0.116 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.528 ' HG2' HH11 ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.932 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.932 HG23 ' OD1' ' A' ' 60' ' ' ASP . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.623 HG23 ' O ' ' A' ' 75' ' ' VAL . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.461 ' C ' HG23 ' A' ' 82' ' ' VAL . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.443 ' H ' HG12 ' A' ' 82' ' ' VAL . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.596 ' HA ' HG23 ' A' ' 31' ' ' THR . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.662 HD23 ' OG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt . . . . . 0 C--O 1.232 0.138 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' C ' HD22 ' A' ' 24' ' ' LEU . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.792 ' N ' HD22 ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HD23 ' A' ' 89' ' ' LEU . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' A' ' 84' ' ' ILE . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.659 HG23 ' ND2' ' A' ' 83' ' ' ASN . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.543 ' C ' HD12 ' A' ' 38' ' ' LEU . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' C ' ' A' ' 37' ' ' SER . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HZ3' HD13 ' A' ' 47' ' ' ILE . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.417 ' C ' HG23 ' A' ' 47' ' ' ILE . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.445 HD13 ' HZ3' ' A' ' 45' ' ' LYS . 39.3 pt . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.894 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.54 HG22 ' HB ' ' A' ' 72' ' ' ILE . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.894 HG23 ' OD1' ' A' ' 60' ' ' ASP . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.659 ' ND2' HG23 ' A' ' 33' ' ' ILE . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' CG2' HG22 ' A' ' 32' ' ' VAL . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.61 ' N ' HD22 ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? . . . . . 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 N--CA 1.461 0.1 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 13' ' ' ILE . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 15' ' ' ILE . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.873 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 85' ' ' ILE . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.438 ' O ' HD12 ' A' ' 38' ' ' LEU . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 8.9 t80 . . . . . 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HG2' HH11 ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 22.5 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.467 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.576 ' H ' HG12 ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.416 HG23 ' O ' ' A' ' 84' ' ' ILE . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.56 HD11 ' CD1' ' A' ' 24' ' ' LEU . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.596 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASN . . . . . 0.659 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.659 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.914 0.388 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 13' ' ' ILE . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.582 ' N ' HD22 ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.625 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' GLY . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.43 ' HB ' ' H ' ' A' ' 86' ' ' GLY . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 84' ' ' ILE . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.456 HG23 ' ND2' ' A' ' 83' ' ' ASN . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.575 ' CD1' HG11 ' A' ' 77' ' ' VAL . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.664 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 . . . . . 0 CA--C 1.521 -0.167 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.641 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.882 HD11 ' CG1' ' A' ' 75' ' ' VAL . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.909 ' H ' HD13 ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.548 HG23 ' HB3' ' A' ' 71' ' ' ALA . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 1.006 HG22 ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 1.006 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB3' HG23 ' A' ' 64' ' ' ILE . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.667 HG12 HG22 ' A' ' 63' ' ' ILE . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.641 HG23 ' OD1' ' A' ' 60' ' ' ASP . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.882 ' CG1' HD11 ' A' ' 62' ' ' ILE . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.824 ' H ' HD12 ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 38' ' ' LEU . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 80' ' ' THR . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.448 ' C ' HG23 ' A' ' 82' ' ' VAL . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.457 HG22 HG22 ' A' ' 32' ' ' VAL . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' A' ' 31' ' ' THR . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.426 ' CG ' ' OD2' ' A' ' 25' ' ' ASP . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 15' ' ' ILE . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.788 ' N ' HD12 ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.541 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.443 ' OG1' HD13 ' A' ' 89' ' ' LEU . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 84' ' ' ILE . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.709 HG23 ' ND2' ' A' ' 83' ' ' ASN . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.458 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 47' ' ' ILE . 10.9 tp . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.688 0.28 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 33' ' ' ILE . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.582 HG22 HG21 ' A' ' 32' ' ' VAL . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.424 ' C ' HG23 ' A' ' 82' ' ' VAL . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.709 ' ND2' HG23 ' A' ' 33' ' ' ILE . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.596 HG22 HG22 ' A' ' 32' ' ' VAL . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.536 ' N ' HD12 ' A' ' 89' ' ' LEU . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.869 0.366 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.881 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.953 HG22 ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.76 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.76 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.741 0.305 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' HD11 ' A' ' 62' ' ' ILE . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.738 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.402 HD11 ' CD1' ' A' ' 59' ' ' TYR . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.461 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.461 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.738 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.731 HG23 ' O ' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.458 HG12 ' N ' ' A' ' 83' ' ' ASN . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.458 ' N ' HG12 ' A' ' 82' ' ' VAL . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.953 ' H ' HG22 ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.671 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.483 ' C ' HD22 ' A' ' 19' ' ' LEU . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.698 ' N ' HD22 ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.643 ' HB ' HG21 ' A' ' 80' ' ' THR . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.57 ' HB ' HG22 ' A' ' 77' ' ' VAL . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.467 ' HB3' HH12 ' A' ' 57' ' ' ARG . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.412 ' HA ' HD13 ' A' ' 47' ' ' ILE . 0.3 OUTLIER . . . . . 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 C--O 1.231 0.08 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.411 HG23 HG13 ' A' ' 56' ' ' VAL . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.411 HG13 HG23 ' A' ' 54' ' ' ILE . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.467 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.681 ' N ' HD12 ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 33' ' ' ILE . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.643 HG21 ' HB ' ' A' ' 32' ' ' VAL . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.479 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.496 ' ND2' HG23 ' A' ' 33' ' ' ILE . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 120.894 0.378 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 15' ' ' ILE . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HZ3' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 27' ' ' GLY . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.558 ' N ' HG22 ' A' ' 26' ' ' THR . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.658 HG23 ' HA ' ' A' ' 85' ' ' ILE . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.584 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.419 ' OE1' ' C ' ' A' ' 81' ' ' PRO . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt . . . . . 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PHE . . . . . 0.624 ' O ' ' CG ' ' A' ' 53' ' ' PHE . 3.5 t80 . . . . . 0 C--O 1.232 0.182 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.598 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.4 HD11 HD23 ' A' ' 89' ' ' LEU . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.598 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 33' ' ' ILE . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.462 ' H ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 83' ' ' ASN . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.401 ' N ' HG12 ' A' ' 82' ' ' VAL . 7.3 m-20 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.408 HD11 ' HB ' ' A' ' 26' ' ' THR . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.658 ' HA ' HG23 ' A' ' 31' ' ' THR . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 89' ' ' LEU . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.695 HD23 ' O ' ' A' ' 90' ' ' LEU . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 . . . . . 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 11' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.827 0.346 . . . . 0.0 110.248 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.718 ' N ' HD13 ' A' ' 10' ' ' LEU . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.556 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.497 HG12 HG23 ' A' ' 64' ' ' ILE . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 77' ' ' VAL . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ARG . . . . . 0.491 HH11 ' HG2' ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.721 0.296 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.495 ' CD1' HD11 ' A' ' 62' ' ' ILE . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.409 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.495 HD11 ' CD1' ' A' ' 59' ' ' TYR . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ILE . . . . . 0.497 HG23 HG12 ' A' ' 15' ' ' ILE . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.556 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.409 HG23 ' OD1' ' A' ' 60' ' ' ASP . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.569 ' H ' HD12 ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 33' ' ' ILE . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.5 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 109.687 -0.928 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -60.0 -31.88 70.34 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.405 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 92.1 mt -51.73 -39.54 24.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.113 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.477 ' O ' ' O ' ' A' ' 1' ' ' PRO . 52.6 m -120.77 135.78 55.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.087 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.627 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -95.27 126.69 40.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.646 -179.713 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.518 ' O ' ' O ' ' A' ' 7' ' ' LYS . 99.3 m95 -57.98 -38.95 77.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.322 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' O ' ' O ' ' A' ' 6' ' ' TRP . 24.1 tttp 55.87 140.63 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.845 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.777 ' CD ' ' H ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -59.25 153.98 44.2 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.212 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -42.36 151.47 0.21 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.398 2.065 . . . . 0.0 112.32 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.407 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER -59.82 -166.54 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.469 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.407 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.694 HD11 HG23 ' A' ' 64' ' ' ILE . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.422 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.412 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.423 HG22 ' O ' ' A' ' 54' ' ' ILE . 17.4 tt -126.13 133.6 68.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -132.66 -103.09 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.66 -126.42 34.97 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 70.3 mt -117.73 123.63 71.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.863 0.363 . . . . 0.0 110.279 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.69 20.45 73.96 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 53' ' ' PHE . . . -136.82 159.3 24.52 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.613 ' CD2' ' O ' ' A' ' 53' ' ' PHE . 72.0 t80 168.26 54.15 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.875 0.397 . . . . 0.0 110.16 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 47' ' ' ILE . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.409 HG12 ' HD3' ' A' ' 79' ' ' PRO . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.559 ' OD1' HG23 ' A' ' 74' ' ' THR . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.482 ' N ' HG22 ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.694 HG23 HD11 ' A' ' 15' ' ' ILE . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.824 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 60' ' ' ASP . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.409 ' HD3' HG12 ' A' ' 56' ' ' VAL . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.74 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.74 ' H ' HG12 ' A' ' 82' ' ' VAL . 4.3 m-20 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.514 ' O ' HG23 ' A' ' 31' ' ' THR . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.613 ' N ' HD12 ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.824 ' NE2' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tt0 -58.5 -36.1 73.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 26.7 mt -65.7 -31.03 51.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.377 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.4 -167.29 42.86 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.476 179.992 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.919 0 N-CA-C 109.53 -0.988 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.4 mt-30 -118.71 151.36 38.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.532 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -58.93 -24.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.119 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.9 t -132.75 156.1 47.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.365 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -106.84 155.09 20.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.685 -179.656 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -58.17 151.11 19.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.361 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.9 mttm 62.67 46.4 5.38 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.518 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.485 ' CB ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -42.03 -63.62 0.84 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.033 -179.929 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 12.3 Cg_endo -57.3 144.82 90.05 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.488 2.125 . . . . 0.0 112.565 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt -84.79 172.23 11.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.157 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD13 ' A' ' 13' ' ' ILE . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.866 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.481 HG12 ' CG2' ' A' ' 84' ' ' ILE . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.546 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.813 HD23 ' H ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.46 HH11 ' HG3' ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt -123.12 130.18 74.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.92 -105.74 1.8 Allowed Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.3 -109.93 2.91 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.2 tt -56.74 -23.93 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.784 0.326 . . . . 0.0 110.471 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 126.12 24.3 1.49 Allowed Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -92.1 51.63 2.82 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 -54.74 91.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.561 ' HG2' HH11 ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 76' ' ' LEU . 17.8 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.476 HG23 ' OD1' ' A' ' 60' ' ' ASP . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 58' ' ' GLN . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.442 ' C ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.481 ' CG2' HG12 ' A' ' 32' ' ' VAL . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.442 HD12 ' CD1' ' A' ' 24' ' ' LEU . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.615 ' O ' HG23 ' A' ' 91' ' ' THR . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.615 HG23 ' O ' ' A' ' 87' ' ' ARG . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.577 ' O ' ' N ' ' A' ' 94' ' ' GLY . 4.2 tp60 -86.56 141.53 28.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 64.6 mt 61.66 -39.5 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 O-C-N 123.209 0.318 . . . . 0.0 111.284 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 92' ' ' GLN . . . 95.15 6.46 60.15 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.534 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.555 179.915 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo . . . . . 0 N--CA 1.481 0.744 0 N-CA-C 109.802 -0.884 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -58.64 -37.27 75.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.673 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 67.9 mt -118.84 134.14 63.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.759 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.3 m -76.32 137.18 39.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.031 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -99.36 141.51 32.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.954 0.407 . . . . 0.0 111.114 -179.359 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -101.5 144.75 29.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.032 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 42.3 mttt -57.19 -62.61 1.64 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.99 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.64 149.98 40.21 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.578 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.81 148.35 70.91 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.447 2.098 . . . . 0.0 111.929 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt -89.72 147.15 24.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.404 HG11 HD11 ' A' ' 24' ' ' LEU . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.479 HG12 HG23 ' A' ' 64' ' ' ILE . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.872 ' N ' HD22 ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.531 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' CG2' ' A' ' 84' ' ' ILE . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.429 HD11 HG11 ' A' ' 75' ' ' VAL . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.578 ' HG2' HH11 ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.597 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt -131.58 152.82 37.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.18 -172.15 52.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 156.33 -47.68 0.48 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.8 mt -56.59 -41.13 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.704 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.2 -78.97 0.74 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.07 129.92 6.48 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -109.75 132.66 53.94 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.819 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.615 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.479 HG23 HG12 ' A' ' 15' ' ' ILE . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.615 HG23 ' OD1' ' A' ' 60' ' ' ASP . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.449 HG21 HD11 ' A' ' 64' ' ' ILE . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.574 ' H ' HG12 ' A' ' 82' ' ' VAL . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.46 ' CG2' HG12 ' A' ' 32' ' ' VAL . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -62.99 -39.17 93.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 25.9 mt -70.1 -28.77 37.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.594 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 93.75 5.32 63.02 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo . . . . . 0 N--CA 1.484 0.915 0 N-CA-C 109.579 -0.97 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -112.34 152.35 28.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.166 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 74.6 mt -114.59 129.81 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.935 0.398 . . . . 0.0 111.06 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -129.35 166.8 18.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.157 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.747 HD23 ' H ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -74.2 129.76 38.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.78 0.324 . . . . 0.0 110.362 179.956 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -95.53 118.43 32.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.689 -179.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -102.95 -73.12 0.67 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.642 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.66 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -44.54 -52.47 17.52 Favored Pre-proline 0 N--CA 1.463 0.188 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.744 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.503 ' O ' ' O ' ' A' ' 8' ' ' ARG . 86.1 Cg_exo -44.83 -178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.543 2.162 . . . . 0.0 112.37 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp -71.54 134.16 46.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.861 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.726 HG12 HG23 ' A' ' 64' ' ' ILE . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.648 HG12 HG21 ' A' ' 80' ' ' THR . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.571 ' O ' ' SD ' ' A' ' 36' ' ' MET . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.476 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt -113.66 119.86 62.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.01 -170.74 19.3 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 67.97 -172.88 32.44 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.59 -28.05 41.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.971 0.415 . . . . 0.0 110.175 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.39 -36.91 92.25 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -171.57 -174.52 39.26 Favored Glycine 0 CA--C 1.526 0.75 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.45 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 -172.68 34.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.688 ' HB3' HD12 ' A' ' 76' ' ' LEU . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 70' ' ' LYS . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.726 HG23 HG12 ' A' ' 15' ' ' ILE . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.485 ' HB3' HD11 ' A' ' 63' ' ' ILE . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.402 ' HA ' HE22 ' A' ' 92' ' ' GLN . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.688 HD12 ' HB3' ' A' ' 58' ' ' GLN . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG12 ' A' ' 32' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 39.4 m-20 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.402 HE22 ' HA ' ' A' ' 71' ' ' ALA . 62.2 tt0 -56.23 -38.11 70.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 35.6 mt -70.59 -23.88 24.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.434 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.84 3.41 58.16 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.531 179.915 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 N--CA 1.485 0.985 0 N-CA-C 109.498 -1.001 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -102.35 140.84 36.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.452 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 5' ' ' LEU . 30.8 mm -113.06 132.53 61.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.438 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.4 p -63.62 -36.97 85.56 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.861 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.41 ' H ' HG22 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -114.9 116.21 28.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.936 0.398 . . . . 0.0 110.83 179.961 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 71.3 t-105 -118.92 142.27 47.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.07 179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.57 115.25 10.53 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.331 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.648 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -88.34 -39.51 0.47 Allowed Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.958 179.865 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.648 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 38.5 Cg_exo -55.22 146.42 60.4 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 C-N-CA 122.533 2.155 . . . . 0.0 112.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 10' ' ' LEU . 4.8 mp -88.1 153.51 21.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.596 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.868 ' H ' HD13 ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.762 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.538 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.461 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.585 HG13 HG13 ' A' ' 77' ' ' VAL . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.829 ' H ' HD12 ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.829 HD12 ' H ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.66 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm -89.44 150.83 3.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.81 27.65 0.65 Allowed Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -66.57 -45.56 83.97 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.591 -0.603 . . . . 0.0 111.591 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 88.6 mt -61.16 -41.37 89.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.66 0.267 . . . . 0.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 162.42 -68.23 0.23 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.644 -0.983 . . . . 0.0 110.644 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -77.4 168.36 54.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -108.39 124.08 49.83 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.064 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.929 HD13 ' H ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.49 ' CE1' HD13 ' A' ' 38' ' ' LEU . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 63' ' ' ILE . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 75' ' ' VAL . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.455 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.813 HG21 HD11 ' A' ' 64' ' ' ILE . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.585 HG13 HG13 ' A' ' 33' ' ' ILE . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 34' ' ' GLU . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.538 HD11 ' OD2' ' A' ' 25' ' ' ASP . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 93' ' ' ILE . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.455 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 7.1 tt0 -61.28 -45.54 94.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.424 HG22 ' O ' ' A' ' 90' ' ' LEU . 14.0 tt -66.17 -28.76 44.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.955 -0.298 . . . . 0.0 110.866 -179.57 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.415 ' O ' ' OXT' ' A' ' 95' ' ' ALA . . . -84.79 -176.03 50.82 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.415 ' OXT' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.548 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo . . . . . 0 N--CA 1.483 0.889 0 N-CA-C 109.488 -1.005 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 55.0 tp60 -56.32 -35.86 68.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.8 pt -117.54 149.44 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 110.704 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.7 m -63.03 -40.17 96.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.564 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -80.09 -179.17 6.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.946 0.403 . . . . 0.0 111.022 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.422 ' N ' ' CD1' ' A' ' 6' ' ' TRP . 39.5 m0 -90.04 138.18 31.73 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.955 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -58.66 -40.02 82.29 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.135 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.403 ' CD ' ' H ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -82.77 133.75 48.46 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.692 -179.648 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.36 159.43 46.76 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.422 2.081 . . . . 0.0 112.061 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt -79.98 149.96 30.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.109 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.818 HD12 ' N ' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.579 HG23 ' CG ' ' A' ' 83' ' ' ASN . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.584 ' C ' ' H ' ' A' ' 36' ' ' MET . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.41 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.584 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.921 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt -130.12 158.27 42.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.27 176.83 27.84 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 92.3 -63.22 2.38 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 72.3 mt -117.47 130.77 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 110.681 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.32 7.45 72.85 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.02 138.47 0.13 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -48.37 105.19 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.238 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.522 ' CG2' HD11 ' A' ' 76' ' ' LEU . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.624 ' HB3' HD12 ' A' ' 76' ' ' LEU . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.694 HG22 HG12 ' A' ' 72' ' ' ILE . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.56 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.694 HG12 HG22 ' A' ' 63' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 58' ' ' GLN . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 33' ' ' ILE . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.433 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.579 ' CG ' HG23 ' A' ' 33' ' ' ILE . 16.7 m-20 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.811 ' O ' HG23 ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.811 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -59.61 -40.25 86.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 73.0 mt -87.05 -34.09 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.668 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.68 -165.7 38.81 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.591 -179.929 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 109.549 -0.981 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -58.59 -35.01 71.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.411 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 85.5 mt -59.51 -35.56 59.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.282 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.0 m -73.37 136.48 44.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.468 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.59 164.63 11.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.581 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -65.59 116.32 6.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -113.96 146.0 40.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.622 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.663 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -70.33 170.92 8.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.063 179.609 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.49 145.32 22.32 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.319 2.012 . . . . 0.0 112.178 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.654 HD22 ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? -85.99 154.04 21.73 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.334 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.423 HD11 ' HZ1' ' A' ' 20' ' ' LYS . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' HG23 ' A' ' 64' ' ' ILE . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.603 ' HZ2' HD21 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.401 ' OG1' ' ND2' ' A' ' 88' ' ' ASN . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.461 HG11 HG21 ' A' ' 80' ' ' THR . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.745 HG23 ' ND2' ' A' ' 83' ' ' ASN . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.523 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.8 mm -115.84 131.15 69.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.67 -47.78 0.26 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.19 -36.53 62.11 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.499 -0.381 . . . . 0.0 112.416 -178.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 69.4 mt -118.89 132.86 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.641 -0.423 . . . . 0.0 111.952 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 69.09 26.23 74.83 Favored Glycine 0 CA--C 1.525 0.665 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.887 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.55 -153.84 52.68 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -101.05 123.36 45.1 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.431 ' OE1' HD23 ' A' ' 76' ' ' LEU . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 63' ' ' ILE . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 75' ' ' VAL . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.402 HG22 HG12 ' A' ' 63' ' ' ILE . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.431 HD23 ' OE1' ' A' ' 58' ' ' GLN . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.63 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.745 ' ND2' HG23 ' A' ' 33' ' ' ILE . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.464 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.558 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.558 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -56.05 -39.42 71.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 75.4 mt -95.37 -75.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.525 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.71 -161.1 36.36 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.577 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo . . . . . 0 N--CA 1.485 0.971 0 N-CA-C 109.556 -0.978 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -58.91 -35.14 72.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 73.0 mt -117.17 138.12 48.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.459 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 27.3 m -107.85 136.01 48.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.575 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.437 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -113.77 149.09 35.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.345 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 93.9 m95 -61.09 143.4 55.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.433 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 16.7 ttmm -57.32 -40.92 78.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -91.22 112.41 53.8 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -78.29 -57.8 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.278 0 C-N-CA 122.012 1.808 . . . . 0.0 112.131 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp -90.46 133.01 35.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.482 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 22' ' ' ALA . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.623 ' HG2' HD23 ' A' ' 19' ' ' LEU . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 15' ' ' ILE . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.623 HD23 ' HG2' ' A' ' 14' ' ' LYS . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.446 ' O ' HG23 ' A' ' 11' ' ' VAL . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . 1.021 HG22 ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.594 HD11 HD11 ' A' ' 38' ' ' LEU . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.407 ' H ' ' H ' ' A' ' 37' ' ' SER . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.594 HD11 HD11 ' A' ' 33' ' ' ILE . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt -127.86 138.79 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.28 18.73 2.87 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.818 -0.705 . . . . 0.0 111.512 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -59.31 -41.32 96.82 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 79.6 mt -63.53 -40.14 87.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.706 0.289 . . . . 0.0 110.985 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.68 -63.34 0.35 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.44 53.97 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.59 123.24 48.63 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.579 -0.449 . . . . 0.0 110.851 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 15.0 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.524 ' OD1' HG23 ' A' ' 74' ' ' THR . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 75' ' ' VAL . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.745 HG22 HG12 ' A' ' 72' ' ' ILE . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.741 HD11 HG11 ' A' ' 75' ' ' VAL . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.026 HG22 ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 1.026 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.745 HG12 HG22 ' A' ' 63' ' ' ILE . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.524 HG23 ' OD1' ' A' ' 60' ' ' ASP . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.741 HG11 HD11 ' A' ' 64' ' ' ILE . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.654 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.654 ' H ' HG12 ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 1.021 ' H ' HG22 ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.479 ' N ' HD22 ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.505 ' N ' ' CG2' ' A' ' 91' ' ' THR . 6.8 tt0 -63.78 -173.51 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.75 HD11 HG21 ' A' ' 66' ' ' ILE . 78.9 mt 60.83 57.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.509 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -56.05 -33.78 61.24 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.555 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 109.674 -0.933 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -108.85 150.96 26.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.418 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.417 ' O ' ' C ' ' A' ' 4' ' ' THR . 28.7 pt -123.78 157.52 30.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.874 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.417 ' C ' ' O ' ' A' ' 3' ' ' ILE . 4.0 m 37.08 54.69 1.25 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.921 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -88.57 129.06 35.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.466 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -133.7 -52.52 0.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.5 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.5 ttmm -121.47 138.63 54.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.254 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.472 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -61.4 129.1 90.74 Favored Pre-proline 0 CA--C 1.534 0.337 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.039 -179.941 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.34 -22.53 25.11 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 122.015 1.81 . . . . 0.0 112.036 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp -90.54 126.98 36.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.377 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.442 ' HG2' HD23 ' A' ' 19' ' ' LEU . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.476 HG22 HG23 ' A' ' 64' ' ' ILE . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.442 HD23 ' HG2' ' A' ' 14' ' ' LYS . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.699 ' OD1' HD11 ' A' ' 84' ' ' ILE . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.406 ' HA2' ' NH1' ' A' ' 87' ' ' ARG . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.613 HG23 ' HA ' ' A' ' 85' ' ' ILE . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG2' HG23 ' A' ' 47' ' ' ILE . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.479 HG23 ' HG2' ' A' ' 45' ' ' LYS . 42.6 pt -122.38 -170.15 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 50' ' ' ILE . . . 138.95 -41.86 1.31 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.0 -73.5 0.13 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.401 ' N ' ' O ' ' A' ' 48' ' ' GLY . 71.3 mt -112.34 141.52 27.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.696 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.58 21.91 45.73 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.479 -1.049 . . . . 0.0 110.479 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.22 -171.2 38.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -109.94 135.78 50.25 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.719 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.701 ' HB3' HD12 ' A' ' 76' ' ' LEU . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.53 HG12 HG22 ' A' ' 72' ' ' ILE . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.761 HD11 ' CG2' ' A' ' 75' ' ' VAL . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.552 HD11 HD23 ' A' ' 89' ' ' LEU . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 53.7 t-80 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.53 HG22 HG12 ' A' ' 63' ' ' ILE . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.761 ' CG2' HD11 ' A' ' 64' ' ' ILE . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.701 HD12 ' HB3' ' A' ' 58' ' ' GLN . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 80' ' ' THR . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.699 HD11 ' OD1' ' A' ' 25' ' ' ASP . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.613 ' HA ' HG23 ' A' ' 31' ' ' THR . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -53.82 -39.48 65.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 21.0 mm -85.11 -31.46 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.02 179.034 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.78 -167.21 38.21 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.568 -179.939 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo . . . . . 0 N--CA 1.482 0.819 0 N-CA-C 109.538 -0.985 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -114.08 149.59 35.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.808 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.517 HD12 HD11 ' A' ' 5' ' ' LEU . 29.4 pt -124.29 153.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.622 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.2 p -110.02 -5.54 15.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.062 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.517 HD11 HD12 ' A' ' 3' ' ' ILE . 0.7 OUTLIER -68.16 -30.52 69.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.843 0.354 . . . . 0.0 110.416 179.842 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -55.17 -26.69 40.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.712 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -62.29 -37.4 85.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.731 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.61 ' O ' ' N ' ' A' ' 10' ' ' LEU . 6.0 mpt_? -46.45 -61.66 2.48 Favored Pre-proline 0 N--CA 1.465 0.281 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.254 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.434 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 50.0 Cg_exo -37.58 -17.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.891 2.394 . . . . 0.0 112.764 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 8' ' ' ARG . 37.3 tp -84.25 130.7 34.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.509 ' C ' HD12 ' A' ' 24' ' ' LEU . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.785 HG21 HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.599 ' N ' HG22 ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 85' ' ' ILE . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG12 ' HB2' ' A' ' 76' ' ' LEU . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.537 ' O ' HD12 ' A' ' 38' ' ' LEU . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 37' ' ' SER . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt -129.89 142.46 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.55 105.78 2.86 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.35 172.84 35.14 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.3 mm -60.58 -47.39 93.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.378 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.07 -36.28 92.69 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 165.04 -125.89 1.42 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -110.57 130.12 55.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HG12 ' A' ' 75' ' ' VAL . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.548 HG12 HG22 ' A' ' 72' ' ' ILE . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.413 ' O ' HD13 ' A' ' 66' ' ' ILE . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.566 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.407 ' CG ' ' O ' ' A' ' 93' ' ' ILE . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.548 HG22 HG12 ' A' ' 63' ' ' ILE . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.697 HG13 ' O ' ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.523 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.752 HG12 ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.752 ' H ' HG12 ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.513 ' O ' ' O ' ' A' ' 25' ' ' ASP . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.785 HH21 HG21 ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -96.54 131.62 42.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.407 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 18.7 tt -170.66 -3.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.386 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.77 -165.78 40.56 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.636 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.489 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.6 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 109.535 -0.987 . . . . 0.0 109.535 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -59.89 -37.64 79.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.406 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.82 -32.38 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.173 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.917 HG22 ' H ' ' A' ' 6' ' ' TRP . 33.1 m -108.64 138.59 44.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.959 0.409 . . . . 0.0 110.978 -179.356 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 pp -95.65 1.14 53.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.809 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.917 ' H ' HG22 ' A' ' 4' ' ' THR . 89.5 m95 -102.85 132.66 48.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.013 0.435 . . . . 0.0 110.928 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -140.84 133.47 28.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.903 179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.1 mtp180 -62.56 148.28 90.94 Favored Pre-proline 0 C--N 1.328 -0.332 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.95 146.09 81.68 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.44 2.093 . . . . 0.0 112.243 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -87.14 149.09 24.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.069 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 11' ' ' VAL . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.49 HG22 ' OE1' ' A' ' 21' ' ' GLU . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 13' ' ' ILE . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' HG22 ' A' ' 12' ' ' THR . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 23' ' ' LEU . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.401 HD12 ' HB ' ' A' ' 85' ' ' ILE . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.467 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 84' ' ' ILE . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.521 HD12 ' CG2' ' A' ' 75' ' ' VAL . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.775 HH21 ' HZ2' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.775 ' HZ2' HH21 ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' VAL . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt -116.52 123.97 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.15 -154.07 8.43 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.04 -124.5 11.45 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 65.2 mt -115.54 130.05 70.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.821 0.343 . . . . 0.0 110.44 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.54 0.52 62.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.36 161.47 32.14 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.499 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 177.67 37.71 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.422 ' H ' ' HB3' ' A' ' 43' ' ' LYS . 18.1 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.757 ' OD1' HG23 ' A' ' 74' ' ' THR . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 59' ' ' TYR . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.757 HG23 ' OD1' ' A' ' 60' ' ' ASP . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.521 ' CG2' HD12 ' A' ' 33' ' ' ILE . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.689 ' N ' HD12 ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.549 ' N ' HG12 ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.502 ' O ' HG23 ' A' ' 31' ' ' THR . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.401 ' HB ' HD12 ' A' ' 24' ' ' LEU . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.467 ' H ' ' HA ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -64.57 -49.39 71.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.9 tt -68.22 -27.73 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.852 0.358 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.2 -164.14 38.24 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.569 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.484 0.931 0 N-CA-C 109.623 -0.953 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -110.53 145.89 36.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.382 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.5 pt -70.79 -11.65 15.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.0 p -101.1 24.7 9.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.561 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 pp -52.27 -36.18 52.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.773 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 5.3 m-90 -54.84 -36.93 65.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.859 0.361 . . . . 0.0 110.364 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -103.87 145.74 29.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.494 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -89.85 115.8 64.8 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.903 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -46.52 141.59 10.63 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.795 1.663 . . . . 0.0 112.024 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -89.67 135.21 33.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.218 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.419 ' HG3' ' N ' ' A' ' 21' ' ' GLU . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.499 ' CD2' HD11 ' A' ' 85' ' ' ILE . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.662 ' OG1' HD23 ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.436 ' O ' HD13 ' A' ' 38' ' ' LEU . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt -133.19 148.09 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 148.63 18.19 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.16 -81.2 0.11 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -117.04 134.85 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.821 0.343 . . . . 0.0 110.221 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.01 31.91 46.46 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.64 -129.98 25.34 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -109.99 132.73 53.89 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.528 ' HG2' HH11 ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.932 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.932 HG23 ' OD1' ' A' ' 60' ' ' ASP . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.623 HG23 ' O ' ' A' ' 75' ' ' VAL . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.461 ' C ' HG23 ' A' ' 82' ' ' VAL . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.443 ' H ' HG12 ' A' ' 82' ' ' VAL . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.596 ' HA ' HG23 ' A' ' 31' ' ' THR . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.662 HD23 ' OG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 -104.73 118.97 37.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 17.7 tt -173.55 -23.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.774 0.321 . . . . 0.0 110.296 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -56.17 -34.75 63.01 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.572 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 N--CA 1.481 0.763 0 N-CA-C 109.593 -0.964 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -86.65 148.63 25.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.486 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.0 tt -121.53 136.98 56.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.749 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.4 p -89.82 162.16 15.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.575 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.808 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -95.51 160.73 14.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.809 179.791 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 30.3 p90 -108.62 133.85 52.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.64 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -138.08 139.51 39.55 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.331 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -54.75 145.88 38.97 Favored Pre-proline 0 C--N 1.328 -0.369 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.216 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.94 145.1 78.96 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.321 2.014 . . . . 0.0 112.13 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt -88.42 146.12 25.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.163 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' C ' HD22 ' A' ' 24' ' ' LEU . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.792 ' N ' HD22 ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HD23 ' A' ' 89' ' ' LEU . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' A' ' 84' ' ' ILE . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.659 HG23 ' ND2' ' A' ' 83' ' ' ASN . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.543 ' C ' HD12 ' A' ' 38' ' ' LEU . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' C ' ' A' ' 37' ' ' SER . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HZ3' HD13 ' A' ' 47' ' ' ILE . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.417 ' C ' HG23 ' A' ' 47' ' ' ILE . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.445 HD13 ' HZ3' ' A' ' 45' ' ' LYS . 39.3 pt -154.96 142.25 12.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.72 -79.72 0.03 OUTLIER Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 103.64 -34.47 5.75 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.159 -0.776 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 56.2 mt -117.81 126.51 74.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 71.95 16.3 76.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.81 156.06 32.48 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -54.58 140.9 33.46 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.894 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.54 HG22 ' HB ' ' A' ' 72' ' ' ILE . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.894 HG23 ' OD1' ' A' ' 60' ' ' ASP . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.659 ' ND2' HG23 ' A' ' 33' ' ' ILE . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' CG2' HG22 ' A' ' 32' ' ' VAL . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.61 ' N ' HD22 ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.57 ' O ' HG22 ' A' ' 93' ' ' ILE . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? -57.52 -43.58 84.41 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 90' ' ' LEU . 9.9 tt -66.79 -25.58 35.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.81 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.07 -166.72 39.07 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.62 179.977 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.431 -1.027 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 90.8 mt-30 -114.13 149.57 35.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.33 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.87 -24.59 26.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.583 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.1 m -101.59 134.1 45.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.444 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.14 -24.57 13.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.76 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -57.09 -39.6 75.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.883 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 32.5 tttp -60.15 -38.1 82.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.613 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.7 mmt180 -81.78 122.56 80.36 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.634 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -77.61 172.53 15.64 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 C-N-CA 122.24 1.96 . . . . 0.0 112.297 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -72.88 158.93 34.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 13' ' ' ILE . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 15' ' ' ILE . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.873 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 85' ' ' ILE . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.438 ' O ' HD12 ' A' ' 38' ' ' LEU . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt -126.75 137.12 58.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.42 170.47 22.65 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.41 -125.67 2.12 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.5 mt -113.15 120.25 62.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.31 17.21 78.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.556 ' O ' ' CB ' ' A' ' 53' ' ' PHE . . . -116.3 -146.9 8.72 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.556 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 8.9 t80 92.52 56.94 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.595 ' HG2' HH11 ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 22.5 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.467 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.576 ' H ' HG12 ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.416 HG23 ' O ' ' A' ' 84' ' ' ILE . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.56 HD11 ' CD1' ' A' ' 24' ' ' LEU . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.596 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . 0.659 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.659 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -123.47 96.24 4.9 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 95' ' ' ALA . 20.3 tt -63.81 -21.1 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.41 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 101.31 5.11 52.86 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.576 ' H ' HG23 ' A' ' 93' ' ' ILE . . . . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.507 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo . . . . . 0 N--CA 1.484 0.922 0 N-CA-C 109.583 -0.968 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -55.67 -36.47 67.13 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.309 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.0 tt -59.67 -23.82 27.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.521 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.444 HG22 ' H ' ' A' ' 6' ' ' TRP . 67.1 m -105.62 132.91 51.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.714 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.444 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -97.41 -12.27 22.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.716 179.937 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.474 ' N ' ' CD1' ' A' ' 6' ' ' TRP . 35.4 m0 -58.4 -32.07 68.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.481 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.1 tttm 62.18 -99.46 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.337 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' H ' ' HG2' ' A' ' 8' ' ' ARG . 19.6 ptt180 -75.6 137.0 70.71 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.209 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.28 -20.98 36.37 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.247 1.965 . . . . 0.0 112.43 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt -90.42 144.13 26.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 13' ' ' ILE . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.582 ' N ' HD22 ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.625 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' GLY . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.43 ' HB ' ' H ' ' A' ' 86' ' ' GLY . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 84' ' ' ILE . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.456 HG23 ' ND2' ' A' ' 83' ' ' ASN . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.575 ' CD1' HG11 ' A' ' 77' ' ' VAL . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.664 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.27 175.4 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.7 -12.96 29.97 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -178.62 -175.59 45.82 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.77 -29.99 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.947 0.404 . . . . 0.0 110.195 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.68 -7.84 25.26 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 78.71 130.94 0.66 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -107.56 7.7 28.87 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.641 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.882 HD11 ' CG1' ' A' ' 75' ' ' VAL . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.909 ' H ' HD13 ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.548 HG23 ' HB3' ' A' ' 71' ' ' ALA . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 1.006 HG22 ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 1.006 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB3' HG23 ' A' ' 64' ' ' ILE . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.667 HG12 HG22 ' A' ' 63' ' ' ILE . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.641 HG23 ' OD1' ' A' ' 60' ' ' ASP . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.882 ' CG1' HD11 ' A' ' 62' ' ' ILE . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.824 ' H ' HD12 ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 38' ' ' LEU . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 80' ' ' THR . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.448 ' C ' HG23 ' A' ' 82' ' ' VAL . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.457 HG22 HG22 ' A' ' 32' ' ' VAL . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' A' ' 31' ' ' THR . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.426 ' CG ' ' OD2' ' A' ' 25' ' ' ASP . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 -100.25 125.75 46.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.795 HG23 ' O ' ' A' ' 93' ' ' ILE . 20.3 tt -159.03 64.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.803 0.335 . . . . 0.0 110.601 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.98 21.04 61.89 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.52 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.484 0.957 0 N-CA-C 109.736 -0.909 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -56.94 -37.81 72.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -117.66 135.11 59.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.892 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 41.1 p -123.23 158.73 30.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.277 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.449 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -131.25 123.51 28.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.63 179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -61.41 -39.43 90.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.511 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.2 mttp -128.25 147.52 50.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.759 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.8 mtt180 -71.48 146.4 91.54 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.175 179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.16 -35.81 50.62 Favored 'Trans proline' 0 N--CA 1.495 1.58 0 C-N-CA 122.437 2.091 . . . . 0.0 112.706 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt -90.74 143.06 27.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 -179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 15' ' ' ILE . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.788 ' N ' HD12 ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.541 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.443 ' OG1' HD13 ' A' ' 89' ' ' LEU . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 84' ' ' ILE . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.709 HG23 ' ND2' ' A' ' 83' ' ' ASN . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.458 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 47' ' ' ILE . 10.9 tp -137.42 154.34 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.51 -33.11 3.07 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.38 -165.51 35.65 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 78.5 mt -59.75 -33.99 54.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.676 0.274 . . . . 0.0 110.894 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.66 -32.05 38.78 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.16 156.37 9.75 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.4 129.32 55.79 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.663 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 33' ' ' ILE . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.582 HG22 HG21 ' A' ' 32' ' ' VAL . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.424 ' C ' HG23 ' A' ' 82' ' ' VAL . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.709 ' ND2' HG23 ' A' ' 33' ' ' ILE . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.596 HG22 HG22 ' A' ' 32' ' ' VAL . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.536 ' N ' HD12 ' A' ' 89' ' ' LEU . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -94.44 122.91 37.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 18.8 tt -174.32 -10.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.036 0.446 . . . . 0.0 110.389 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.634 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -115.82 -43.32 0.68 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.634 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.6 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PRO . . . . . 0.462 ' O ' ' O ' ' A' ' 2' ' ' GLN . 14.3 Cg_exo . . . . . 0 N--CA 1.484 0.945 0 N-CA-C 109.491 -1.004 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.462 ' O ' ' O ' ' A' ' 1' ' ' PRO . 46.5 tt0 43.65 97.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.651 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -114.12 128.95 70.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.186 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.9 p -115.91 -4.3 12.08 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 120.816 -0.353 . . . . 0.0 111.563 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.457 ' H ' HD12 ' A' ' 5' ' ' LEU . 0.2 OUTLIER -133.15 108.85 9.07 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.745 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.2 m-90 -64.51 -40.36 95.49 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -99.59 141.21 32.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.664 ' CG ' HH11 ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.82 112.9 54.74 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.631 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -49.86 -12.9 0.45 Allowed 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.098 1.865 . . . . 0.0 112.111 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp -87.09 135.46 33.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.422 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.881 ' N ' HD22 ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.953 HG22 ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.76 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.76 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt -140.71 163.77 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.69 -22.24 30.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 50.82 -128.58 29.61 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.502 ' C ' ' H ' ' A' ' 52' ' ' GLY . 18.9 tt -61.33 -27.84 42.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.758 0.313 . . . . 0.0 110.907 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.32 17.81 1.37 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 50' ' ' ILE . . . 100.22 148.95 23.16 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.17 126.19 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.184 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' HD11 ' A' ' 62' ' ' ILE . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.738 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.402 HD11 ' CD1' ' A' ' 59' ' ' TYR . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.461 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.461 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.738 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.731 HG23 ' O ' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.458 HG12 ' N ' ' A' ' 83' ' ' ASN . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.458 ' N ' HG12 ' A' ' 82' ' ' VAL . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.953 ' H ' HG22 ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.671 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 -96.97 118.46 33.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.422 HD12 ' HA ' ' A' ' 93' ' ' ILE . 11.1 tp -171.22 -23.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 110.381 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.712 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -55.0 -33.47 57.27 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.712 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.5 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo . . . . . 0 N--CA 1.484 0.921 0 N-CA-C 109.554 -0.979 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -119.32 164.23 15.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.092 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.6 mm -98.79 144.52 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.953 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 m -59.94 138.29 57.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.682 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.498 HD23 ' H ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -79.55 149.97 31.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.856 -179.564 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -88.87 131.94 34.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.548 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -105.12 -28.03 11.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.029 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 1.2 ttt180 -50.02 -48.43 78.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.291 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 32.5 Cg_exo -55.65 -17.52 17.84 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.411 2.074 . . . . 0.0 112.053 -179.799 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp -89.9 128.12 36.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.562 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.483 ' C ' HD22 ' A' ' 19' ' ' LEU . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.698 ' N ' HD22 ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.643 ' HB ' HG21 ' A' ' 80' ' ' THR . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.57 ' HB ' HG22 ' A' ' 77' ' ' VAL . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.467 ' HB3' HH12 ' A' ' 57' ' ' ARG . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.412 ' HA ' HD13 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -136.02 150.2 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 134.71 -10.96 4.58 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.91 -169.17 40.97 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.6 tt -56.54 -31.23 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.92 0.39 . . . . 0.0 110.027 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.0 -1.14 30.16 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.04 120.06 0.01 OUTLIER Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -96.74 4.63 51.69 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.411 HG23 HG13 ' A' ' 56' ' ' VAL . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.411 HG13 HG23 ' A' ' 54' ' ' ILE . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.467 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.681 ' N ' HD12 ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 33' ' ' ILE . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.643 HG21 ' HB ' ' A' ' 32' ' ' VAL . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.479 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.496 ' ND2' HG23 ' A' ' 33' ' ' ILE . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 -97.82 127.08 43.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.8 tt -159.25 6.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.971 0.415 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -83.1 179.1 52.94 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.635 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo . . . . . 0 N--CA 1.482 0.826 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -58.86 -36.91 75.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.538 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.81 -26.92 39.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.4 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.4 m -87.89 137.45 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.809 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.77 141.97 46.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.35 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m-90 -62.12 137.7 58.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.876 0.37 . . . . 0.0 110.411 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.8 mttp -61.0 -37.9 84.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.856 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.1 mmt180 -91.27 111.1 46.97 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -80.18 157.49 23.15 Favored 'Trans proline' 0 N--CA 1.489 1.252 0 C-N-CA 122.159 1.906 . . . . 0.0 111.787 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt -87.02 136.05 33.06 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.378 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 15' ' ' ILE . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HZ3' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 27' ' ' GLY . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.558 ' N ' HG22 ' A' ' 26' ' ' THR . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.658 HG23 ' HA ' ' A' ' 85' ' ' ILE . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.584 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.419 ' OE1' ' C ' ' A' ' 81' ' ' PRO . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.472 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt -129.45 143.83 39.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.74 171.41 37.41 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . -151.63 -111.7 0.51 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 80.7 mt -57.86 -37.38 60.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.886 0.374 . . . . 0.0 110.196 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -71.04 1.3 Allowed Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -84.15 -177.07 51.33 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.455 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PHE . . . . . 0.624 ' O ' ' CG ' ' A' ' 53' ' ' PHE . 3.5 t80 163.76 77.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.598 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.4 HD11 HD23 ' A' ' 89' ' ' LEU . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.598 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 33' ' ' ILE . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.462 ' H ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 83' ' ' ASN . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.401 ' N ' HG12 ' A' ' 82' ' ' VAL . 7.3 m-20 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.408 HD11 ' HB ' ' A' ' 26' ' ' THR . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.658 ' HA ' HG23 ' A' ' 31' ' ' THR . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 89' ' ' LEU . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 93' ' ' ILE . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -55.57 -35.41 65.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.741 HG22 ' O ' ' A' ' 90' ' ' LEU . 13.4 tt -57.49 -25.28 23.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.756 -179.172 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.5 -165.88 37.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.684 -179.916 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.003 0 N-CA-C 109.667 -0.936 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 51.27 60.73 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.59 -24.73 26.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.677 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.8 p -80.22 160.44 25.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.537 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.89 43.84 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.641 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -105.34 129.25 53.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.438 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 56.1 tttp -99.25 -72.89 0.64 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.748 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -89.98 149.73 42.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.678 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -43.53 95.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 122.114 1.876 . . . . 0.0 111.659 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 11' ' ' VAL . 0.2 OUTLIER -90.6 128.37 36.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.248 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.718 ' N ' HD13 ' A' ' 10' ' ' LEU . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.556 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.497 HG12 HG23 ' A' ' 64' ' ' ILE . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 77' ' ' VAL . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ARG . . . . . 0.491 HH11 ' HG2' ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt -138.57 166.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -152.58 27.92 0.85 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 120.396 -0.907 . . . . 0.0 112.123 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.28 -41.66 93.08 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.224 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.0 mm -65.57 -40.87 89.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.866 0.365 . . . . 0.0 110.939 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 156.08 -64.02 0.32 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.81 175.2 55.1 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 178.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -110.03 127.05 54.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 117.278 0.539 . . . . 0.0 111.179 -179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.495 ' CD1' HD11 ' A' ' 62' ' ' ILE . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.409 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.495 HD11 ' CD1' ' A' ' 59' ' ' TYR . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ILE . . . . . 0.497 HG23 HG12 ' A' ' 15' ' ' ILE . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.556 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.409 HG23 ' OD1' ' A' ' 60' ' ' ASP . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.569 ' H ' HD12 ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 33' ' ' ILE . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 9.8 mt -67.63 -35.77 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 110.517 179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.12 -35.05 82.39 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.685 -179.889 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.407 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER . . . . . 0 CA--C 1.528 0.113 0 CA-C-O 120.718 0.294 . . . . 0.0 110.469 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.407 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.694 HD11 HG23 ' A' ' 64' ' ' ILE . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.422 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.422 HG23 ' ND2' ' A' ' 83' ' ' ASN . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.412 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.423 HG22 ' O ' ' A' ' 54' ' ' ILE . 17.4 tt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.613 ' O ' ' CD2' ' A' ' 53' ' ' PHE . 72.0 t80 . . . . . 0 N--CA 1.468 0.468 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 47' ' ' ILE . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.409 HG12 ' HD3' ' A' ' 79' ' ' PRO . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.559 ' OD1' HG23 ' A' ' 74' ' ' THR . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.482 ' N ' HG22 ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.694 HG23 HD11 ' A' ' 15' ' ' ILE . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.824 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 60' ' ' ASP . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.409 ' HD3' HG12 ' A' ' 56' ' ' VAL . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.74 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.74 ' H ' HG12 ' A' ' 82' ' ' VAL . 1.7 m120 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.514 ' O ' HG23 ' A' ' 31' ' ' THR . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.824 ' NE2' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tt0 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt . . . . . 0 C--O 1.232 0.154 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD13 ' A' ' 13' ' ' ILE . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.866 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.481 HG12 ' CG2' ' A' ' 84' ' ' ILE . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.546 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.813 ' H ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.46 ' HG3' HH11 ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.561 HH11 ' HG2' ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 76' ' ' LEU . 48.0 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.476 HG23 ' OD1' ' A' ' 60' ' ' ASP . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 58' ' ' GLN . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.442 ' C ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.481 ' CG2' HG12 ' A' ' 32' ' ' VAL . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.442 HD12 ' CD1' ' A' ' 24' ' ' LEU . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.615 ' O ' HG23 ' A' ' 91' ' ' THR . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.615 HG23 ' O ' ' A' ' 87' ' ' ARG . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 4.2 tp60 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.404 HG11 HD11 ' A' ' 24' ' ' LEU . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.479 HG12 HG23 ' A' ' 64' ' ' ILE . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.872 HD22 ' N ' ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.531 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' CG2' ' A' ' 84' ' ' ILE . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.429 HD11 HG11 ' A' ' 75' ' ' VAL . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.578 HH11 ' HG2' ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.597 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt . . . . . 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.717 0.294 . . . . 0.0 110.819 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.615 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.479 HG23 HG12 ' A' ' 15' ' ' ILE . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.615 HG23 ' OD1' ' A' ' 60' ' ' ASP . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.449 HG21 HD11 ' A' ' 64' ' ' ILE . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.574 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.574 ' H ' HG12 ' A' ' 82' ' ' VAL . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.46 ' CG2' HG12 ' A' ' 32' ' ' VAL . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.921 0.391 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.726 HG12 HG23 ' A' ' 64' ' ' ILE . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.648 HG12 HG21 ' A' ' 80' ' ' THR . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.736 ' H ' HD22 ' A' ' 83' ' ' ASN . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.476 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt . . . . . 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.688 ' HB3' HD12 ' A' ' 76' ' ' LEU . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 70' ' ' LYS . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.726 HG23 HG12 ' A' ' 15' ' ' ILE . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.485 ' HB3' HD11 ' A' ' 63' ' ' ILE . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.402 ' HA ' HE22 ' A' ' 92' ' ' GLN . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.688 HD12 ' HB3' ' A' ' 58' ' ' GLN . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG12 ' A' ' 32' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.736 HD22 ' H ' ' A' ' 34' ' ' GLU . 9.6 m120 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.402 HE22 ' HA ' ' A' ' 71' ' ' ALA . 62.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 mp . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.854 0.359 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.868 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.762 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.538 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.461 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.585 HG13 HG13 ' A' ' 77' ' ' VAL . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.829 ' H ' HD12 ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.829 HD12 ' H ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.66 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm . . . . . 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 . . . . . 0 N--CA 1.462 0.13 0 CA-C-O 120.762 0.315 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.929 HD13 ' H ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.49 ' CE1' HD13 ' A' ' 38' ' ' LEU . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 63' ' ' ILE . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 75' ' ' VAL . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.455 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.813 HG21 HD11 ' A' ' 64' ' ' ILE . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.585 HG13 HG13 ' A' ' 33' ' ' ILE . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 34' ' ' GLU . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.538 HD11 ' OD2' ' A' ' 25' ' ' ASP . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.455 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 7.1 tt0 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt . . . . . 0 N--CA 1.458 -0.068 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.818 HD12 ' N ' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.592 HG23 ' ND2' ' A' ' 83' ' ' ASN . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.717 ' H ' ' ND2' ' A' ' 83' ' ' ASN . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.41 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.584 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.921 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 . . . . . 0 C--O 1.231 0.105 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.522 ' CG2' HD11 ' A' ' 76' ' ' LEU . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.624 ' HB3' HD12 ' A' ' 76' ' ' LEU . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.694 HG22 HG12 ' A' ' 72' ' ' ILE . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.56 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.694 HG12 HG22 ' A' ' 63' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 58' ' ' GLN . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 33' ' ' ILE . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.433 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.717 ' ND2' ' H ' ' A' ' 34' ' ' GLU . 4.8 m120 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.811 ' O ' HG23 ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.811 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 . . . . . 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.654 HD22 ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? . . . . . 0 N--CA 1.458 -0.074 0 CA-C-O 120.735 0.302 . . . . 0.0 110.334 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.423 HD11 ' HZ1' ' A' ' 20' ' ' LYS . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' HG23 ' A' ' 64' ' ' ILE . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.603 ' HZ2' HD21 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.401 ' OG1' ' ND2' ' A' ' 88' ' ' ASN . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.461 HG11 HG21 ' A' ' 80' ' ' THR . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.745 HG23 ' ND2' ' A' ' 83' ' ' ASN . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.523 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.8 mm . . . . . 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.431 ' OE1' HD23 ' A' ' 76' ' ' LEU . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 63' ' ' ILE . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 75' ' ' VAL . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.402 HG22 HG12 ' A' ' 63' ' ' ILE . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.431 HD23 ' OE1' ' A' ' 58' ' ' GLN . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.63 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.745 ' ND2' HG23 ' A' ' 33' ' ' ILE . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.464 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.558 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.558 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.726 0.298 . . . . 0.0 110.482 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 22' ' ' ALA . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.623 ' HG2' HD23 ' A' ' 19' ' ' LEU . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.415 HD13 HG21 ' A' ' 15' ' ' ILE . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.623 HD23 ' HG2' ' A' ' 14' ' ' LYS . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.446 ' O ' HG23 ' A' ' 11' ' ' VAL . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 1.021 HG22 ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.594 HD11 HD11 ' A' ' 38' ' ' LEU . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.407 ' H ' ' H ' ' A' ' 37' ' ' SER . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.594 HD11 HD11 ' A' ' 33' ' ' ILE . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.764 0.316 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.439 ' NE2' HG21 ' A' ' 74' ' ' THR . 52.4 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.524 ' OD1' HG23 ' A' ' 74' ' ' THR . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 75' ' ' VAL . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.745 HG22 HG12 ' A' ' 72' ' ' ILE . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.741 HD11 HG11 ' A' ' 75' ' ' VAL . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.026 HG22 ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 1.026 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.593 ' HB2' HE22 ' A' ' 92' ' ' GLN . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.745 HG12 HG22 ' A' ' 63' ' ' ILE . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.524 HG23 ' OD1' ' A' ' 60' ' ' ASP . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.741 HG11 HD11 ' A' ' 64' ' ' ILE . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.654 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.654 ' H ' HG12 ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 1.021 ' H ' HG22 ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.593 HE22 ' HB2' ' A' ' 71' ' ' ALA . 1.6 tt0 . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.877 0.37 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.442 ' HG2' HD23 ' A' ' 19' ' ' LEU . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.476 HG22 HG23 ' A' ' 64' ' ' ILE . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.442 HD23 ' HG2' ' A' ' 14' ' ' LYS . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.699 ' OD1' HD11 ' A' ' 84' ' ' ILE . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.406 ' HA2' ' NH1' ' A' ' 87' ' ' ARG . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.613 HG23 ' HA ' ' A' ' 85' ' ' ILE . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG2' HG23 ' A' ' 47' ' ' ILE . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.479 HG23 ' HG2' ' A' ' 45' ' ' LYS . 42.6 pt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.736 0.303 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.701 ' HB3' HD12 ' A' ' 76' ' ' LEU . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.53 HG12 HG22 ' A' ' 72' ' ' ILE . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.761 HD11 ' CG2' ' A' ' 75' ' ' VAL . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.552 HD11 HD23 ' A' ' 89' ' ' LEU . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.53 HG22 HG12 ' A' ' 63' ' ' ILE . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.761 ' CG2' HD11 ' A' ' 64' ' ' ILE . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.701 HD12 ' HB3' ' A' ' 58' ' ' GLN . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 80' ' ' THR . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.699 HD11 ' OD1' ' A' ' 25' ' ' ASP . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.613 ' HA ' HG23 ' A' ' 31' ' ' THR . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.58 HD12 ' N ' ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 37.3 tp . . . . . 0 CA--C 1.528 0.107 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.509 ' C ' HD12 ' A' ' 24' ' ' LEU . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.785 HG21 HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.599 ' N ' HG22 ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 85' ' ' ILE . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.433 HG12 ' HB2' ' A' ' 76' ' ' LEU . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.537 ' O ' HD12 ' A' ' 38' ' ' LEU . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 37' ' ' SER . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HG12 ' A' ' 75' ' ' VAL . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.548 HG12 HG22 ' A' ' 72' ' ' ILE . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.413 ' O ' HD13 ' A' ' 66' ' ' ILE . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.566 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.548 HG22 HG12 ' A' ' 63' ' ' ILE . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.523 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.752 HG12 ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.752 ' H ' HG12 ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.513 ' HA ' HG23 ' A' ' 31' ' ' THR . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.785 HH21 HG21 ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 . . . . . 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt . . . . . 0 C--O 1.232 0.151 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 11' ' ' VAL . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.49 HG22 ' OE1' ' A' ' 21' ' ' GLU . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 13' ' ' ILE . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' HG22 ' A' ' 12' ' ' THR . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 23' ' ' LEU . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.401 HD12 ' HB ' ' A' ' 85' ' ' ILE . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.467 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 84' ' ' ILE . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.521 HD12 ' CG2' ' A' ' 75' ' ' VAL . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.775 HH21 ' HZ2' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.775 ' HZ2' HH21 ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' VAL . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.422 ' H ' ' HB3' ' A' ' 43' ' ' LYS . 48.2 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.757 ' OD1' HG23 ' A' ' 74' ' ' THR . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 59' ' ' TYR . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.757 HG23 ' OD1' ' A' ' 60' ' ' ASP . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.521 ' CG2' HD12 ' A' ' 33' ' ' ILE . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.689 HD12 ' N ' ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.549 ' N ' HG12 ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.502 ' O ' HG23 ' A' ' 31' ' ' THR . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.401 ' HB ' HD12 ' A' ' 24' ' ' LEU . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.467 ' H ' ' HA ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.886 0.374 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.419 ' HG3' ' N ' ' A' ' 21' ' ' GLU . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.499 ' CD2' HD11 ' A' ' 85' ' ' ILE . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.662 ' OG1' HD23 ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.436 ' O ' HD13 ' A' ' 38' ' ' LEU . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 . . . . . 0 C--O 1.231 0.116 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.528 HH11 ' HG2' ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.932 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.932 HG23 ' OD1' ' A' ' 60' ' ' ASP . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.623 HG23 ' O ' ' A' ' 75' ' ' VAL . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.461 ' C ' HG23 ' A' ' 82' ' ' VAL . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.443 ' H ' HG12 ' A' ' 82' ' ' VAL . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.596 ' HA ' HG23 ' A' ' 31' ' ' THR . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.662 HD23 ' OG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt . . . . . 0 C--O 1.232 0.138 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' C ' HD22 ' A' ' 24' ' ' LEU . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.792 HD22 ' N ' ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HD23 ' A' ' 89' ' ' LEU . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' A' ' 84' ' ' ILE . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.659 HG23 ' ND2' ' A' ' 83' ' ' ASN . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.543 ' C ' HD12 ' A' ' 38' ' ' LEU . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' C ' ' A' ' 37' ' ' SER . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HZ3' HD13 ' A' ' 47' ' ' ILE . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.417 ' C ' HG23 ' A' ' 47' ' ' ILE . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.445 HD13 ' HZ3' ' A' ' 45' ' ' LYS . 39.3 pt . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.72 HE21 HG21 ' A' ' 74' ' ' THR . 60.7 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.894 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.54 HG22 ' HB ' ' A' ' 72' ' ' ILE . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.894 HG23 ' OD1' ' A' ' 60' ' ' ASP . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.659 ' ND2' HG23 ' A' ' 33' ' ' ILE . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' CG2' HG22 ' A' ' 32' ' ' VAL . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.61 HD22 ' N ' ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? . . . . . 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 N--CA 1.461 0.1 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 13' ' ' ILE . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 15' ' ' ILE . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.873 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 85' ' ' ILE . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.438 ' O ' HD12 ' A' ' 38' ' ' LEU . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.641 HH11 ' NE2' ' A' ' 61' ' ' GLN . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 8.9 t80 . . . . . 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.595 HH11 ' HG2' ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.641 ' NE2' HH11 ' A' ' 41' ' ' ARG . 86.1 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.467 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.621 ' N ' ' CD2' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.576 ' H ' HG12 ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' O ' HG23 ' A' ' 84' ' ' ILE . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.56 HD11 ' CD1' ' A' ' 24' ' ' LEU . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.596 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.659 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.659 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.914 0.388 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 13' ' ' ILE . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.582 HD22 ' N ' ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.556 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.625 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' GLY . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.43 ' HB ' ' H ' ' A' ' 86' ' ' GLY . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 84' ' ' ILE . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.456 HG23 ' ND2' ' A' ' 83' ' ' ASN . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.575 ' CD1' HG11 ' A' ' 77' ' ' VAL . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.664 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 . . . . . 0 CA--C 1.521 -0.167 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.641 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.882 HD11 ' CG1' ' A' ' 75' ' ' VAL . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.909 HD13 ' H ' ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.548 HG23 ' HB3' ' A' ' 71' ' ' ALA . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 1.006 HG22 ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 1.006 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB3' HG23 ' A' ' 64' ' ' ILE . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.667 HG12 HG22 ' A' ' 63' ' ' ILE . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.641 HG23 ' OD1' ' A' ' 60' ' ' ASP . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.882 ' CG1' HD11 ' A' ' 62' ' ' ILE . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.824 ' H ' HD12 ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 38' ' ' LEU . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 80' ' ' THR . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.448 ' C ' HG23 ' A' ' 82' ' ' VAL . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.457 HG22 HG22 ' A' ' 32' ' ' VAL . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' A' ' 31' ' ' THR . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.426 ' CG ' ' OD2' ' A' ' 25' ' ' ASP . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 15' ' ' ILE . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.788 ' N ' HD12 ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.541 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.443 ' OG1' HD13 ' A' ' 89' ' ' LEU . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 84' ' ' ILE . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.709 HG23 ' ND2' ' A' ' 83' ' ' ASN . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.458 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 47' ' ' ILE . 10.9 tp . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.688 0.28 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 33' ' ' ILE . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.582 HG22 HG21 ' A' ' 32' ' ' VAL . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.424 ' C ' HG23 ' A' ' 82' ' ' VAL . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.709 ' ND2' HG23 ' A' ' 33' ' ' ILE . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.596 HG22 HG22 ' A' ' 32' ' ' VAL . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 89' ' ' LEU . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.869 0.366 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.881 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.953 HG22 ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.76 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.76 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt . . . . . 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.741 0.305 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' HD11 ' A' ' 62' ' ' ILE . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.738 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.402 HD11 ' CD1' ' A' ' 59' ' ' TYR . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.461 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.461 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.738 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.731 HG23 ' O ' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.458 HG12 ' N ' ' A' ' 83' ' ' ASN . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.458 ' N ' HG12 ' A' ' 82' ' ' VAL . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.953 ' H ' HG22 ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.671 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.887 0.375 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.483 ' C ' HD22 ' A' ' 19' ' ' LEU . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.698 HD22 ' N ' ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.643 ' HB ' HG21 ' A' ' 80' ' ' THR . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.57 ' HB ' HG22 ' A' ' 77' ' ' VAL . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.467 ' HB3' HH12 ' A' ' 57' ' ' ARG . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.412 ' HA ' HD13 ' A' ' 47' ' ' ILE . 0.3 OUTLIER . . . . . 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 C--O 1.231 0.08 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.411 HG23 HG13 ' A' ' 56' ' ' VAL . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.411 HG13 HG23 ' A' ' 54' ' ' ILE . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.467 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.681 HD12 ' N ' ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 33' ' ' ILE . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.643 HG21 ' HB ' ' A' ' 32' ' ' VAL . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.479 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.496 ' ND2' HG23 ' A' ' 33' ' ' ILE . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 120.894 0.378 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 15' ' ' ILE . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HZ3' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 27' ' ' GLY . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.558 ' N ' HG22 ' A' ' 26' ' ' THR . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.658 HG23 ' HA ' ' A' ' 85' ' ' ILE . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.584 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.538 ' H ' HD22 ' A' ' 83' ' ' ASN . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.472 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt . . . . . 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . 0.624 ' CG ' ' O ' ' A' ' 53' ' ' PHE . 3.5 t80 . . . . . 0 C--O 1.232 0.182 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.598 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.4 HD11 HD23 ' A' ' 89' ' ' LEU . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.598 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 33' ' ' ILE . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.462 ' H ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 83' ' ' ASN . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.538 HD22 ' H ' ' A' ' 34' ' ' GLU . 3.2 m120 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.408 HD11 ' HB ' ' A' ' 26' ' ' THR . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.658 ' HA ' HG23 ' A' ' 31' ' ' THR . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 89' ' ' LEU . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.695 ' O ' HD23 ' A' ' 90' ' ' LEU . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 . . . . . 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 11' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.827 0.346 . . . . 0.0 110.248 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.718 ' N ' HD13 ' A' ' 10' ' ' LEU . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.556 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.497 HG12 HG23 ' A' ' 64' ' ' ILE . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 77' ' ' VAL . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ARG . . . . . 0.491 ' HG2' HH11 ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.721 0.296 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.495 ' CD1' HD11 ' A' ' 62' ' ' ILE . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.409 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.495 HD11 ' CD1' ' A' ' 59' ' ' TYR . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . 0.497 HG23 HG12 ' A' ' 15' ' ' ILE . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.556 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.409 HG23 ' OD1' ' A' ' 60' ' ' ASP . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.569 ' H ' HD12 ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 33' ' ' ILE . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.5 Cg_endo . . . . . 0 N--CA 1.483 0.879 0 N-CA-C 109.687 -0.928 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -60.0 -31.88 70.34 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.405 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 92.1 mt -51.73 -39.54 24.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.113 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.477 ' O ' ' O ' ' A' ' 1' ' ' PRO . 52.6 m -120.77 135.78 55.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.087 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.627 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -95.27 126.69 40.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.646 -179.713 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.518 ' O ' ' O ' ' A' ' 7' ' ' LYS . 99.3 m95 -57.98 -38.95 77.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.322 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' O ' ' O ' ' A' ' 6' ' ' TRP . 24.1 tttp 55.87 140.63 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.845 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.777 ' CD ' ' H ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -59.25 153.98 44.2 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.212 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -42.36 151.47 0.21 Allowed 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.398 2.065 . . . . 0.0 112.32 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.407 ' HG ' ' H ' ' A' ' 11' ' ' VAL . 0.8 OUTLIER -59.82 -166.54 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.469 -179.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.407 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 14.2 p -129.33 144.58 37.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.66 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.2 p -129.71 160.81 32.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.641 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.4 157.89 29.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.358 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 34.4 mttp -120.48 117.33 27.38 Favored 'General case' 0 C--O 1.234 0.254 0 C-N-CA 120.722 -0.391 . . . . 0.0 110.869 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.694 HD11 HG23 ' A' ' 64' ' ' ILE . 35.2 mm -117.17 101.59 12.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.91 15.38 81.39 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.8 6.76 60.46 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -97.83 140.31 32.4 Favored 'General case' 0 C--N 1.33 -0.253 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.174 179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 55.8 mt -90.04 127.35 36.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.441 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.573 ' NZ ' ' SD ' ' A' ' 36' ' ' MET . 40.3 mttm -135.36 156.18 49.36 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.773 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -110.22 134.66 52.0 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -147.6 151.91 37.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.063 0.459 . . . . 0.0 111.31 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 65.3 mt -107.02 147.28 30.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.239 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 71.1 mt -87.67 137.67 32.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.839 0.352 . . . . 0.0 110.565 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.422 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.0 t0 -141.56 94.86 2.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.476 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.4 m -61.65 -21.04 64.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.984 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.99 -18.38 79.09 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' O ' ' CA ' ' A' ' 86' ' ' GLY . . . -90.86 117.17 29.26 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.847 0.356 . . . . 0.0 111.006 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.8 m-20 -66.81 -35.94 81.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.174 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -116.58 -178.18 3.36 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.889 0.376 . . . . 0.0 111.258 -179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 84' ' ' ILE . 98.0 m -117.17 134.24 55.02 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.352 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 39.5 t -126.29 136.21 61.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.216 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.422 HG23 ' ND2' ' A' ' 83' ' ' ASN . 73.2 mt -119.33 137.11 54.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.828 0.347 . . . . 0.0 111.051 -179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -48.48 154.72 0.6 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.47 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.7 tp10 -54.21 136.73 42.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.99 0.424 . . . . 0.0 110.355 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.573 ' SD ' ' NZ ' ' A' ' 20' ' ' LYS . 21.4 ttt -168.66 168.97 10.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.718 -179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.412 ' H ' ' HG2' ' A' ' 36' ' ' MET . 48.0 m -104.93 138.79 40.62 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.195 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.98 148.63 49.56 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.559 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.71 149.33 43.06 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.331 2.021 . . . . 0.0 111.535 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 105.97 168.76 23.26 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.5 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -65.57 150.14 48.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.121 0.486 . . . . 0.0 111.632 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 48.8 p-90 -137.36 165.41 26.28 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.718 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 8.2 mtmt -140.02 144.11 36.84 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.354 -0.538 . . . . 0.0 111.015 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -76.09 135.6 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 122.415 2.077 . . . . 0.0 111.966 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tttm -131.24 143.25 50.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.394 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 68.9 mtm -121.82 145.65 47.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.369 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.423 HG22 ' O ' ' A' ' 54' ' ' ILE . 17.4 tt -126.13 133.6 68.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.281 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -132.66 -103.09 0.85 Allowed Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 63.66 -126.42 34.97 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 70.3 mt -117.73 123.63 71.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.863 0.363 . . . . 0.0 110.279 179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 77.69 20.45 73.96 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 53' ' ' PHE . . . -136.82 159.3 24.52 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.613 ' O ' ' CD2' ' A' ' 53' ' ' PHE . 72.0 t80 168.26 54.15 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 O-C-N 123.875 0.397 . . . . 0.0 110.16 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.423 ' O ' HG22 ' A' ' 47' ' ' ILE . 14.6 tt -130.29 149.2 33.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.967 0.413 . . . . 0.0 111.387 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 16.9 tttp -91.56 127.91 37.19 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.833 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.409 HG12 ' HD3' ' A' ' 79' ' ' PRO . 30.3 m -132.4 167.56 26.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.265 179.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 77' ' ' VAL . 14.4 ptm180 -118.92 154.07 33.56 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.416 ' OE1' ' CD2' ' A' ' 76' ' ' LEU . 28.7 pt20 -141.95 159.51 42.08 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.251 -0.579 . . . . 0.0 112.434 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -120.52 132.83 55.37 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.264 178.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.559 ' OD1' HG23 ' A' ' 74' ' ' THR . 89.2 m-20 -110.05 9.56 24.17 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.496 0.925 . . . . 0.0 113.496 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -144.63 51.48 1.26 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.936 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.482 HG22 ' N ' ' A' ' 63' ' ' ILE . 82.3 mt -116.75 155.03 18.33 Favored 'Isoleucine or valine' 0 C--O 1.234 0.254 0 CA-C-O 121.159 0.504 . . . . 0.0 111.339 179.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.482 ' N ' HG22 ' A' ' 62' ' ' ILE . 15.9 tt -111.23 135.45 50.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.257 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.694 HG23 HD11 ' A' ' 15' ' ' ILE . 81.1 mt -116.43 136.06 54.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.851 -179.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -104.64 122.37 45.49 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.305 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.9 mt -129.41 127.91 65.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.859 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 46.43 44.03 12.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.846 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.05 16.98 73.3 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.299 -0.477 . . . . 0.0 112.15 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -116.13 136.94 52.56 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 117.208 0.504 . . . . 0.0 110.698 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.2 mttt -85.44 147.12 26.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.733 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.824 ' HB1' ' NE2' ' A' ' 92' ' ' GLN . . . -154.26 135.53 14.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.972 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 69.5 mt -121.35 130.42 74.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.817 0.342 . . . . 0.0 110.91 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.43 179.59 48.08 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.39 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 60' ' ' ASP . 63.6 m -73.28 135.68 44.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.702 0.287 . . . . 0.0 110.469 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.3 t -129.67 96.93 3.19 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.955 0.407 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.416 ' CD2' ' OE1' ' A' ' 58' ' ' GLN . 24.8 mt -65.1 136.74 57.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.526 -178.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 57' ' ' ARG . 58.2 t -117.6 128.28 74.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.722 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.14 174.85 21.95 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.409 ' HD3' HG12 ' A' ' 56' ' ' VAL . 77.1 Cg_endo -79.84 17.41 1.29 Allowed 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 123.364 2.71 . . . . 0.0 113.431 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 80' ' ' THR . 0.7 OUTLIER -58.89 147.66 72.12 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.723 -0.391 . . . . 0.0 110.419 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -39.76 -62.55 0.35 Allowed 'Trans proline' 0 C--N 1.313 -1.306 0 C-N-CA 122.508 2.139 . . . . 0.0 112.733 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.74 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.4 t -126.91 -142.73 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.99 0.424 . . . . 0.0 110.799 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.74 ' H ' HG12 ' A' ' 82' ' ' VAL . 1.7 m120 -113.75 135.66 53.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.757 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.514 ' O ' HG23 ' A' ' 31' ' ' THR . 16.2 tt -126.72 135.26 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.834 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 85' ' ' ILE . 2.5 mp -102.95 135.25 41.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.048 0.452 . . . . 0.0 111.271 -179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' A' ' 28' ' ' ALA . . . -105.3 -178.42 24.16 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -56.8 -24.74 52.91 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 21.6 t-20 -53.24 -45.8 68.89 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.398 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 9.1 mp -87.68 -39.99 14.53 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.461 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 6.8 tp -54.46 -44.15 72.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.897 -179.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 62.1 p -78.32 -24.5 46.56 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.792 0.329 . . . . 0.0 110.721 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.824 ' NE2' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tt0 -58.5 -36.1 73.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.404 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 26.7 mt -65.7 -31.03 51.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.377 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.4 -167.29 42.86 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.476 179.992 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.919 0 N-CA-C 109.53 -0.988 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.4 mt-30 -118.71 151.36 38.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.532 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -58.93 -24.87 27.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.119 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 5.9 t -132.75 156.1 47.68 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.365 179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.555 ' O ' HD12 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -106.84 155.09 20.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.685 -179.656 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -58.17 151.11 19.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.361 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.9 mttm 62.67 46.4 5.38 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.518 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.485 ' CB ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -42.03 -63.62 0.84 Allowed Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.033 -179.929 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 12.3 Cg_endo -57.3 144.82 90.05 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.488 2.125 . . . . 0.0 112.565 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.7 mt -84.79 172.23 11.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.157 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.5 t -78.77 136.5 23.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.8 m -119.75 145.91 46.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.654 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.416 HG21 HD13 ' A' ' 13' ' ' ILE . 24.8 pt -119.85 155.66 22.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.183 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 16.4 mtpt -119.25 110.69 17.31 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.651 -0.42 . . . . 0.0 110.791 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 75.4 mt -125.6 114.31 38.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.619 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.77 9.76 70.72 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.35 2.78 61.78 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -96.81 145.39 25.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.747 0.308 . . . . 0.0 110.247 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.5 mt -95.73 121.78 37.81 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.143 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 92.3 mttt -133.65 156.9 47.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.798 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -109.39 146.03 35.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.929 179.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.69 148.95 32.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.991 0.424 . . . . 0.0 110.827 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 69.7 mt -111.41 145.07 39.58 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.385 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.866 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.1 mm? -89.35 134.3 34.13 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.4 t0 -138.59 101.76 4.43 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.179 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.1 m -59.91 -23.44 63.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.617 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.01 37.58 3.31 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -143.66 95.93 2.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.576 -0.312 . . . . 0.0 110.506 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -62.2 -38.15 88.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.777 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -101.5 173.06 6.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.8 t -131.91 143.83 50.42 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.264 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.481 HG12 ' CG2' ' A' ' 84' ' ' ILE . 8.3 p -147.14 148.13 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.856 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.0 pt -122.1 155.68 26.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.546 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.1 tt0 -49.76 152.21 1.55 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.266 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.499 ' O ' ' C ' ' A' ' 36' ' ' MET . 84.2 tt0 -36.12 -65.7 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.112 -178.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.499 ' C ' ' O ' ' A' ' 35' ' ' GLU . 89.4 mtp -27.16 110.0 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.967 0.413 . . . . 0.0 111.952 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 38' ' ' LEU . 25.6 t -157.47 116.22 3.23 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.028 179.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.813 ' H ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -32.1 154.57 0.04 OUTLIER Pre-proline 0 CA--C 1.531 0.226 0 CA-C-O 120.856 0.36 . . . . 0.0 111.362 -178.924 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -57.69 -152.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.028 2.485 . . . . 0.0 112.324 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 112.4 -137.71 14.45 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.46 ' HG3' HH11 ' A' ' 41' ' ' ARG . 30.8 ttm-85 -119.02 139.25 52.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.376 . . . . 0.0 110.509 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -140.96 162.67 34.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.216 179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -140.35 148.5 54.16 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.474 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -69.17 129.57 18.46 Favored 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.403 2.069 . . . . 0.0 112.132 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.7 tttt -135.0 142.78 46.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.457 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 70.9 mtm -118.18 141.65 48.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.424 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.1 mt -123.12 130.18 74.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.541 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.92 -105.74 1.8 Allowed Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.3 -109.93 2.91 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.2 tt -56.74 -23.93 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.784 0.326 . . . . 0.0 110.471 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 126.12 24.3 1.49 Allowed Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -92.1 51.63 2.82 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 67.0 t80 -54.74 91.62 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.787 0.327 . . . . 0.0 110.921 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 tt -128.6 148.26 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.24 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 44.3 tttp -93.12 122.33 35.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.801 0.334 . . . . 0.0 110.65 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.87 163.99 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.362 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.561 HH11 ' HG2' ' A' ' 57' ' ' ARG . 19.4 mtt-85 -114.92 145.0 42.67 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.535 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 76' ' ' LEU . 48.0 tt0 -107.52 127.47 53.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.211 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -113.38 132.14 55.72 Favored 'General case' 0 C--O 1.231 0.101 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.409 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 62' ' ' ILE . 66.2 m-20 -113.25 -149.8 0.45 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.461 -179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 35.5 22.73 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.591 ' N ' ' O ' ' A' ' 60' ' ' ASP . 27.5 mt -113.49 142.76 24.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.378 0 CA-C-O 121.248 0.547 . . . . 0.0 111.442 179.704 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 30.7 pt -121.53 154.99 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.956 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 79.7 mt -119.27 133.95 64.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.214 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.82 129.6 55.05 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.489 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.66 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.3 mt -128.07 119.41 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.524 ' C ' ' O ' ' A' ' 66' ' ' ILE . . . -20.41 79.32 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.902 0.751 . . . . 0.0 111.428 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.66 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 158.2 -55.27 0.37 Allowed Glycine 0 CA--C 1.529 0.937 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.84 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.586 ' ND1' ' O ' ' A' ' 68' ' ' GLY . 36.5 m80 -158.28 163.27 37.56 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 117.399 0.6 . . . . 0.0 111.755 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.5 pttt -94.99 145.93 24.6 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.846 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.8 143.51 51.23 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.312 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 10.7 tt -123.36 130.92 73.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.41 -177.88 48.47 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.618 -0.801 . . . . 0.0 111.512 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.476 HG23 ' OD1' ' A' ' 60' ' ' ASP . 65.9 m -78.94 141.35 37.63 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.814 0.34 . . . . 0.0 110.751 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 75' ' ' VAL . 24.2 m -134.79 101.56 3.43 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.064 0.459 . . . . 0.0 110.782 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 58' ' ' GLN . 12.0 mt -64.42 143.98 57.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.404 0.621 . . . . 0.0 111.38 -178.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.0 t -114.06 130.8 67.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.511 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.61 162.13 24.85 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -70.17 -17.21 35.86 Favored 'Trans proline' 0 C--N 1.307 -1.647 0 C-N-CA 123.033 2.489 . . . . 0.0 112.763 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 8.6 t -52.52 143.7 26.85 Favored Pre-proline 0 CA--C 1.532 0.282 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.661 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.442 ' C ' HG23 ' A' ' 82' ' ' VAL . 36.3 Cg_endo -67.06 159.07 53.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.564 2.176 . . . . 0.0 112.368 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 49.8 -154.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.839 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' A' ' 34' ' ' GLU . 74.1 m-20 -135.77 150.02 49.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.714 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.481 ' CG2' HG12 ' A' ' 32' ' ' VAL . 14.4 tt -125.8 136.86 59.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.11 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.442 HD12 ' CD1' ' A' ' 24' ' ' LEU . 79.7 mt -111.5 142.98 22.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.32 -179.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.07 -172.07 13.3 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.615 ' O ' HG23 ' A' ' 91' ' ' THR . 94.5 mtt180 -55.28 -26.25 38.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.617 -0.291 . . . . 0.0 111.679 -179.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -50.86 -42.09 58.57 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.026 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 4.2 mp -86.41 -36.9 18.86 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.424 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 67.1 mt -57.28 -41.14 79.21 Favored 'General case' 0 N--CA 1.462 0.172 0 C-N-CA 120.36 -0.536 . . . . 0.0 110.595 -179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.615 HG23 ' O ' ' A' ' 87' ' ' ARG . 68.2 p -63.22 -19.59 64.66 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.912 0.386 . . . . 0.0 110.357 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.577 ' O ' ' N ' ' A' ' 94' ' ' GLY . 4.2 tp60 -86.56 141.53 28.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.89 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 64.6 mt 61.66 -39.5 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 O-C-N 123.209 0.318 . . . . 0.0 111.284 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 92' ' ' GLN . . . 95.15 6.46 60.15 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.534 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.555 179.915 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo . . . . . 0 N--CA 1.481 0.744 0 N-CA-C 109.802 -0.884 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -58.64 -37.27 75.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.849 0.357 . . . . 0.0 110.673 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 67.9 mt -118.84 134.14 63.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.759 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 47.3 m -76.32 137.18 39.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.031 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -99.36 141.51 32.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.954 0.407 . . . . 0.0 111.114 -179.359 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -101.5 144.75 29.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.032 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 42.3 mttt -57.19 -62.61 1.64 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.99 -179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.64 149.98 40.21 Favored Pre-proline 0 C--N 1.329 -0.296 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.578 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.81 148.35 70.91 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.447 2.098 . . . . 0.0 111.929 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.6 mt -89.72 147.15 24.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.901 0.381 . . . . 0.0 110.411 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.404 HG11 HD11 ' A' ' 24' ' ' LEU . 12.0 p -128.13 144.03 39.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.37 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.7 p -129.08 159.9 34.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.85 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 pt -120.73 155.32 24.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.037 179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.9 mttt -125.95 117.81 24.06 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.75 -179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.479 HG12 HG23 ' A' ' 64' ' ' ILE . 67.4 mt -130.58 120.12 47.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.757 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.31 7.53 82.52 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.75 7.88 59.77 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -104.68 152.91 21.93 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.785 0.326 . . . . 0.0 110.448 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.872 HD22 ' N ' ' A' ' 19' ' ' LEU . 1.5 mm? -97.74 127.13 43.48 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.538 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 49.4 mttm -133.73 155.41 49.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.285 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -112.41 137.44 50.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.127 179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -145.0 150.84 37.6 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.629 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.8 mt -106.84 140.56 39.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.529 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.424 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.9 139.23 30.75 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.025 179.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.531 ' CG ' ' H ' ' A' ' 26' ' ' THR . 17.9 t70 -159.05 -176.37 5.82 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.541 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.607 ' O ' ' N ' ' A' ' 28' ' ' ALA . 39.8 m -48.82 -32.95 9.57 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 30' ' ' ASP . . . 27.53 35.35 0.01 OUTLIER Glycine 0 C--N 1.336 0.547 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 179.086 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.607 ' N ' ' O ' ' A' ' 26' ' ' THR . . . 38.15 -137.67 0.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.1 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.3 m-20 -100.53 4.32 43.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.804 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' O ' ' O ' ' A' ' 27' ' ' GLY . 92.4 m-20 -130.92 175.02 9.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.123 0.487 . . . . 0.0 111.389 -179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.5 t -132.75 153.82 50.83 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.293 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' CG2' ' A' ' 84' ' ' ILE . 10.8 p -138.97 143.63 31.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.721 -0.391 . . . . 0.0 111.107 179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.429 HD11 HG11 ' A' ' 75' ' ' VAL . 44.8 mt -115.77 144.71 22.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.68 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.436 ' CD ' ' O ' ' A' ' 81' ' ' PRO . 84.1 tt0 -46.32 147.0 1.22 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.576 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.507 ' O ' ' O ' ' A' ' 36' ' ' MET . 11.3 pt-20 -50.52 146.0 5.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.618 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.507 ' O ' ' O ' ' A' ' 35' ' ' GLU . 55.7 ttp 39.68 100.02 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.797 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.84 17.78 1.26 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.401 179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.1 pp 179.14 141.81 0.3 Allowed Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.504 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -72.87 162.69 40.43 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 122.46 2.107 . . . . 0.0 112.298 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 124.48 -167.46 16.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.519 -0.633 . . . . 0.0 111.519 179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.578 HH11 ' HG2' ' A' ' 41' ' ' ARG . 16.0 mtt-85 -115.34 165.35 13.06 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.597 ' HE1' ' HA ' ' A' ' 44' ' ' PRO . 0.4 OUTLIER -137.49 172.27 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.293 -179.579 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.489 ' N ' ' CD1' ' A' ' 42' ' ' TRP . 11.6 mttm -107.51 113.99 61.14 Favored Pre-proline 0 CA--C 1.536 0.428 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.749 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HA ' ' HE1' ' A' ' 42' ' ' TRP . 45.2 Cg_exo -49.37 115.67 1.88 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.983 1.789 . . . . 0.0 112.233 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 38.0 tttm -136.23 143.56 44.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.122 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 10.3 mmt -121.96 147.21 46.33 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.509 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 38.0 pt -131.58 152.82 37.77 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.633 179.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.18 -172.15 52.44 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 156.33 -47.68 0.48 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 87.8 mt -56.59 -41.13 72.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.778 0.323 . . . . 0.0 110.704 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -116.2 -78.97 0.74 Allowed Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.07 129.92 6.48 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -109.75 132.66 53.94 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.819 -179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.4 mt -114.32 144.58 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.646 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 43.3 mtmt -83.06 103.02 12.18 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.2 t -102.38 140.12 21.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.264 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 77.1 mtm180 -97.76 129.11 44.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.406 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 61.4 tt0 -99.89 119.38 38.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.392 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -105.87 121.73 44.66 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.615 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.9 m-20 -115.36 162.48 17.07 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.258 0.552 . . . . 0.0 112.197 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 62.79 38.89 11.33 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-N 115.035 -0.984 . . . . 0.0 112.363 178.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 16.9 tt -114.32 147.55 17.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.742 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 17.2 tt -112.63 133.91 56.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.384 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.479 HG23 HG12 ' A' ' 15' ' ' ILE . 74.9 mt -121.86 139.85 47.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.741 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -103.07 122.47 44.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 67.5 mt -129.85 127.91 64.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 44.51 42.96 6.01 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.947 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.98 14.55 78.67 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 121.246 -0.502 . . . . 0.0 111.935 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -118.7 136.39 53.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 117.105 0.453 . . . . 0.0 110.509 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 46.5 mtmt -88.74 150.46 22.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.84 137.46 18.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.796 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.5 mt -126.37 126.8 69.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -179.11 48.96 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.843 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.615 HG23 ' OD1' ' A' ' 60' ' ' ASP . 97.4 m -77.26 141.06 40.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.537 -0.332 . . . . 0.0 110.503 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.449 HG21 HD11 ' A' ' 64' ' ' ILE . 31.9 t -139.53 107.49 3.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.173 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 18.9 mt -71.29 146.67 48.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.437 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.14 128.55 74.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.445 179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -123.54 171.12 15.95 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.384 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.403 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.2 Cg_endo -59.74 -21.09 61.8 Favored 'Trans proline' 0 N--CA 1.494 1.558 0 C-N-CA 123.476 2.784 . . . . 0.0 113.099 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 79' ' ' PRO . 1.0 OUTLIER -39.74 139.93 0.88 Allowed Pre-proline 0 CA--C 1.534 0.354 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.434 -179.275 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.436 ' O ' ' CD ' ' A' ' 34' ' ' GLU . 69.1 Cg_endo -75.33 -13.76 20.66 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 122.449 2.1 . . . . 0.0 113.111 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.574 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.3 OUTLIER -127.94 -159.17 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.201 0.524 . . . . 0.0 111.419 -179.091 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.574 ' H ' HG12 ' A' ' 82' ' ' VAL . 37.5 m-20 -128.53 131.7 48.26 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.493 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.46 ' CG2' HG12 ' A' ' 32' ' ' VAL . 16.6 tt -124.0 140.22 48.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.971 0.415 . . . . 0.0 110.508 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 79.3 mt -109.55 145.88 15.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.798 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -124.72 -176.25 14.54 Favored Glycine 0 CA--C 1.53 1.025 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.019 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.59 ' NH1' ' OG1' ' A' ' 91' ' ' THR . 28.1 ttt-85 -53.58 -25.07 15.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.208 -0.496 . . . . 0.0 112.129 -179.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -54.11 -46.76 72.23 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.013 -179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 7.9 mp -80.32 -39.87 27.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.439 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 61.7 mt -56.39 -39.41 72.93 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.887 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.59 ' OG1' ' NH1' ' A' ' 87' ' ' ARG . 37.4 m -58.96 -44.86 91.57 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.068 -179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.3 tt0 -62.99 -39.17 93.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.379 . . . . 0.0 110.564 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 25.9 mt -70.1 -28.77 37.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.594 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 93.75 5.32 63.02 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.537 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo . . . . . 0 N--CA 1.484 0.915 0 N-CA-C 109.579 -0.97 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -112.34 152.35 28.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.166 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 74.6 mt -114.59 129.81 70.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.935 0.398 . . . . 0.0 111.06 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 20.8 p -129.35 166.8 18.79 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.157 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.747 ' H ' HD23 ' A' ' 5' ' ' LEU . 0.1 OUTLIER -74.2 129.76 38.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.78 0.324 . . . . 0.0 110.362 179.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -95.53 118.43 32.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.689 -179.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.9 mttm -102.95 -73.12 0.67 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.642 -179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.66 HH11 ' CG ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -44.54 -52.47 17.52 Favored Pre-proline 0 N--CA 1.463 0.188 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.744 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.503 ' O ' ' O ' ' A' ' 8' ' ' ARG . 86.1 Cg_exo -44.83 -178.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.543 2.162 . . . . 0.0 112.37 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 tp -71.54 134.16 46.29 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.861 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -128.18 145.81 34.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.346 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 30.9 p -81.9 162.68 22.66 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.844 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.8 pt -122.23 158.7 25.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.308 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.491 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 68.7 mttm -119.4 118.82 32.18 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.568 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.726 HG12 HG23 ' A' ' 64' ' ' ILE . 71.6 mt -128.06 108.98 18.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.656 179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.95 6.08 81.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 98.4 12.12 45.98 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -104.94 149.53 25.65 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -98.44 123.56 42.65 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.917 0.389 . . . . 0.0 110.647 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -140.6 163.02 33.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.509 -179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -117.56 144.26 45.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.031 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.53 153.99 42.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.972 0.415 . . . . 0.0 111.105 -179.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 42.2 mt -102.13 148.36 25.49 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.175 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.1 mp -92.4 132.96 36.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.601 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.6 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 18.5 t70 -78.16 137.92 38.43 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.44 179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 26.3 m -70.38 -29.82 66.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.017 0.437 . . . . 0.0 110.266 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.485 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . 161.59 84.92 0.05 OUTLIER Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.6 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -136.43 -14.19 1.73 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.661 0.267 . . . . 0.0 110.897 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.499 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 88.0 m-20 55.09 43.97 28.74 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.818 0.342 . . . . 0.0 110.574 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 92.6 m-20 -140.16 125.05 18.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.482 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.53 113.78 21.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.789 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.648 HG12 HG21 ' A' ' 80' ' ' THR . 21.9 t -131.1 131.43 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.916 179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -126.3 143.97 38.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.136 0.494 . . . . 0.0 111.912 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.736 ' H ' HD22 ' A' ' 83' ' ' ASN . 82.9 tt0 -57.89 152.36 16.23 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.693 178.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.579 ' OE2' ' NH1' ' A' ' 57' ' ' ARG . 83.5 tt0 -71.03 140.3 50.72 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.812 -0.355 . . . . 0.0 110.381 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.571 ' SD ' ' O ' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -131.13 -103.94 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 110.657 -179.943 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.476 ' H ' ' CG ' ' A' ' 36' ' ' MET . 92.6 p -148.02 73.79 1.27 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.012 179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.44 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 96.6 mt -119.18 87.87 35.92 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.075 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -76.98 -175.4 2.63 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.417 2.078 . . . . 0.0 111.89 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 121.77 -100.41 0.72 Allowed Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 78.3 mtm180 -119.59 148.18 43.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.929 0.395 . . . . 0.0 110.755 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -110.5 126.95 54.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.633 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -126.19 87.58 55.91 Favored Pre-proline 0 C--N 1.331 -0.234 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.275 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -53.71 135.76 63.19 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 C-N-CA 122.395 2.063 . . . . 0.0 111.994 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.1 tptt -136.96 142.31 42.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.998 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 3.3 ptp -137.11 131.72 33.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.324 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.456 ' O ' ' N ' ' A' ' 53' ' ' PHE . 57.6 mt -113.66 119.86 62.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.01 -170.74 19.3 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 67.97 -172.88 32.44 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.59 -28.05 41.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.971 0.415 . . . . 0.0 110.175 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -60.39 -36.91 92.25 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -171.57 -174.52 39.26 Favored Glycine 0 CA--C 1.526 0.75 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.45 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.456 ' N ' ' O ' ' A' ' 47' ' ' ILE . 37.4 p90 -172.68 34.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.659 0.266 . . . . 0.0 110.569 -179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.5 tt -134.42 153.26 35.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.948 0.404 . . . . 0.0 111.331 -179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 71.7 mttt -95.73 124.13 39.61 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.048 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.95 169.91 20.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 121.098 0.475 . . . . 0.0 111.56 -179.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.579 ' NH1' ' OE2' ' A' ' 35' ' ' GLU . 11.8 ptp180 -117.63 149.75 40.17 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.467 179.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.688 ' HB3' HD12 ' A' ' 76' ' ' LEU . 26.3 pt20 -142.77 159.16 42.77 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.579 -178.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 95.7 m-85 -120.07 132.51 55.47 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.064 178.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -96.68 3.73 52.27 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -177.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -141.73 54.91 1.5 Allowed 'General case' 0 C--N 1.331 -0.237 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.701 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.0 mm -102.91 146.94 10.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.992 0.425 . . . . 0.0 110.943 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.485 HD11 ' HB3' ' A' ' 70' ' ' LYS . 15.5 tt -117.12 132.74 65.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.144 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.726 HG23 HG12 ' A' ' 15' ' ' ILE . 62.4 mt -119.71 144.62 27.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.718 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 59.9 mp0 -107.23 115.71 30.66 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 121.051 0.453 . . . . 0.0 110.224 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 73.3 mt -128.38 132.21 68.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 51.19 36.3 15.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.871 179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.39 15.43 78.99 Favored Glycine 0 CA--C 1.526 0.78 0 C-N-CA 121.138 -0.553 . . . . 0.0 111.807 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -119.91 138.5 53.4 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.949 0.375 . . . . 0.0 110.952 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.485 ' HB3' HD11 ' A' ' 63' ' ' ILE . 40.6 mttt -88.64 127.93 35.58 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.023 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.402 ' HA ' HE22 ' A' ' 92' ' ' GLN . . . -120.39 136.56 54.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.182 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.2 mt -121.49 130.18 74.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.902 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -179.99 -179.45 48.8 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 86.9 m -76.41 142.8 40.96 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.651 0.262 . . . . 0.0 110.302 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -139.25 106.05 2.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 120.492 -0.483 . . . . 0.0 111.45 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.688 HD12 ' HB3' ' A' ' 58' ' ' GLN . 6.1 tp -71.01 119.69 15.49 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.448 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' A' ' 57' ' ' ARG . 43.4 t -101.91 129.23 53.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.761 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -139.64 173.37 22.87 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.407 ' O ' ' C ' ' A' ' 80' ' ' THR . 17.8 Cg_endo -61.01 -19.61 63.85 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 123.126 2.551 . . . . 0.0 112.909 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.648 HG21 HG12 ' A' ' 32' ' ' VAL . 0.2 OUTLIER -38.37 100.96 0.22 Allowed Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.603 -179.659 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -55.28 -4.59 0.47 Allowed 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.369 2.046 . . . . 0.0 112.703 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.405 ' H ' ' C ' ' A' ' 80' ' ' THR . 0.2 OUTLIER -111.6 173.24 2.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.315 0.579 . . . . 0.0 111.478 -178.94 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.736 HD22 ' H ' ' A' ' 34' ' ' GLU . 9.6 m120 -126.32 123.3 37.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.238 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -133.45 142.39 41.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.861 0.363 . . . . 0.0 110.954 179.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 32.5 pt -118.11 149.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.558 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -104.02 179.28 25.01 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.053 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 55.8 mtp180 -61.29 -22.94 65.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.326 -0.437 . . . . 0.0 111.113 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -55.39 -45.14 76.65 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.155 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.571 HD12 ' N ' ' A' ' 89' ' ' LEU . 6.3 mp -74.49 -41.16 61.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.541 179.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 62.9 mt -62.21 -41.16 98.11 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.51 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 46.7 m -60.44 -39.87 89.07 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.402 HE22 ' HA ' ' A' ' 71' ' ' ALA . 62.2 tt0 -56.23 -38.11 70.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.247 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 35.6 mt -70.59 -23.88 24.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.434 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.84 3.41 58.16 Favored Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.531 179.915 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 N--CA 1.485 0.985 0 N-CA-C 109.498 -1.001 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -102.35 140.84 36.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.452 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 5' ' ' LEU . 30.8 mm -113.06 132.53 61.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.438 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 71.4 p -63.62 -36.97 85.56 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.861 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.41 ' H ' HG22 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -114.9 116.21 28.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.936 0.398 . . . . 0.0 110.83 179.961 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 71.3 t-105 -118.92 142.27 47.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.07 179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.57 115.25 10.53 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.331 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.648 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -88.34 -39.51 0.47 Allowed Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.958 179.865 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.648 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 38.5 Cg_exo -55.22 146.42 60.4 Favored 'Trans proline' 0 N--CA 1.493 1.457 0 C-N-CA 122.533 2.155 . . . . 0.0 112.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.434 ' H ' HD12 ' A' ' 10' ' ' LEU . 4.8 mp -88.1 153.51 21.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.596 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.2 p -79.2 149.86 5.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.487 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.9 t -130.99 159.04 38.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.571 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.63 161.95 29.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.766 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 46.5 tttm -128.43 120.95 27.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.441 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.868 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.1 OUTLIER -143.35 136.89 25.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.788 179.572 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 70.38 -0.54 24.72 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.94 8.39 55.54 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -113.71 149.1 35.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.684 0.278 . . . . 0.0 110.33 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.762 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.1 mp -94.71 134.24 37.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.866 0.365 . . . . 0.0 110.613 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -145.72 165.15 29.61 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.789 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -115.67 147.98 40.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.042 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.93 151.7 39.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.89 0.376 . . . . 0.0 110.741 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 71.0 mt -102.6 145.54 29.49 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 64.0 mt -88.7 138.47 31.39 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.363 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.538 ' OD2' HD11 ' A' ' 84' ' ' ILE . 60.3 t0 -139.81 92.64 2.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.806 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.593 ' O ' ' NE ' ' A' ' 87' ' ' ARG . 44.5 m -62.27 -24.26 67.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.7 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.09 -13.96 62.87 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.299 -0.72 . . . . 0.0 111.299 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -117.42 144.56 44.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.726 0.298 . . . . 0.0 110.88 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.461 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 51.8 p30 -105.23 -9.08 17.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.777 179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 87.6 m-20 -104.89 162.01 13.69 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.739 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.8 m -125.1 131.39 53.31 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.977 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.5 m -138.9 151.39 23.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.362 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.585 HG13 HG13 ' A' ' 77' ' ' VAL . 31.5 pt -126.07 151.59 32.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.346 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' A' ' 78' ' ' GLY . 85.9 tt0 -69.04 -74.91 0.12 Allowed 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.326 0.584 . . . . 0.0 111.574 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -90.61 156.19 18.31 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.133 -179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.562 ' N ' ' SD ' ' A' ' 36' ' ' MET . 0.0 OUTLIER -89.57 -175.18 4.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.158 -179.477 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.829 ' H ' HD12 ' A' ' 38' ' ' LEU . 3.0 t 163.9 40.22 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.32 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.829 HD12 ' H ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -129.93 77.92 75.85 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.869 -179.384 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -53.46 153.44 17.83 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 C-N-CA 122.901 2.4 . . . . 0.0 111.999 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.8 -124.93 6.12 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.66 ' CG ' HH11 ' A' ' 41' ' ' ARG . 3.1 mtt-85 -116.52 151.29 36.43 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.034 0.445 . . . . 0.0 111.061 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 16.5 p-90 -139.14 163.32 32.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.415 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.4 mmmt -114.37 124.78 30.16 Favored Pre-proline 0 CA--C 1.534 0.338 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.457 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -72.71 137.59 27.61 Favored 'Trans proline' 0 N--CA 1.492 1.435 0 C-N-CA 121.919 1.746 . . . . 0.0 112.209 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.4 tttt -140.47 144.11 35.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.137 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 59.7 mtt -107.22 99.57 9.1 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.887 -0.325 . . . . 0.0 111.207 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 43.3 mm -89.44 150.83 3.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.99 0.424 . . . . 0.0 110.932 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.81 27.65 0.65 Allowed Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -66.57 -45.56 83.97 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.591 -0.603 . . . . 0.0 111.591 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 88.6 mt -61.16 -41.37 89.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.66 0.267 . . . . 0.0 111.365 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 162.42 -68.23 0.23 Allowed Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.644 -0.983 . . . . 0.0 110.644 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -77.4 168.36 54.45 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -108.39 124.08 49.83 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.064 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.929 HD13 ' H ' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -132.05 153.1 37.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.729 179.384 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 79.7 mttt -88.91 127.6 35.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.55 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.47 167.61 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.397 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 72.6 mtm180 -113.12 139.56 48.63 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.409 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -138.06 155.87 48.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.002 0.43 . . . . 0.0 111.349 -179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.49 ' CE1' HD13 ' A' ' 38' ' ' LEU . 61.2 m-85 -119.54 127.79 53.33 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.941 179.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -99.93 3.65 44.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.694 -179.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 66.0 tp60 -152.92 63.81 0.78 Allowed 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 5.2 tp -121.47 153.29 25.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.466 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 63' ' ' ILE . 17.1 tt -110.63 134.36 53.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.286 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.813 HD11 HG21 ' A' ' 75' ' ' VAL . 82.1 mt -123.61 143.25 37.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.068 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -105.99 127.26 53.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.783 179.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.6 ' O ' ' N ' ' A' ' 68' ' ' GLY . 71.5 mt -126.15 120.19 56.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.107 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.15 -59.75 0.12 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.91 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -176.38 15.9 0.04 OUTLIER Glycine 0 CA--C 1.527 0.801 0 C-N-CA 121.038 -0.601 . . . . 0.0 111.785 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -123.23 138.85 54.54 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.878 0.339 . . . . 0.0 110.282 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 39.9 mtmt -96.69 140.48 31.22 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.944 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.455 ' HB1' ' OE1' ' A' ' 92' ' ' GLN . . . -148.79 148.64 30.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.225 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 65.6 mt -120.8 131.04 73.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.85 175.72 43.25 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 66.2 m -77.26 132.92 38.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.706 0.288 . . . . 0.0 110.624 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.813 HG21 HD11 ' A' ' 64' ' ' ILE . 96.6 t -137.06 102.76 2.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.241 0 CA-C-O 120.94 0.4 . . . . 0.0 111.121 179.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.486 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -73.46 133.38 43.66 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.211 -178.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.585 HG13 HG13 ' A' ' 33' ' ' ILE . 40.2 t -110.66 129.05 66.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.604 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 34' ' ' GLU . . . -154.33 169.9 32.75 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -70.84 20.05 0.22 Allowed 'Trans proline' 0 C--N 1.302 -1.888 0 C-N-CA 122.967 2.445 . . . . 0.0 112.917 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -65.29 152.55 91.65 Favored Pre-proline 0 C--N 1.329 -0.285 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.455 ' O ' ' O ' ' A' ' 82' ' ' VAL . 10.0 Cg_endo -56.02 140.13 85.92 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 122.399 2.066 . . . . 0.0 112.491 -179.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.97 -150.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.183 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.706 179.522 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 -125.68 138.54 53.9 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.588 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.538 HD11 ' OD2' ' A' ' 25' ' ' ASP . 15.7 tt -127.63 138.99 53.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.197 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.6 mt -113.21 131.79 63.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.884 0.373 . . . . 0.0 110.698 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -90.82 -179.61 43.2 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.593 ' NE ' ' O ' ' A' ' 26' ' ' THR . 97.6 mtt180 -62.15 -18.37 60.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.679 0.276 . . . . 0.0 111.358 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -55.97 -48.04 76.53 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.519 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 88.6 mt -92.52 -42.79 9.51 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.943 -0.303 . . . . 0.0 111.509 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.424 ' O ' HG22 ' A' ' 93' ' ' ILE . 7.3 tt -53.4 -40.85 65.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.328 -178.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 70.1 p -78.1 -28.26 48.63 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.941 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.455 ' OE1' ' HB1' ' A' ' 71' ' ' ALA . 7.1 tt0 -61.28 -45.54 94.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.404 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.424 HG22 ' O ' ' A' ' 90' ' ' LEU . 14.0 tt -66.17 -28.76 44.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 120.955 -0.298 . . . . 0.0 110.866 -179.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.415 ' O ' ' OXT' ' A' ' 95' ' ' ALA . . . -84.79 -176.03 50.82 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.415 ' OXT' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.548 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo . . . . . 0 N--CA 1.483 0.889 0 N-CA-C 109.488 -1.005 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 55.0 tp60 -56.32 -35.86 68.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.8 pt -117.54 149.44 19.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 110.704 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.7 m -63.03 -40.17 96.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.564 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.668 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -80.09 -179.17 6.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.946 0.403 . . . . 0.0 111.022 -179.276 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.422 ' CD1' ' N ' ' A' ' 6' ' ' TRP . 39.5 m0 -90.04 138.18 31.73 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.955 179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -58.66 -40.02 82.29 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.135 -179.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.403 ' CD ' ' H ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -82.77 133.75 48.46 Favored Pre-proline 0 CA--C 1.535 0.402 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.692 -179.648 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.36 159.43 46.76 Favored 'Trans proline' 0 N--CA 1.492 1.421 0 C-N-CA 122.422 2.081 . . . . 0.0 112.061 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.1 mt -79.98 149.96 30.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.109 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.3 p -125.61 140.99 46.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.677 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 20.1 p -130.69 162.21 29.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.451 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.7 pt -123.17 158.36 28.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.823 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 43.7 mttm -128.14 121.48 29.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.187 179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.9 mt -130.12 118.89 45.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 C-N-CA 120.677 -0.409 . . . . 0.0 111.135 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 76.16 6.68 83.57 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.5 11.27 54.33 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.1 mt-30 -104.89 146.5 28.92 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.818 HD12 ' N ' ' A' ' 19' ' ' LEU . 4.5 mp -93.58 126.3 38.66 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.842 0.353 . . . . 0.0 110.563 -179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 35.9 mttp -139.11 160.07 40.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.761 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -112.95 140.39 47.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.218 -0.446 . . . . 0.0 109.922 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.53 152.14 41.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.929 0.395 . . . . 0.0 110.788 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 61.8 mt -102.05 143.26 32.11 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.599 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 68.7 mt -93.04 135.25 34.38 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.263 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.8 t70 -101.82 149.15 24.47 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.807 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 40.9 m -69.59 -28.51 66.02 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.959 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.6 51.85 0.09 OUTLIER Glycine 0 CA--C 1.526 0.742 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.597 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -68.55 -28.42 66.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.75 0.309 . . . . 0.0 110.547 179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.503 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 47.4 t0 57.17 30.46 18.36 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.887 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.0 m-20 -161.33 142.16 11.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.631 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 86.1 m -125.68 122.1 35.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.198 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.53 137.89 47.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.959 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.592 HG23 ' ND2' ' A' ' 83' ' ' ASN . 27.4 mt -116.82 138.38 47.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.326 179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.717 ' H ' ' ND2' ' A' ' 83' ' ' ASN . 85.9 tt0 -52.02 155.78 1.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.539 179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.41 ' N ' ' HG2' ' A' ' 34' ' ' GLU . 52.6 mt-10 -51.4 -0.1 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.372 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.584 ' H ' ' C ' ' A' ' 34' ' ' GLU . 23.1 ttt -93.51 105.86 17.88 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.4 OUTLIER 162.87 123.51 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.6 -179.428 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.921 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.8 OUTLIER 27.87 62.15 0.65 Allowed Pre-proline 0 N--CA 1.464 0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.423 179.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -69.2 116.31 4.44 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 C-N-CA 122.487 2.124 . . . . 0.0 112.136 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 123.01 138.89 5.37 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 41' ' ' ARG . 0.0 OUTLIER 54.38 96.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.907 0.384 . . . . 0.0 110.313 -179.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.624 ' CD2' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -148.57 -168.15 3.01 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.709 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.488 ' CD ' ' OD2' ' A' ' 60' ' ' ASP . 3.1 tttp -114.5 105.03 54.18 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.39 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -55.21 130.65 41.82 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.041 1.827 . . . . 0.0 112.578 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 58' ' ' GLN . 11.6 mmtp -143.43 156.4 44.64 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.297 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 69.0 mtm -129.82 143.62 50.9 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.964 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.6 pt -130.12 158.27 42.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.344 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -149.27 176.83 27.84 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.09 -0.804 . . . . 0.0 111.09 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 92.3 -63.22 2.38 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 72.3 mt -117.47 130.77 71.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.723 0.297 . . . . 0.0 110.681 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 88.32 7.45 72.85 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.02 138.47 0.13 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 57.2 t80 -48.37 105.19 0.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.238 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 15.5 tt -132.71 154.27 39.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.956 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 49.9 mttp -90.51 121.15 32.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.65 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.522 ' CG2' HD11 ' A' ' 76' ' ' LEU . 25.9 m -124.74 163.62 24.76 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.111 0 CA-C-O 120.781 0.324 . . . . 0.0 110.77 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.436 ' NH1' ' CZ2' ' A' ' 42' ' ' TRP . 95.1 mtt180 -121.54 147.8 45.33 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.645 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.624 ' HB3' HD12 ' A' ' 76' ' ' LEU . 1.5 pt20 -143.64 162.03 36.99 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 120.39 -0.524 . . . . 0.0 112.064 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -113.01 116.17 29.53 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.287 178.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' OD2' ' CD ' ' A' ' 43' ' ' LYS . 89.6 m-20 -70.79 -25.3 62.82 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 113.504 0.927 . . . . 0.0 113.504 -177.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 46.7 tt0 -137.55 66.24 1.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.508 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 7.1 tt -114.35 146.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.975 179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.694 HG22 HG12 ' A' ' 72' ' ' ILE . 19.1 pt -104.56 140.41 22.71 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 CA-C-O 121.017 0.437 . . . . 0.0 111.331 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 76.0 mt -120.91 136.69 57.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.35 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -109.51 126.54 53.64 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.509 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.56 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.7 mt -127.8 124.77 63.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.677 179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 64.49 -58.51 0.23 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 175.91 24.61 0.03 OUTLIER Glycine 0 CA--C 1.527 0.81 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.519 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -123.94 138.65 54.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.819 0.343 . . . . 0.0 110.445 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 37.1 mttt -93.68 137.73 32.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.447 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -142.62 148.67 37.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.55 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.694 HG12 HG22 ' A' ' 63' ' ' ILE . 64.9 mt -119.1 129.21 75.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.939 -179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -171.09 173.71 44.74 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.346 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 41.6 m -78.1 142.68 37.94 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 7.1 t -134.78 101.59 3.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 C-N-CA 120.288 -0.565 . . . . 0.0 112.0 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 58' ' ' GLN . 24.4 tp -74.89 123.21 24.65 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.787 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 33' ' ' ILE . 34.8 t -107.26 130.88 58.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.538 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -142.87 171.85 24.7 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -60.42 -18.7 54.99 Favored 'Trans proline' 0 N--CA 1.497 1.679 0 C-N-CA 123.275 2.65 . . . . 0.0 113.136 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.3 t -42.93 144.43 1.06 Allowed Pre-proline 0 C--N 1.328 -0.366 0 C-N-CA 120.961 -0.295 . . . . 0.0 110.539 -179.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -68.07 155.27 70.21 Favored 'Trans proline' 0 N--CA 1.495 1.57 0 C-N-CA 122.647 2.231 . . . . 0.0 112.649 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.433 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 38.62 -158.17 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.062 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.717 ' ND2' ' H ' ' A' ' 34' ' ' GLU . 4.8 m120 -126.68 147.53 49.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.838 -179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -127.81 136.77 59.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.1 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 74.1 mt -113.18 130.87 66.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.981 0.42 . . . . 0.0 110.845 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -89.61 -177.24 45.54 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.537 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.811 ' O ' HG23 ' A' ' 91' ' ' THR . 12.3 ptm180 -64.91 -18.87 65.59 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.583 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 33.5 p-10 -55.84 -42.42 75.75 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.203 -179.288 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.583 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 9.3 mp -91.82 -41.2 10.78 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.859 -0.337 . . . . 0.0 111.258 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.6 tp -54.29 -39.64 67.14 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.018 -179.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.811 HG23 ' O ' ' A' ' 87' ' ' ARG . 71.2 p -67.59 -33.21 74.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.76 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -59.61 -40.25 86.93 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.42 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 73.0 mt -87.05 -34.09 7.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.668 179.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.68 -165.7 38.81 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.591 -179.929 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo . . . . . 0 N--CA 1.483 0.903 0 N-CA-C 109.549 -0.981 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -58.59 -35.01 71.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.411 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 85.5 mt -59.51 -35.56 59.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.282 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.0 m -73.37 136.48 44.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.468 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.59 164.63 11.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.581 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 74.1 t-105 -65.59 116.32 6.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.485 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 62.7 mttt -113.96 146.0 40.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.622 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.663 HH11 ' CG ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -70.33 170.92 8.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.063 179.609 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -50.49 145.32 22.32 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.319 2.012 . . . . 0.0 112.178 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.654 HD22 ' N ' ' A' ' 10' ' ' LEU . 2.8 mm? -85.99 154.04 21.73 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.334 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.3 136.63 29.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.571 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 5.8 t -129.57 157.84 40.94 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.642 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.423 HD11 ' HZ1' ' A' ' 20' ' ' LYS . 27.1 pt -123.83 162.09 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.859 -179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -133.38 125.06 28.32 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.718 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.507 ' CG2' HG23 ' A' ' 64' ' ' ILE . 28.7 pt -144.85 140.22 23.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.342 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 46.5 39.53 10.34 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.04 8.32 58.09 Favored Glycine 0 CA--C 1.526 0.769 0 C-N-CA 121.08 -0.581 . . . . 0.0 112.09 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -101.91 140.16 36.57 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.314 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 42.3 mt -103.24 126.71 50.55 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.175 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.603 ' HZ2' HD21 ' A' ' 83' ' ' ASN . 6.2 mtmp? -140.21 162.01 36.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.3 mm-40 -108.33 153.26 23.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.789 179.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.05 150.03 39.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.013 0.435 . . . . 0.0 111.058 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.5 mt -106.01 141.66 37.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.273 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 46.8 mt -90.67 138.3 31.68 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -141.81 90.91 2.31 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.965 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.3 m -61.99 -25.92 67.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.82 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -66.87 -14.61 63.43 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -115.08 136.85 52.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.778 0.323 . . . . 0.0 110.727 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -95.18 -22.64 17.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.495 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -90.42 158.92 16.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.878 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.401 ' OG1' ' ND2' ' A' ' 88' ' ' ASN . 89.5 m -119.5 129.81 54.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.077 179.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.461 HG11 HG21 ' A' ' 80' ' ' THR . 25.3 t -133.15 137.59 53.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.05 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.745 HG23 ' ND2' ' A' ' 83' ' ' ASN . 69.1 mt -120.03 136.38 57.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.732 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.505 ' OE1' ' O ' ' A' ' 80' ' ' THR . 22.0 tp10 -59.53 143.37 50.34 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.222 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.45 130.94 44.36 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.46 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 3.9 mtp -172.73 136.04 0.7 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.401 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 15.6 t 50.93 -127.33 2.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.984 0.421 . . . . 0.0 110.446 -179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.1 mm? 59.13 112.99 0.02 OUTLIER Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.537 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.523 ' C ' ' H ' ' A' ' 41' ' ' ARG . 75.7 Cg_exo -44.85 167.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.258 1.972 . . . . 0.0 112.523 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.598 ' O ' ' CE2' ' A' ' 42' ' ' TRP . . . -61.29 4.4 0.37 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.523 ' H ' ' C ' ' A' ' 39' ' ' PRO . 40.8 ttp180 -92.19 122.75 34.97 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.896 0.379 . . . . 0.0 111.2 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.694 ' CD1' ' NH2' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -163.26 -175.24 4.17 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.49 179.249 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.92 93.86 47.93 Favored Pre-proline 0 CA--C 1.532 0.286 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.442 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -50.9 135.29 43.18 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.439 2.093 . . . . 0.0 112.507 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 10.9 mmtm -150.74 157.88 43.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.974 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 56.7 ttp -136.28 137.96 41.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.8 mm -115.84 131.15 69.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -122.67 -47.78 0.26 Allowed Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -55.19 -36.53 62.11 Favored Glycine 0 CA--C 1.527 0.837 0 C-N-CA 121.499 -0.381 . . . . 0.0 112.416 -178.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 69.4 mt -118.89 132.86 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 120.641 -0.423 . . . . 0.0 111.952 -178.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 69.09 26.23 74.83 Favored Glycine 0 CA--C 1.525 0.665 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.887 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.55 -153.84 52.68 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.289 -1.124 . . . . 0.0 110.289 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -101.05 123.36 45.1 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.394 . . . . 0.0 110.818 179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.0 tp -149.7 152.99 11.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -106.44 116.97 32.85 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.394 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.2 m -127.2 162.69 31.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.042 0.448 . . . . 0.0 111.105 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.694 ' NH2' ' CD1' ' A' ' 42' ' ' TRP . 22.0 mtp180 -115.46 144.91 43.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.729 179.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.431 ' OE1' HD23 ' A' ' 76' ' ' LEU . 14.7 pt20 -142.77 160.54 40.12 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.157 -0.617 . . . . 0.0 111.837 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -109.47 112.48 24.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.376 179.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -68.64 -27.33 65.91 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 113.728 1.01 . . . . 0.0 113.728 -178.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 68.9 tp60 -153.76 78.9 1.14 Allowed 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.118 -178.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.3 tt -115.84 149.42 18.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.428 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.41 HD13 HG21 ' A' ' 63' ' ' ILE . 51.3 mt -101.57 130.96 50.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.672 -179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.527 HD11 HG11 ' A' ' 75' ' ' VAL . 71.1 mt -123.09 139.81 48.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.606 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -96.49 117.28 30.57 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 74.1 mt -127.07 125.52 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.235 -179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.74 46.13 24.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.791 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 60.92 21.12 58.42 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.245 -0.742 . . . . 0.0 111.245 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -123.58 141.88 51.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.835 0.35 . . . . 0.0 110.175 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 51.6 mttp -81.75 140.48 34.24 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.812 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.28 136.9 19.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.802 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.402 HG22 HG12 ' A' ' 63' ' ' ILE . 12.6 pt -127.45 133.55 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.712 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -176.53 176.08 47.74 Favored Glycine 0 CA--C 1.523 0.535 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.439 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 78.8 m -82.1 140.33 33.9 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.785 0.326 . . . . 0.0 110.928 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.766 HG23 ' O ' ' A' ' 75' ' ' VAL . 10.8 m -139.79 104.55 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.18 179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.431 HD23 ' OE1' ' A' ' 58' ' ' GLN . 1.1 mt -67.82 134.2 50.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.254 0.55 . . . . 0.0 111.485 -178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 25.2 t -109.14 129.61 63.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.771 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -152.45 173.34 31.54 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.605 -179.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.54 -18.0 61.24 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 123.28 2.653 . . . . 0.0 113.031 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.505 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.3 OUTLIER -42.15 147.6 0.55 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.809 -179.362 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.423 ' O ' ' C ' ' A' ' 82' ' ' VAL . 27.5 Cg_endo -63.82 149.54 90.48 Favored 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.732 2.288 . . . . 0.0 112.799 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.63 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.3 t 32.78 -149.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.499 179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.745 ' ND2' HG23 ' A' ' 33' ' ' ILE . 23.7 m-20 -124.83 150.48 46.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.844 -179.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.78 138.93 53.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 27.1 mm -109.56 130.03 63.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.804 -0.358 . . . . 0.0 110.571 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -100.28 177.2 28.45 Favored Glycine 0 CA--C 1.527 0.82 0 C-N-CA 121.071 -0.585 . . . . 0.0 111.678 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.464 ' O ' ' OG1' ' A' ' 91' ' ' THR . 58.8 mtp180 -59.25 -20.67 56.11 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.676 0.274 . . . . 0.0 111.114 179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.558 ' OD1' ' N ' ' A' ' 89' ' ' LEU . 35.7 p-10 -56.61 -63.52 1.17 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.411 -179.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.558 ' N ' ' OD1' ' A' ' 88' ' ' ASN . 44.5 mt -67.38 -38.48 84.81 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.318 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 80.7 mt -61.29 -36.34 79.81 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.016 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.464 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 90.3 m -58.87 -38.82 79.67 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.469 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -56.05 -39.42 71.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.555 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 75.4 mt -95.37 -75.6 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.525 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.71 -161.1 36.36 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 111.026 -0.83 . . . . 0.0 111.026 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.577 -179.939 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo . . . . . 0 N--CA 1.485 0.971 0 N-CA-C 109.556 -0.978 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -58.91 -35.14 72.57 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.463 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 73.0 mt -117.17 138.12 48.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.459 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 27.3 m -107.85 136.01 48.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.575 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.437 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -113.77 149.09 35.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.345 179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 93.9 m95 -61.09 143.4 55.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.433 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 16.7 ttmm -57.32 -40.92 78.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.352 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -91.22 112.41 53.8 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.382 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -78.29 -57.8 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.278 0 C-N-CA 122.012 1.808 . . . . 0.0 112.131 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 33.5 tp -90.46 133.01 35.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.482 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 22' ' ' ALA . 6.2 m -87.75 138.38 19.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.569 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 17.0 p -129.52 160.17 34.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 25.6 pt -122.35 158.33 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.126 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.623 ' HG2' HD23 ' A' ' 19' ' ' LEU . 5.3 mtpm? -128.65 123.61 33.65 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.927 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.415 HD13 HG21 ' A' ' 15' ' ' ILE . 20.9 pt -139.73 131.63 33.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.547 179.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.3 0.61 46.73 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.3 12.2 52.24 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -108.98 146.63 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.337 . . . . 0.0 110.119 179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.623 HD23 ' HG2' ' A' ' 14' ' ' LYS . 17.0 mt -91.9 127.96 37.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.094 0.473 . . . . 0.0 111.064 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 8.7 tptt -133.93 155.63 49.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.435 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.13 144.45 35.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.726 -0.39 . . . . 0.0 110.509 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.446 ' O ' HG23 ' A' ' 11' ' ' VAL . . . -147.31 147.93 30.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.652 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.4 mp -110.99 147.47 34.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.482 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 41.0 mt -81.85 141.84 33.07 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' A' ' 28' ' ' ALA . 8.7 p-10 -98.77 165.15 11.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.157 0.504 . . . . 0.0 111.303 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 58.9 m -65.29 -29.17 69.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.194 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 154.12 87.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.604 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -111.75 143.4 42.74 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.744 0.306 . . . . 0.0 110.519 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -60.27 -37.03 79.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -131.27 176.02 8.63 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.92 0.391 . . . . 0.0 110.893 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 1.021 HG22 ' H ' ' A' ' 86' ' ' GLY . 9.5 p -113.95 153.24 29.62 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.249 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 24.5 m -137.92 137.29 44.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.616 179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.594 HD11 HD11 ' A' ' 38' ' ' LEU . 34.3 pt -132.23 158.52 43.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.919 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.493 ' OE1' ' O ' ' A' ' 80' ' ' THR . 52.0 tp10 -86.57 128.81 35.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.007 0.432 . . . . 0.0 110.385 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -52.95 138.24 30.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.116 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.407 ' H ' ' H ' ' A' ' 37' ' ' SER . 3.6 mtp 178.57 0.4 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.009 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' A' ' 38' ' ' LEU . 48.0 t -164.94 -147.6 0.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.589 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.594 HD11 HD11 ' A' ' 33' ' ' ILE . 10.3 mt 65.14 66.97 0.83 Allowed Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.362 179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -63.24 146.48 93.93 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.751 2.3 . . . . 0.0 111.606 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.25 -159.6 19.82 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.582 ' NH1' ' O ' ' A' ' 42' ' ' TRP . 28.6 ttt-85 -96.12 147.65 23.51 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.846 0.355 . . . . 0.0 110.658 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.582 ' O ' ' NH1' ' A' ' 41' ' ' ARG . 0.0 OUTLIER -107.18 161.11 15.06 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.164 -179.595 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 6.1 mttp -111.55 101.96 52.17 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.077 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -50.82 132.59 37.47 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.286 1.99 . . . . 0.0 112.763 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -144.81 147.69 33.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.903 179.521 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.7 mtt -111.36 137.15 49.49 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.649 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 12.9 tt -127.86 138.79 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.304 179.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -140.28 18.73 2.87 Favored Glycine 0 CA--C 1.524 0.611 0 C-N-CA 120.818 -0.705 . . . . 0.0 111.512 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -59.31 -41.32 96.82 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 79.6 mt -63.53 -40.14 87.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.706 0.289 . . . . 0.0 110.985 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 154.68 -63.34 0.35 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.44 53.97 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -108.59 123.24 48.63 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.579 -0.449 . . . . 0.0 110.851 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.7 tt -131.66 148.31 32.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.961 179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 22.1 mtpt -91.93 128.9 37.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.912 0.387 . . . . 0.0 110.763 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.9 m -126.68 161.89 32.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.384 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -109.39 130.81 55.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.371 . . . . 0.0 110.782 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.439 ' NE2' HG21 ' A' ' 74' ' ' THR . 52.4 tt0 -108.63 131.31 55.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.28 -179.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -106.68 118.6 37.1 Favored 'General case' 0 C--N 1.332 -0.181 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.287 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.524 ' OD1' HG23 ' A' ' 74' ' ' THR . 84.1 m-20 -108.91 160.33 16.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.002 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 60.12 40.07 18.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.245 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 75' ' ' VAL . 13.4 tt -112.5 140.38 32.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 120.896 0.379 . . . . 0.0 110.374 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.745 HG22 HG12 ' A' ' 72' ' ' ILE . 19.9 pt -101.48 136.73 31.97 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.056 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.741 HD11 HG11 ' A' ' 75' ' ' VAL . 76.2 mt -121.01 135.41 61.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.017 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 87.1 mt-10 -100.07 120.37 39.74 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.523 -0.471 . . . . 0.0 110.847 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.026 HG22 ' H ' ' A' ' 67' ' ' ALA . 24.9 mt -95.75 -155.59 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 1.026 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -56.93 72.11 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.782 0.325 . . . . 0.0 110.934 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.79 16.95 79.15 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.602 -0.599 . . . . 0.0 111.602 179.431 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -128.27 142.34 51.18 Favored 'General case' 0 N--CA 1.462 0.157 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.098 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -95.5 142.82 27.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.659 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.593 ' HB2' HE22 ' A' ' 92' ' ' GLN . . . -147.23 149.87 33.76 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.406 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.745 HG12 HG22 ' A' ' 63' ' ' ILE . 56.6 mt -122.71 126.32 73.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.924 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.29 168.5 40.5 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.355 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.524 HG23 ' OD1' ' A' ' 60' ' ' ASP . 47.0 m -79.03 143.38 35.7 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.661 0.267 . . . . 0.0 110.885 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.741 HG11 HD11 ' A' ' 64' ' ' ILE . 34.8 m -139.01 104.28 2.21 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.483 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.5 mt -67.58 146.72 53.61 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.63 -178.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.9 t -115.14 126.73 72.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.461 179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.449 ' O ' ' OE1' ' A' ' 34' ' ' GLU . . . -140.89 173.47 23.18 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 -179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -73.0 27.07 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.67 0 C-N-CA 123.293 2.662 . . . . 0.0 112.667 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.493 ' O ' ' OE1' ' A' ' 34' ' ' GLU . 0.0 OUTLIER -62.58 149.99 87.3 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.533 -179.854 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -62.28 -30.78 81.74 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.355 2.037 . . . . 0.0 112.443 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.654 HG12 ' H ' ' A' ' 83' ' ' ASN . 2.8 t -146.52 -135.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 121.235 0.54 . . . . 0.0 111.031 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.654 ' H ' HG12 ' A' ' 82' ' ' VAL . 77.1 m-20 -129.53 131.76 46.68 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.993 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.9 tt -130.56 140.91 47.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.957 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -104.01 135.27 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.928 0.394 . . . . 0.0 111.367 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 1.021 ' H ' HG22 ' A' ' 31' ' ' THR . . . -90.65 178.78 42.81 Favored Glycine 0 CA--C 1.526 0.749 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.658 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -61.69 -25.53 67.47 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -54.3 -48.32 71.41 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.571 -179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.479 HD22 ' N ' ' A' ' 89' ' ' LEU . 4.1 mm? -81.4 -40.57 23.23 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.766 0.317 . . . . 0.0 111.433 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 7.3 tt -53.57 -37.18 62.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.833 -179.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.505 ' CG2' ' N ' ' A' ' 92' ' ' GLN . 4.5 t -43.19 -42.44 4.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.482 -179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.593 HE22 ' HB2' ' A' ' 71' ' ' ALA . 1.6 tt0 -63.78 -173.51 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.143 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.75 HD11 HG21 ' A' ' 66' ' ' ILE . 78.9 mt 60.83 57.25 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.509 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -56.05 -33.78 61.24 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.441 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.555 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo . . . . . 0 N--CA 1.484 0.927 0 N-CA-C 109.674 -0.933 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -108.85 150.96 26.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.418 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.417 ' O ' ' C ' ' A' ' 4' ' ' THR . 28.7 pt -123.78 157.52 30.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.874 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.417 ' C ' ' O ' ' A' ' 3' ' ' ILE . 4.0 m 37.08 54.69 1.25 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.921 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -88.57 129.06 35.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.466 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -133.7 -52.52 0.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.5 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 6.5 ttmm -121.47 138.63 54.21 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.254 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.472 HH11 ' CG ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -61.4 129.1 90.74 Favored Pre-proline 0 CA--C 1.534 0.337 0 C-N-CA 120.767 -0.373 . . . . 0.0 110.039 -179.941 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.34 -22.53 25.11 Favored 'Trans proline' 0 N--CA 1.492 1.428 0 C-N-CA 122.015 1.81 . . . . 0.0 112.036 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 17.5 tp -90.54 126.98 36.1 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.377 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.4 p -134.7 142.13 41.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.6 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 29.9 p -126.75 156.9 40.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.504 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 pt -124.5 160.04 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.647 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.442 ' HG2' HD23 ' A' ' 19' ' ' LEU . 44.3 mtpt -126.3 121.41 32.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.6 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.476 HG22 HG23 ' A' ' 64' ' ' ILE . 27.7 pt -142.43 137.48 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.405 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.58 -4.54 6.89 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.8 13.13 35.36 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 -179.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -116.95 149.83 39.53 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.442 HD23 ' HG2' ' A' ' 14' ' ' LYS . 5.2 mt -91.9 130.16 37.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.96 0.41 . . . . 0.0 110.771 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -132.64 157.98 43.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.52 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -114.73 145.68 41.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.33 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -149.78 151.71 34.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.945 0.402 . . . . 0.0 111.069 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 49.9 mt -101.06 148.72 24.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.133 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 67.7 mt -80.92 134.98 35.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.568 -179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.699 ' OD1' HD11 ' A' ' 84' ' ' ILE . 22.0 t70 -88.44 144.47 26.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.679 179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 60.3 m -61.68 -27.86 68.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.981 0.42 . . . . 0.0 110.048 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.406 ' HA2' ' NH1' ' A' ' 87' ' ' ARG . . . 168.74 74.26 0.04 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' N ' ' OD2' ' A' ' 25' ' ' ASP . . . -97.08 131.01 44.29 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.0 -0.371 . . . . 0.0 110.0 179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.12 -40.4 97.51 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.893 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.1 m-20 -116.3 165.46 13.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.034 0.445 . . . . 0.0 111.231 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.613 HG23 ' HA ' ' A' ' 85' ' ' ILE . 97.0 m -115.08 137.18 52.3 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.815 179.451 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 11.4 p -138.95 140.14 39.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.082 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.9 pt -129.78 157.98 42.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.453 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -57.63 151.39 17.29 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.045 179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -90.52 135.4 33.72 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.306 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.604 ' O ' ' N ' ' A' ' 38' ' ' LEU . 46.9 ttm -153.7 145.85 23.76 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.473 ' C ' ' O ' ' A' ' 36' ' ' MET . 46.7 t -32.58 88.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.891 -179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.604 ' N ' ' O ' ' A' ' 36' ' ' MET . 1.7 tp -125.83 82.82 63.64 Favored Pre-proline 0 C--O 1.232 0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.503 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.461 ' O ' ' O ' ' A' ' 38' ' ' LEU . 77.6 Cg_exo -47.35 -173.57 0.0 OUTLIER 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 122.792 2.328 . . . . 0.0 112.58 -179.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.66 -123.72 6.54 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.483 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 30.3 mmt180 -118.57 142.55 47.51 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 25.4 p-90 -115.22 129.79 56.74 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.956 0.408 . . . . 0.0 111.092 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.6 mmtt -118.89 109.91 38.97 Favored Pre-proline 0 CA--C 1.535 0.381 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.825 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -72.71 139.65 31.16 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 C-N-CA 121.79 1.66 . . . . 0.0 112.87 -179.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG2' HG23 ' A' ' 47' ' ' ILE . 15.5 tttp -135.14 141.81 46.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.423 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -112.24 89.73 3.15 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 120.629 -0.429 . . . . 0.0 111.435 -179.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.479 HG23 ' HG2' ' A' ' 45' ' ' LYS . 42.6 pt -122.38 -170.15 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.775 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 50' ' ' ILE . . . 138.95 -41.86 1.31 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.0 -73.5 0.13 Allowed Glycine 0 CA--C 1.527 0.795 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.401 ' N ' ' O ' ' A' ' 48' ' ' GLY . 71.3 mt -112.34 141.52 27.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.696 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 87.58 21.91 45.73 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.479 -1.049 . . . . 0.0 110.479 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 89.22 -171.2 38.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -109.94 135.78 50.25 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.719 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.7 tt -117.59 144.78 24.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.895 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -82.65 115.68 21.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.83 0.348 . . . . 0.0 110.738 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.4 t -115.2 136.76 50.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.084 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.458 ' O ' ' O ' ' A' ' 77' ' ' VAL . 41.8 ttm180 -97.26 143.09 28.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.688 -179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.701 ' HB3' HD12 ' A' ' 76' ' ' LEU . 18.4 pt20 -144.66 160.2 41.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.009 0.433 . . . . 0.0 111.768 -179.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.483 ' CE2' ' O ' ' A' ' 41' ' ' ARG . 93.4 m-85 -113.85 121.37 43.8 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.478 178.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -79.35 -13.82 59.38 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -177.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 47.2 tt0 -150.82 69.81 0.98 Allowed 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.662 -179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.1 tt -116.31 155.81 17.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.295 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.53 HG12 HG22 ' A' ' 72' ' ' ILE . 67.8 mt -108.38 133.33 53.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.882 0.372 . . . . 0.0 111.055 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.761 HD11 ' CG2' ' A' ' 75' ' ' VAL . 75.5 mt -119.46 136.04 57.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.607 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 78.3 mm-40 -103.61 120.83 41.68 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.234 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.552 HD11 HD23 ' A' ' 89' ' ' LEU . 73.7 mt -127.47 125.27 65.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.219 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 49.16 46.66 22.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.205 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 65.96 19.08 67.38 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.705 -0.558 . . . . 0.0 111.705 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -118.86 139.2 52.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.888 0.344 . . . . 0.0 110.521 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 57.9 mttm -82.28 146.3 29.53 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.555 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.71 139.07 19.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.178 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.53 HG22 HG12 ' A' ' 63' ' ' ILE . 14.1 pt -128.84 133.41 66.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 C-N-CA 120.74 -0.384 . . . . 0.0 111.017 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.11 179.2 47.36 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.4 m -75.41 138.17 41.5 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.761 ' CG2' HD11 ' A' ' 64' ' ' ILE . 98.0 t -128.41 96.24 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.692 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.701 HD12 ' HB3' ' A' ' 58' ' ' GLN . 23.2 tp -63.99 122.82 17.45 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' A' ' 57' ' ' ARG . 21.4 t -113.77 127.51 71.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.718 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -137.76 171.15 23.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.435 ' O ' ' C ' ' A' ' 80' ' ' THR . 21.0 Cg_endo -61.98 -20.07 68.25 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 123.44 2.76 . . . . 0.0 113.358 -179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.542 HG23 ' O ' ' A' ' 80' ' ' THR . 9.2 t -39.99 123.64 1.61 Allowed Pre-proline 0 CA--C 1.533 0.323 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -72.98 8.73 1.58 Allowed 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.218 1.945 . . . . 0.0 113.401 -178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.475 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER -127.56 -175.58 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.286 0 CA-C-O 121.099 0.476 . . . . 0.0 111.385 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 82.6 m-20 -139.01 127.98 23.69 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.937 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.699 HD11 ' OD1' ' A' ' 25' ' ' ASP . 15.9 tt -128.45 136.26 60.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.048 179.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.613 ' HA ' HG23 ' A' ' 31' ' ' THR . 67.3 mt -108.28 135.22 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 121.009 0.433 . . . . 0.0 111.17 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -103.76 -171.58 25.52 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.828 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.653 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -60.85 -19.46 60.03 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.488 -0.356 . . . . 0.0 111.941 -179.639 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -54.47 -48.61 71.59 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.29 -0.564 . . . . 0.0 111.084 -179.117 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.58 HD12 ' N ' ' A' ' 89' ' ' LEU . 10.2 mp -86.08 -43.49 13.04 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.725 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 74.3 mt -58.83 -42.98 90.54 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.984 -179.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.556 HG22 ' O ' ' A' ' 87' ' ' ARG . 5.1 t -65.27 -36.95 85.7 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.755 0.312 . . . . 0.0 110.983 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 46.0 tt0 -53.82 -39.48 65.56 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.412 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 21.0 mm -85.11 -31.46 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.02 179.034 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.78 -167.21 38.21 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.568 -179.939 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo . . . . . 0 N--CA 1.482 0.819 0 N-CA-C 109.538 -0.985 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -114.08 149.59 35.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.808 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.517 HD12 HD11 ' A' ' 5' ' ' LEU . 29.4 pt -124.29 153.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.622 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 81.2 p -110.02 -5.54 15.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.062 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.517 HD11 HD12 ' A' ' 3' ' ' ILE . 0.7 OUTLIER -68.16 -30.52 69.66 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.843 0.354 . . . . 0.0 110.416 179.842 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 1.5 p-90 -55.17 -26.69 40.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.712 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -62.29 -37.4 85.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.731 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.61 ' O ' ' N ' ' A' ' 10' ' ' LEU . 6.0 mpt_? -46.45 -61.66 2.48 Favored Pre-proline 0 N--CA 1.465 0.281 0 C-N-CA 120.962 -0.295 . . . . 0.0 111.254 -179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.434 ' CD ' ' CB ' ' A' ' 8' ' ' ARG . 50.0 Cg_exo -37.58 -17.0 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.891 2.394 . . . . 0.0 112.764 179.435 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 8' ' ' ARG . 37.3 tp -84.25 130.7 34.8 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.858 0.361 . . . . 0.0 110.393 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 40.8 t -114.2 135.16 54.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.565 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 27.2 m -99.46 132.5 44.75 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.625 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 40.0 pt -126.23 162.13 30.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.128 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.7 tttt -134.78 121.81 21.23 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.646 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 43.6 pt -142.44 139.77 28.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 68.85 6.85 53.79 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.04 2.39 71.47 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.709 -0.957 . . . . 0.0 110.709 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.435 ' CB ' ' NZ ' ' A' ' 20' ' ' LYS . 92.2 mm-40 -106.19 150.3 25.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.871 0.367 . . . . 0.0 110.437 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.3 mt -96.62 126.9 42.11 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.074 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.435 ' NZ ' ' CB ' ' A' ' 18' ' ' GLN . 43.0 mttp -146.39 165.66 28.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.006 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -117.69 146.84 43.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.929 179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -143.7 153.22 42.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.951 0.405 . . . . 0.0 110.861 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.509 ' C ' HD12 ' A' ' 24' ' ' LEU . 53.9 mt -97.17 136.82 37.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.838 179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.803 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.5 mp -98.89 124.43 43.82 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.497 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 85' ' ' ILE . 17.1 t70 -173.38 157.53 3.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.27 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.785 HG21 HH21 ' A' ' 87' ' ' ARG . 46.3 m -78.53 -114.38 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.599 ' N ' HG22 ' A' ' 26' ' ' THR . . . 57.59 13.79 12.77 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -162.02 135.89 6.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -62.28 -40.02 94.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -127.68 167.92 15.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.89 -179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 85' ' ' ILE . 24.7 m -81.76 137.09 35.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.018 -179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.433 HG12 ' HB2' ' A' ' 76' ' ' LEU . 26.8 m -133.14 144.75 35.47 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.163 179.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 pt -130.92 157.46 43.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 C-N-CA 120.756 -0.378 . . . . 0.0 111.363 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.8 pt-20 -65.11 164.34 13.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.536 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -88.68 140.27 29.62 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.26 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 69.4 mtm -139.76 -75.81 0.35 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.571 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.537 ' O ' HD12 ' A' ' 38' ' ' LEU . 41.3 t 179.86 105.18 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.054 179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 37' ' ' SER . 5.6 mp -119.95 89.92 43.13 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.997 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_exo -48.03 154.55 2.19 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.367 2.044 . . . . 0.0 112.155 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.0 -141.96 16.04 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 -116.15 148.98 39.78 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.26 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.507 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -109.68 160.29 16.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 -179.573 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.433 ' NZ ' ' OD2' ' A' ' 60' ' ' ASP . 20.7 mttt -115.48 90.31 25.06 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.337 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -52.96 137.38 61.6 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 122.728 2.286 . . . . 0.0 112.882 -179.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -147.08 151.06 36.24 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.153 179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 52.1 ttm -110.13 132.94 53.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.719 0.295 . . . . 0.0 110.296 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 16.6 tt -129.89 142.46 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.927 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -84.55 105.78 2.86 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.35 172.84 35.14 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.3 mm -60.58 -47.39 93.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.883 0.373 . . . . 0.0 110.378 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -62.07 -36.28 92.69 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 165.04 -125.89 1.42 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -110.57 130.12 55.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.891 0.377 . . . . 0.0 110.516 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.1 tp -130.65 147.93 33.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.244 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -87.23 127.24 35.16 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.275 179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.2 p -124.66 143.87 36.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.867 0.365 . . . . 0.0 110.217 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 -110.1 151.29 27.41 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -135.88 158.58 44.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.923 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.4 t80 -118.77 132.83 56.15 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.458 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 92.1 m-20 -110.43 156.46 20.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.193 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 67.1 33.2 5.75 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.185 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HG12 ' A' ' 75' ' ' VAL . 18.1 tt -110.62 142.66 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.922 0.391 . . . . 0.0 110.829 -179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.548 HG12 HG22 ' A' ' 72' ' ' ILE . 44.4 mt -109.44 136.61 44.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.747 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 33.9 pt -127.97 153.12 36.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.414 179.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.413 ' O ' HD13 ' A' ' 66' ' ' ILE . 95.8 mt-10 -112.86 122.97 49.23 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.566 ' O ' ' N ' ' A' ' 68' ' ' GLY . 42.2 mm -121.52 121.98 65.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.214 -179.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 63.48 -61.08 0.16 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.041 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 179.11 25.36 0.04 OUTLIER Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.407 ' CG ' ' O ' ' A' ' 93' ' ' ILE . 86.4 t60 -127.8 140.02 52.3 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.872 0.367 . . . . 0.0 110.502 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 14.6 mttt -90.38 124.31 34.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.323 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.56 142.68 50.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.593 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.548 HG22 HG12 ' A' ' 63' ' ' ILE . 9.8 pt -124.08 133.96 67.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.49 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 173.49 -176.56 46.1 Favored Glycine 0 CA--C 1.525 0.658 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.705 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 54.5 m -78.17 143.39 37.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.725 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.697 ' O ' HG13 ' A' ' 75' ' ' VAL . 7.8 p -136.56 100.57 2.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.453 179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.523 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.2 mp -62.26 137.16 58.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.293 0.568 . . . . 0.0 111.428 -178.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.0 t -116.66 129.97 72.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.228 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -135.01 165.17 24.7 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -66.02 -18.3 56.67 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 123.076 2.517 . . . . 0.0 113.039 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.4 t -53.57 139.99 48.23 Favored Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 120.909 -0.316 . . . . 0.0 110.535 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.19 156.95 50.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 122.446 2.097 . . . . 0.0 112.58 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.752 HG12 ' H ' ' A' ' 83' ' ' ASN . 3.4 t 65.88 178.01 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.097 179.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.752 ' H ' HG12 ' A' ' 82' ' ' VAL . 75.5 m-20 -126.64 140.05 52.71 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.682 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.1 tt -128.3 136.34 60.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.052 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.513 ' HA ' HG23 ' A' ' 31' ' ' THR . 68.9 mt -108.17 130.17 61.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.719 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -88.99 -178.74 45.97 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.56 -0.616 . . . . 0.0 111.56 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.785 HH21 HG21 ' A' ' 26' ' ' THR . 12.1 ptp180 -65.37 -18.44 65.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.594 -0.303 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 44.1 t30 -56.85 -55.29 36.36 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 120.801 -0.36 . . . . 0.0 111.087 -179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 52.2 mt -75.46 -36.85 60.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.834 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 3.5 tp -55.11 -38.77 68.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.94 0.4 . . . . 0.0 110.241 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.7 m -61.67 -37.79 85.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.821 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -96.54 131.62 42.97 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.69 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.407 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 18.7 tt -170.66 -3.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.386 179.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.77 -165.78 40.56 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.372 0 CA-C-O 117.921 -1.038 . . . . 0.0 110.636 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.489 ' O ' ' O ' ' A' ' 4' ' ' THR . 9.6 Cg_endo . . . . . 0 N--CA 1.484 0.914 0 N-CA-C 109.535 -0.987 . . . . 0.0 109.535 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -59.89 -37.64 79.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.406 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.82 -32.38 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.173 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.917 HG22 ' H ' ' A' ' 6' ' ' TRP . 33.1 m -108.64 138.59 44.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.959 0.409 . . . . 0.0 110.978 -179.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 pp -95.65 1.14 53.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.809 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.917 ' H ' HG22 ' A' ' 4' ' ' THR . 89.5 m95 -102.85 132.66 48.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.013 0.435 . . . . 0.0 110.928 -179.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 tptt -140.84 133.47 28.71 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.903 179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 15.1 mtp180 -62.56 148.28 90.94 Favored Pre-proline 0 C--N 1.328 -0.332 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.165 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.95 146.09 81.68 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.44 2.093 . . . . 0.0 112.243 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.8 mt -87.14 149.09 24.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.069 179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 11' ' ' VAL . 1.5 m -105.04 134.05 47.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.013 0.435 . . . . 0.0 111.277 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.49 HG22 ' OE1' ' A' ' 21' ' ' GLU . 20.1 p -126.72 158.29 36.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.81 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.405 HG21 HD13 ' A' ' 13' ' ' ILE . 30.1 pt -122.06 157.6 26.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.895 0.379 . . . . 0.0 110.919 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 39.8 mtpt -128.83 126.39 39.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.382 179.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 76.2 mt -131.89 114.15 23.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.99 179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.02 3.42 68.67 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.88 14.94 30.15 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 89.5 mm-40 -105.18 148.38 26.98 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.1 mt -100.09 127.5 46.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.932 0.396 . . . . 0.0 111.094 -179.29 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -137.79 160.12 40.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.499 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.49 ' OE1' HG22 ' A' ' 12' ' ' THR . 76.7 mm-40 -109.95 146.58 34.97 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.41 148.91 32.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.973 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 23' ' ' LEU . 5.2 mp -104.26 145.32 30.4 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.49 179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.401 HD12 ' HB ' ' A' ' 85' ' ' ILE . 28.3 tp -94.05 127.09 39.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.433 . . . . 0.0 109.95 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -131.03 99.02 4.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.944 0.402 . . . . 0.0 111.181 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.5 m -67.55 -21.81 65.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.703 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.51 -19.48 79.28 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.319 -0.712 . . . . 0.0 111.319 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -104.04 125.88 50.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.731 0.301 . . . . 0.0 110.751 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.467 ' HA ' ' H ' ' A' ' 87' ' ' ARG . 85.3 m-20 -83.73 -39.03 20.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.063 0.459 . . . . 0.0 110.537 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -79.51 152.96 29.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.113 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 84' ' ' ILE . 54.8 m -118.92 129.32 55.12 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.143 179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.4 t -133.29 131.58 58.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.521 HD12 ' CG2' ' A' ' 75' ' ' VAL . 54.5 mt -120.05 136.61 56.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.184 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.429 ' CB ' ' O ' ' A' ' 80' ' ' THR . 14.5 pt-20 -53.67 159.17 1.65 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.782 179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -89.49 136.78 32.83 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.979 179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.9 mtp 175.23 -167.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 110.728 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 38' ' ' LEU . 66.4 p 46.09 -148.64 0.11 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.642 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.504 ' O ' ' O ' ' A' ' 37' ' ' SER . 0.8 OUTLIER -26.83 148.11 0.03 OUTLIER Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.105 -179.425 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -56.89 140.0 90.79 Favored 'Trans proline' 0 N--CA 1.493 1.461 0 C-N-CA 122.254 1.969 . . . . 0.0 112.248 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 41' ' ' ARG . . . -87.98 119.03 5.2 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.775 HH21 ' HZ2' ' A' ' 43' ' ' LYS . 38.4 ttp180 -59.74 -121.28 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 71.4 t-105 -175.86 88.89 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.703 -0.399 . . . . 0.0 111.447 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.775 ' HZ2' HH21 ' A' ' 41' ' ' ARG . 1.1 tppm? -114.73 87.25 14.27 Favored Pre-proline 0 C--N 1.33 -0.24 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_exo -46.08 101.13 0.04 OUTLIER 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 123.027 2.485 . . . . 0.0 114.015 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' VAL . 16.9 tttt -135.1 134.12 39.95 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 12.5 ptt? -142.64 155.25 44.91 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.268 -0.573 . . . . 0.0 111.419 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.8 mt -116.52 123.97 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.543 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -127.15 -154.07 8.43 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.04 -124.5 11.45 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 65.2 mt -115.54 130.05 70.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.821 0.343 . . . . 0.0 110.44 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 95.54 0.52 62.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.36 161.47 32.14 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.499 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 177.67 37.71 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.772 0.32 . . . . 0.0 110.404 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 13.8 tt -133.21 151.22 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 0.0 111.078 -179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 56.3 mttm -90.71 124.14 34.86 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.944 179.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 45' ' ' LYS . 39.6 t -120.22 143.06 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.177 -178.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.638 ' NH2' ' CD2' ' A' ' 59' ' ' TYR . 1.1 ttt-85 -90.1 138.24 31.67 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.422 ' H ' ' HB3' ' A' ' 43' ' ' LYS . 48.2 tt0 -113.51 128.83 56.58 Favored 'General case' 0 N--CA 1.464 0.268 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.743 -179.358 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.638 ' CD2' ' NH2' ' A' ' 57' ' ' ARG . 0.1 OUTLIER -112.39 127.27 55.97 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.48 179.322 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.757 ' OD1' HG23 ' A' ' 74' ' ' THR . 80.8 m-20 -122.61 169.23 11.24 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.308 0.575 . . . . 0.0 112.047 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 65.22 35.95 7.43 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.103 179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.539 HD11 ' CD1' ' A' ' 59' ' ' TYR . 91.7 mt -120.52 150.41 23.3 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-O 121.059 0.457 . . . . 0.0 110.919 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 72.3 mt -101.3 135.56 37.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.773 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.2 tt -123.06 141.24 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.847 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -107.72 122.03 45.91 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.709 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 70.6 mt -127.92 127.26 67.84 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 50.36 41.63 24.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.333 179.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.94 11.95 81.2 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 120.923 -0.656 . . . . 0.0 111.576 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.65 134.78 54.7 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.265 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -96.63 141.44 29.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.145 -179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -150.52 150.95 31.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.464 179.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.4 tt -124.57 136.62 60.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.428 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 174.75 -173.22 46.03 Favored Glycine 0 CA--C 1.526 0.719 0 C-N-CA 120.43 -0.891 . . . . 0.0 111.93 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.757 HG23 ' OD1' ' A' ' 60' ' ' ASP . 88.4 m -74.54 136.63 42.14 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.531 -0.334 . . . . 0.0 110.84 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.521 ' CG2' HD12 ' A' ' 33' ' ' ILE . 1.1 p -136.27 101.9 2.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.605 179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.689 HD12 ' N ' ' A' ' 76' ' ' LEU . 6.6 mp -61.7 130.23 44.83 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.387 0.613 . . . . 0.0 111.976 -178.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 43.6 t -109.7 129.61 64.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.821 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.4 165.19 24.17 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.877 -0.677 . . . . 0.0 111.425 -179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -66.39 -20.32 54.9 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 123.093 2.529 . . . . 0.0 113.075 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 34' ' ' GLU . 14.5 t -62.28 135.05 94.96 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 121.025 -0.27 . . . . 0.0 111.271 -179.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_endo -79.65 26.24 0.57 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 122.608 2.205 . . . . 0.0 112.182 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.549 HG12 ' N ' ' A' ' 83' ' ' ASN . 62.0 t -124.24 159.0 30.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 121.278 0.561 . . . . 0.0 111.908 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.549 ' N ' HG12 ' A' ' 82' ' ' VAL . 76.2 m-20 -127.51 129.95 48.3 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.241 179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.502 ' O ' HG23 ' A' ' 31' ' ' THR . 15.0 tt -128.18 138.49 54.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.401 ' HB ' HD12 ' A' ' 24' ' ' LEU . 28.2 mm -109.62 138.08 38.78 Favored 'Isoleucine or valine' 0 C--O 1.232 0.184 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.608 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -144.87 -154.44 6.14 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.467 ' H ' ' HA ' ' A' ' 29' ' ' ASP . 44.8 ttp180 -38.92 -36.1 0.25 Allowed 'General case' 0 CA--C 1.517 -0.289 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.633 ' O ' ' N ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -67.46 144.05 55.91 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 178.562 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 64.3 mt 59.25 -40.87 0.07 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.938 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.633 ' N ' ' O ' ' A' ' 88' ' ' ASN . 30.3 tp -56.78 -44.88 82.3 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 120.638 -0.425 . . . . 0.0 110.912 -179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 63.5 p -74.94 -32.51 61.77 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.184 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -64.57 -49.39 71.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.271 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.9 tt -68.22 -27.73 38.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.852 0.358 . . . . 0.0 110.79 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 85.2 -164.14 38.24 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.071 -0.966 . . . . 0.0 110.569 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo . . . . . 0 N--CA 1.484 0.931 0 N-CA-C 109.623 -0.953 . . . . 0.0 109.623 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 32.3 mm-40 -110.53 145.89 36.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.382 179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.5 pt -70.79 -11.65 15.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.403 179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.0 p -101.1 24.7 9.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.561 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.3 pp -52.27 -36.18 52.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.773 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 5.3 m-90 -54.84 -36.93 65.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.859 0.361 . . . . 0.0 110.364 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -103.87 145.74 29.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.494 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -89.85 115.8 64.8 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.903 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -46.52 141.59 10.63 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.795 1.663 . . . . 0.0 112.024 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 mm? -89.67 135.21 33.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.218 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 44.9 t -112.64 131.01 65.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.547 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.5 p -122.27 151.61 40.9 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.994 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 pt -129.98 162.99 36.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.02 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -122.36 115.18 21.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.694 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.33 129.91 42.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.097 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.4 5.31 77.1 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.8 6.83 63.38 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.649 -0.981 . . . . 0.0 110.649 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 98.2 mm-40 -119.13 155.08 32.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.705 0.288 . . . . 0.0 110.241 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.759 HD12 ' N ' ' A' ' 19' ' ' LEU . 5.0 mp -89.36 126.72 35.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.468 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.419 ' HG3' ' N ' ' A' ' 21' ' ' GLU . 1.2 tptp -135.94 156.11 49.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.944 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.419 ' N ' ' HG3' ' A' ' 20' ' ' LYS . 95.1 mt-10 -114.58 146.09 41.19 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.59 152.95 41.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.881 0.372 . . . . 0.0 111.148 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 60.1 mt -102.95 146.84 27.71 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.194 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.499 ' CD2' HD11 ' A' ' 85' ' ' ILE . 49.2 mt -88.38 136.53 32.94 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.655 -179.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -98.03 148.6 23.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.425 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.1 m -67.6 -30.09 69.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.813 179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' A' ' 28' ' ' ALA . . . -142.34 -86.94 0.09 OUTLIER Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.498 ' O ' ' O ' ' A' ' 27' ' ' GLY . . . 47.95 102.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.876 0.369 . . . . 0.0 110.09 -179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.13 -39.58 75.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.944 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -119.53 176.23 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.158 -179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.662 ' OG1' HD23 ' A' ' 89' ' ' LEU . 53.3 m -114.53 138.4 50.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.684 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 42.6 t -129.82 133.32 64.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.357 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.4 pt -127.04 154.48 37.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.448 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -66.42 153.99 41.36 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.365 179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.432 ' OE1' ' C ' ' A' ' 35' ' ' GLU . 12.8 tm-20 -71.93 141.71 49.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.455 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.436 ' O ' HD13 ' A' ' 38' ' ' LEU . 83.6 mtp -158.43 169.16 25.08 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.836 179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.0 m -53.5 101.73 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.582 ' O ' ' O ' ' A' ' 39' ' ' PRO . 4.6 mp -113.41 161.03 29.23 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.416 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.582 ' O ' ' O ' ' A' ' 38' ' ' LEU . 45.8 Cg_exo -36.25 -122.96 0.0 OUTLIER 'Trans proline' 0 N--CA 1.499 1.835 0 C-N-CA 124.001 3.134 . . . . 0.0 114.014 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.22 39.23 0.82 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.595 ' O ' ' CD2' ' A' ' 59' ' ' TYR . 28.5 ttt-85 -137.57 116.81 12.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.799 0.333 . . . . 0.0 110.732 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 54.8 p-90 -153.46 162.24 41.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 27.2 mttp -146.72 149.0 35.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.413 179.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -70.43 136.86 32.23 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.554 2.17 . . . . 0.0 112.617 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.4 tttp -149.62 137.97 20.67 Favored 'General case' 0 C--N 1.33 -0.25 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.2 mtm -112.98 144.51 42.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.008 0.433 . . . . 0.0 111.091 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.4 tt -133.19 148.09 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.533 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -119.26 148.63 18.19 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.16 -81.2 0.11 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -117.04 134.85 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.821 0.343 . . . . 0.0 110.221 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.01 31.91 46.46 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.64 -129.98 25.34 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -109.99 132.73 53.89 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 14.3 tt -125.22 147.86 29.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.665 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 34.0 mttp -92.01 128.56 37.9 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.669 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.7 m -129.54 164.27 32.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.27 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.528 HH11 ' HG2' ' A' ' 57' ' ' ARG . 35.5 mtt-85 -112.95 141.46 46.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.893 0.377 . . . . 0.0 110.619 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -118.31 138.07 52.64 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.876 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.595 ' CD2' ' O ' ' A' ' 41' ' ' ARG . 24.1 m-85 -119.31 134.67 55.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.323 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.932 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.2 m-20 -122.38 169.99 10.4 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.188 0.518 . . . . 0.0 111.499 -179.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 23.2 mt-30 63.15 37.37 11.44 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.329 -0.85 . . . . 0.0 111.931 179.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 79.3 mt -116.03 146.03 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.821 0.343 . . . . 0.0 110.442 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -105.37 142.19 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.752 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 17.6 tt -124.75 137.88 55.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.372 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.14 125.27 50.86 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.54 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 76.5 mt -127.71 123.74 61.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.737 179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.87 -60.68 0.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.715 179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -179.68 21.72 0.04 OUTLIER Glycine 0 CA--C 1.527 0.834 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.77 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.2 m80 -122.72 138.21 54.68 Favored 'General case' 0 C--N 1.331 -0.213 0 O-C-N 122.573 -0.369 . . . . 0.0 110.592 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 49.9 mtpt -95.08 137.56 33.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.34 147.38 33.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.318 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 19.0 tt -126.27 134.46 66.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.768 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.83 -178.5 47.41 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.932 HG23 ' OD1' ' A' ' 60' ' ' ASP . 91.3 m -75.57 136.12 40.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.778 0.323 . . . . 0.0 110.599 -179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.623 HG23 ' O ' ' A' ' 75' ' ' VAL . 35.5 m -131.78 98.72 3.4 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.124 0.487 . . . . 0.0 110.699 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 46.9 mt -65.04 139.83 58.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.25 -178.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.408 ' O ' ' O ' ' A' ' 57' ' ' ARG . 53.9 t -118.13 130.33 73.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.614 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -136.67 166.89 24.72 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -61.45 -19.89 66.24 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 123.287 2.658 . . . . 0.0 113.0 -179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.3 t -50.46 140.32 18.54 Favored Pre-proline 0 CA--C 1.535 0.368 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.773 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.461 ' C ' HG23 ' A' ' 82' ' ' VAL . 58.5 Cg_endo -72.91 168.11 25.54 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.682 2.254 . . . . 0.0 112.664 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 ' C ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 47.89 -172.74 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.99 179.609 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.443 ' H ' HG12 ' A' ' 82' ' ' VAL . 74.9 m-20 -127.18 138.07 53.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.109 0.48 . . . . 0.0 111.222 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 15.4 tt -134.09 138.16 50.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.784 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.596 ' HA ' HG23 ' A' ' 31' ' ' THR . 29.4 pt -116.98 161.26 15.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.836 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -126.46 -171.15 13.06 Favored Glycine 0 CA--C 1.523 0.578 0 C-N-CA 120.939 -0.648 . . . . 0.0 111.63 -179.255 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -53.31 -27.3 22.41 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.312 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -55.16 -44.47 75.19 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.646 -0.421 . . . . 0.0 110.526 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.662 HD23 ' OG1' ' A' ' 31' ' ' THR . 3.9 mm? -76.46 -41.3 47.82 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.937 179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 71.0 mt -60.81 -39.82 90.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.669 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 39.9 m -57.11 -40.27 76.73 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.899 0.38 . . . . 0.0 110.279 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 50.5 tt0 -104.73 118.97 37.87 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.258 179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 17.7 tt -173.55 -23.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.774 0.321 . . . . 0.0 110.296 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -56.17 -34.75 63.01 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.572 179.973 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 N--CA 1.481 0.763 0 N-CA-C 109.593 -0.964 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 89.6 mt-30 -86.65 148.63 25.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.486 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.0 tt -121.53 136.98 56.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.749 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 21.4 p -89.82 162.16 15.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.575 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.808 HD22 ' C ' ' A' ' 5' ' ' LEU . 0.0 OUTLIER -95.51 160.73 14.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.809 179.791 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 30.3 p90 -108.62 133.85 52.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.64 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 20.9 tttt -138.08 139.51 39.55 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.331 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 29.3 mtt180 -54.75 145.88 38.97 Favored Pre-proline 0 C--N 1.328 -0.369 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.216 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.94 145.1 78.96 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.321 2.014 . . . . 0.0 112.13 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 53.8 mt -88.42 146.12 25.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.163 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.98 144.03 36.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.887 0.375 . . . . 0.0 110.591 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.7 p -127.06 157.4 39.72 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.407 179.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.2 pt -129.7 164.08 33.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.359 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.4 mttm -120.88 114.7 21.96 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.265 179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.28 130.22 38.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.847 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 69.15 2.78 33.99 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.667 -0.573 . . . . 0.0 111.667 179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.15 5.16 56.28 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.889 -0.885 . . . . 0.0 110.889 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -120.03 152.94 36.76 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.669 0.271 . . . . 0.0 110.291 179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.0 mp -94.2 132.34 38.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.844 0.354 . . . . 0.0 110.729 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -130.92 156.82 44.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.566 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -106.25 137.77 43.61 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.551 -0.536 . . . . 0.0 109.551 179.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.85 150.22 36.74 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.079 -179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' C ' HD22 ' A' ' 24' ' ' LEU . 46.3 mt -103.1 143.93 31.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.059 179.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.792 HD22 ' N ' ' A' ' 24' ' ' LEU . 2.4 mm? -91.77 117.94 30.23 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.388 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -117.97 110.82 18.17 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.106 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 3.7 m -90.37 56.67 3.43 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.442 -0.344 . . . . 0.0 111.057 -179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 167.47 65.22 0.03 OUTLIER Glycine 0 CA--C 1.524 0.607 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.362 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -149.67 -32.14 0.21 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.74 0.305 . . . . 0.0 110.667 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 57.8 t0 54.69 35.78 24.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.384 -179.767 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 63.3 m-20 -160.73 135.91 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.651 179.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HD23 ' A' ' 89' ' ' LEU . 94.6 m -124.34 129.47 50.78 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.426 179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' A' ' 84' ' ' ILE . 35.0 m -138.22 144.07 31.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.938 0.399 . . . . 0.0 110.813 179.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.659 HG23 ' ND2' ' A' ' 83' ' ' ASN . 70.9 mt -120.98 139.43 48.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.397 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -53.82 148.29 10.46 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.315 179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' ' O ' ' A' ' 78' ' ' GLY . 48.6 tp10 -79.72 136.42 36.76 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.831 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 65.4 mtt -143.83 -75.09 0.25 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.33 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.543 ' C ' HD12 ' A' ' 38' ' ' LEU . 5.9 m -176.22 107.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.567 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' C ' ' A' ' 37' ' ' SER . 8.7 mp -121.41 83.84 40.9 Favored Pre-proline 0 C--N 1.332 -0.177 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.653 -179.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -50.46 156.05 4.51 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 122.786 2.324 . . . . 0.0 112.253 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 118.88 -129.4 8.11 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.206 -0.757 . . . . 0.0 111.206 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.604 ' O ' ' CE1' ' A' ' 59' ' ' TYR . 96.6 mtt180 -109.78 149.8 29.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.668 0.27 . . . . 0.0 110.28 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 5.0 p-90 -123.85 150.05 45.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.078 -179.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 11.4 tttt -123.05 110.68 31.06 Favored Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 116.035 -0.529 . . . . 0.0 109.897 179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.07 137.47 29.09 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 121.744 1.629 . . . . 0.0 112.911 -178.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.445 ' HZ3' HD13 ' A' ' 47' ' ' ILE . 20.4 tptm -138.21 143.99 40.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.666 179.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.417 ' C ' HG23 ' A' ' 47' ' ' ILE . 51.6 ttp -116.8 92.95 4.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.614 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.445 HD13 ' HZ3' ' A' ' 45' ' ' LYS . 39.3 pt -154.96 142.25 12.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.98 0.419 . . . . 0.0 111.718 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -154.72 -79.72 0.03 OUTLIER Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 103.64 -34.47 5.75 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.159 -0.776 . . . . 0.0 111.159 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 56.2 mt -117.81 126.51 74.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 71.95 16.3 76.5 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.81 156.06 32.48 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -54.58 140.9 33.46 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.7 0.286 . . . . 0.0 110.807 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.5 tt -122.08 145.99 27.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.158 179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -88.78 121.15 30.85 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.829 -0.349 . . . . 0.0 111.184 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.01 165.17 26.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.23 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 44.0 ttm180 -106.13 135.5 47.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.533 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.72 HE21 HG21 ' A' ' 74' ' ' THR . 60.7 tt0 -110.59 127.32 55.18 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.975 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.604 ' CE1' ' O ' ' A' ' 41' ' ' ARG . 1.7 m-85 -113.73 125.66 54.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.017 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.894 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.7 m-20 -116.62 165.36 13.35 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.754 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 45.0 tt0 66.6 33.53 6.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.281 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 31.7 mm -115.0 140.8 34.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.337 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.54 HG22 ' HB ' ' A' ' 72' ' ' ILE . 47.0 pt -110.71 147.53 14.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.882 -179.599 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 39.8 pt -129.45 156.29 41.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.147 179.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -114.8 126.6 55.02 Favored 'General case' 0 C--N 1.329 -0.302 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.257 179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.579 ' O ' ' N ' ' A' ' 68' ' ' GLY . 74.2 mt -125.5 124.88 67.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.336 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -64.28 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.519 -179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.579 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -175.68 19.65 0.05 OUTLIER Glycine 0 CA--C 1.528 0.869 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -126.12 138.13 53.66 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.809 0.305 . . . . 0.0 110.364 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -98.44 145.47 26.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.913 0.387 . . . . 0.0 110.867 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -146.2 149.97 34.95 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.278 179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.6 tt -121.72 134.09 66.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 0.0 110.633 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -177.73 -177.03 46.24 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.894 HG23 ' OD1' ' A' ' 60' ' ' ASP . 37.5 m -72.06 132.7 44.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.735 0.303 . . . . 0.0 110.587 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 35.0 t -131.26 97.28 2.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.696 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 7.2 tt -80.26 129.01 34.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.258 0.552 . . . . 0.0 111.682 -178.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 10.8 p -114.07 137.15 48.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.461 -179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.409 ' O ' ' N ' ' A' ' 35' ' ' GLU . . . -146.2 175.51 25.63 Favored Glycine 0 CA--C 1.53 0.99 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.59 -8.34 22.95 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 123.299 2.666 . . . . 0.0 113.512 -179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' THR . 0.1 OUTLIER -48.89 152.21 1.89 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.696 0.284 . . . . 0.0 110.832 -179.414 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 82' ' ' VAL . 30.4 Cg_endo -65.59 151.83 83.58 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.87 2.38 . . . . 0.0 112.817 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 83' ' ' ASN . 1.1 t 32.86 -151.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.833 -0.622 . . . . 0.0 111.319 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.659 ' ND2' HG23 ' A' ' 33' ' ' ILE . 44.9 m-20 -132.34 144.32 50.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.795 -179.686 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' CG2' HG22 ' A' ' 32' ' ' VAL . 15.2 tt -129.97 139.72 50.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.815 178.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 26.4 mm -108.69 129.94 62.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.792 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -96.78 173.33 29.35 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 111.184 -0.766 . . . . 0.0 111.184 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -59.79 -28.09 67.13 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -56.39 -46.18 80.22 Favored 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.598 -179.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.61 HD22 ' N ' ' A' ' 89' ' ' LEU . 3.0 mm? -76.28 -38.29 56.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.64 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.57 ' O ' HG22 ' A' ' 93' ' ' ILE . 6.8 tp -60.13 -39.12 85.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.625 -179.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 51.2 m -64.3 -34.84 79.07 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 7.4 tm0? -57.52 -43.58 84.41 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.979 -178.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.57 HG22 ' O ' ' A' ' 90' ' ' LEU . 9.9 tt -66.79 -25.58 35.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.81 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.07 -166.72 39.07 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.62 179.977 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo . . . . . 0 N--CA 1.483 0.89 0 N-CA-C 109.431 -1.027 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 90.8 mt-30 -114.13 149.57 35.41 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.33 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.87 -24.59 26.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.583 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 57.1 m -101.59 134.1 45.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.444 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.14 -24.57 13.92 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.76 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -57.09 -39.6 75.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.883 -179.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 32.5 tttp -60.15 -38.1 82.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.613 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 11.7 mmt180 -81.78 122.56 80.36 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.634 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -77.61 172.53 15.64 Favored 'Trans proline' 0 N--CA 1.492 1.417 0 C-N-CA 122.24 1.96 . . . . 0.0 112.297 179.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.9 mt -72.88 158.93 34.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.12 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.0 t -88.0 130.54 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.002 0.429 . . . . 0.0 110.911 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.0 p -129.95 160.78 32.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.155 179.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 13' ' ' ILE . 30.2 pt -121.28 157.68 24.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.958 0.409 . . . . 0.0 111.042 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 57.7 tttp -127.07 119.26 26.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.944 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 15' ' ' ILE . 23.8 pt -145.66 139.04 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.594 -179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.5 5.01 1.54 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.233 178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.41 2.04 56.66 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.7 mt-30 -101.88 143.27 31.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.737 0.303 . . . . 0.0 110.425 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 69.4 mt -100.51 127.26 46.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.336 -0.393 . . . . 0.0 109.964 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.537 ' CE ' ' OE2' ' A' ' 34' ' ' GLU . 6.0 tptt -139.63 158.7 43.67 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.353 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -110.97 141.09 44.89 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -140.64 152.62 45.55 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.624 -0.43 . . . . 0.0 111.107 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 64.2 mt -99.68 145.57 27.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.374 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.873 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.5 mm? -90.8 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.101 179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -141.93 93.42 2.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.808 0.337 . . . . 0.0 110.742 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.551 ' O ' ' NH1' ' A' ' 87' ' ' ARG . 50.7 m -62.72 -19.41 63.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.747 179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -85.3 -14.09 69.54 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.62 -0.592 . . . . 0.0 111.62 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -85.28 115.0 22.79 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.31 -39.21 89.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.86 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -119.32 175.08 5.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.629 -179.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 85' ' ' ILE . 14.4 p -119.09 146.77 44.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.938 0.399 . . . . 0.0 110.782 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.8 t -135.41 131.93 51.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.123 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 30.6 pt -126.84 148.68 31.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 111.33 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.537 ' OE2' ' CE ' ' A' ' 20' ' ' LYS . 17.3 pt-20 -60.73 156.74 16.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.209 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -90.42 140.01 30.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.471 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 61.0 mtt -153.59 -69.3 0.14 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.224 179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.438 ' O ' HD12 ' A' ' 38' ' ' LEU . 3.2 m -173.53 81.87 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.07 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.584 ' O ' ' CE2' ' A' ' 59' ' ' TYR . 2.6 mp -123.13 80.85 51.65 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 110.132 179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 38' ' ' LEU . 50.8 Cg_exo -50.21 -161.44 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.942 2.428 . . . . 0.0 112.608 -179.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 109.29 -113.17 3.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.641 HH11 ' NE2' ' A' ' 61' ' ' GLN . 57.8 mtp180 -118.62 151.58 37.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.978 0.418 . . . . 0.0 111.005 -179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.546 ' CZ3' ' NE ' ' A' ' 57' ' ' ARG . 0.7 OUTLIER -117.31 112.55 20.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.562 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 3.5 mttp -126.22 86.58 57.78 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.397 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.05 135.87 44.56 Favored 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 122.428 2.085 . . . . 0.0 112.3 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 69.4 tttt -139.32 148.17 42.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.464 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 1.3 ttp -120.51 143.74 48.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.634 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 15.2 tt -126.75 137.12 58.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.274 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.42 170.47 22.65 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 148.41 -125.67 2.12 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.5 mt -113.15 120.25 62.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 73.31 17.21 78.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.556 ' O ' ' CB ' ' A' ' 53' ' ' PHE . . . -116.3 -146.9 8.72 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.556 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 8.9 t80 92.52 56.94 0.0 OUTLIER 'General case' 0 N--CA 1.462 0.154 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 19.8 tt -130.61 151.61 36.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.315 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 73.3 tttt -90.94 126.27 36.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.211 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.8 m -125.39 164.27 24.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.595 -179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.595 HH11 ' HG2' ' A' ' 57' ' ' ARG . 2.1 mmt-85 -112.24 140.49 46.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.971 0.415 . . . . 0.0 110.885 -179.476 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -107.87 121.62 45.12 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.169 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE2' ' O ' ' A' ' 38' ' ' LEU . 62.5 m-85 -108.51 126.39 52.87 Favored 'General case' 0 C--O 1.23 0.057 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.161 179.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.496 ' OD1' HG23 ' A' ' 74' ' ' THR . 88.4 m-20 -125.73 170.4 11.59 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.512 -179.046 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.641 ' NE2' HH11 ' A' ' 41' ' ' ARG . 86.1 mt-30 65.79 31.54 9.46 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.343 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 17.8 tt -109.58 143.03 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.949 0.404 . . . . 0.0 110.52 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 55.1 mt -100.19 130.3 49.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.548 -179.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 67.9 mt -117.67 132.64 66.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.247 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -106.67 125.0 50.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.388 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 68' ' ' GLY . 62.4 mt -125.27 121.57 60.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.548 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.467 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 66.73 -55.98 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.548 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 173.89 24.55 0.02 OUTLIER Glycine 0 CA--C 1.528 0.89 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.625 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -124.13 141.3 52.17 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.778 0.323 . . . . 0.0 110.563 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 18.1 mttp -94.51 137.75 33.25 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.531 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.4 152.28 36.73 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.838 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 53.5 mt -115.48 127.3 73.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.71 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.9 162.52 34.16 Favored Glycine 0 CA--C 1.525 0.712 0 C-N-CA 119.79 -1.195 . . . . 0.0 112.443 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.496 HG23 ' OD1' ' A' ' 60' ' ' ASP . 18.4 m -83.22 143.8 30.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.076 -0.562 . . . . 0.0 110.624 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -138.9 106.55 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.955 0.407 . . . . 0.0 111.12 179.445 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.621 ' N ' ' CD2' ' A' ' 76' ' ' LEU . 0.7 OUTLIER -70.93 143.06 51.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.617 -178.678 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 93.6 t -108.7 129.64 62.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.73 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.47 175.27 22.11 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.425 ' O ' ' C ' ' A' ' 80' ' ' THR . 29.0 Cg_endo -64.34 -13.4 38.04 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 123.279 2.652 . . . . 0.0 113.568 -179.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 79' ' ' PRO . 9.3 t -39.7 140.76 0.8 Allowed Pre-proline 0 C--N 1.33 -0.251 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.254 -179.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -70.26 -27.22 24.37 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.517 2.145 . . . . 0.0 113.254 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.8 OUTLIER -128.41 -149.3 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-O 121.181 0.515 . . . . 0.0 111.46 -179.187 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.576 ' H ' HG12 ' A' ' 82' ' ' VAL . 67.3 m-20 -126.87 139.1 53.33 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.573 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' O ' HG23 ' A' ' 84' ' ' ILE . 12.7 tt -130.08 130.19 65.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.511 179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.56 HD11 ' CD1' ' A' ' 24' ' ' LEU . 40.5 pt -128.91 165.46 28.67 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.821 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 88' ' ' ASN . . . -166.92 -125.92 0.8 Allowed Glycine 0 CA--C 1.529 0.92 0 C-N-CA 120.973 -0.632 . . . . 0.0 111.65 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.596 ' CG ' HH11 ' A' ' 87' ' ' ARG . 5.5 mtt-85 -40.52 -34.26 0.34 Allowed 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.659 ' O ' ' N ' ' A' ' 90' ' ' LEU . 52.3 t30 -66.27 145.46 55.72 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.582 -0.895 . . . . 0.0 108.582 178.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 63.5 mt 58.75 -40.73 0.06 Allowed 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.941 178.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.659 ' N ' ' O ' ' A' ' 88' ' ' ASN . 8.0 tp -58.74 -45.21 90.2 Favored 'General case' 0 N--CA 1.461 0.09 0 C-N-CA 120.567 -0.453 . . . . 0.0 110.883 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 50.4 m -59.75 -42.03 92.29 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.646 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -123.47 96.24 4.9 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.832 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 95' ' ' ALA . 20.3 tt -63.81 -21.1 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.41 179.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 101.31 5.11 52.86 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.576 ' H ' HG23 ' A' ' 93' ' ' ILE . . . . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.507 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo . . . . . 0 N--CA 1.484 0.922 0 N-CA-C 109.583 -0.968 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tt0 -55.67 -36.47 67.13 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.309 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 19.0 tt -59.67 -23.82 27.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.521 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.444 HG22 ' H ' ' A' ' 6' ' ' TRP . 67.1 m -105.62 132.91 51.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.714 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.444 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.1 OUTLIER -97.41 -12.27 22.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.716 179.937 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.474 ' CD1' ' N ' ' A' ' 6' ' ' TRP . 35.4 m0 -58.4 -32.07 68.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.481 -179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.1 tttm 62.18 -99.46 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.337 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.426 ' H ' ' HG2' ' A' ' 8' ' ' ARG . 19.6 ptt180 -75.6 137.0 70.71 Favored Pre-proline 0 CA--C 1.534 0.334 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.209 179.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.28 -20.98 36.37 Favored 'Trans proline' 0 N--CA 1.493 1.466 0 C-N-CA 122.247 1.965 . . . . 0.0 112.43 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.3 mt -90.42 144.13 26.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.902 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 46.9 t -113.31 136.53 49.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.211 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -123.85 154.3 39.83 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.936 0.398 . . . . 0.0 110.694 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 13' ' ' ILE . 33.4 pt -129.21 164.38 31.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.823 -179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -125.88 121.96 34.68 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.657 179.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 77.0 mt -125.84 111.25 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.648 179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 75.8 7.51 83.7 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.98 11.36 53.27 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 95.8 mt-30 -104.95 150.28 25.04 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.896 0.379 . . . . 0.0 110.605 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.582 HD22 ' N ' ' A' ' 19' ' ' LEU . 2.9 mm? -91.4 112.7 24.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.546 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -130.38 156.7 44.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.396 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 58.0 mp0 -107.79 147.14 31.25 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -144.82 151.16 38.36 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.076 0.465 . . . . 0.0 111.162 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 52.8 mt -106.7 159.96 15.82 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.108 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 24' ' ' LEU . 5.9 mp -78.28 172.59 13.36 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.803 0.335 . . . . 0.0 110.384 -179.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.556 ' O ' ' N ' ' A' ' 27' ' ' GLY . 23.4 p-10 -55.97 6.25 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.682 -179.189 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.625 ' H ' ' C ' ' A' ' 24' ' ' LEU . 56.2 m -65.44 61.02 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.282 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 25' ' ' ASP . . . 151.66 9.31 0.1 Allowed Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.002 -0.618 . . . . 0.0 112.183 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.453 ' HB2' ' O ' ' A' ' 27' ' ' GLY . . . 176.67 129.72 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.257 0.528 . . . . 0.0 110.887 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.621 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 54.4 p30 -67.88 -28.94 67.95 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.858 179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.621 ' N ' ' OD1' ' A' ' 29' ' ' ASP . 86.0 m-20 -97.43 -169.86 1.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.519 179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.43 ' HB ' ' H ' ' A' ' 86' ' ' GLY . 7.5 t -131.76 142.09 49.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.668 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 84' ' ' ILE . 29.8 m -143.84 146.1 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.581 179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.456 HG23 ' ND2' ' A' ' 83' ' ' ASN . 36.0 mm -116.64 133.34 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.562 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.69 148.22 16.79 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.035 179.295 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -77.52 133.37 38.56 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.925 0.393 . . . . 0.0 110.539 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 86.9 mtp -152.31 -75.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.401 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 27.5 t -165.88 119.03 1.12 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.416 179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.575 ' CD1' HG11 ' A' ' 77' ' ' VAL . 1.8 mp -135.18 81.8 43.42 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.712 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -52.46 152.73 15.23 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.594 2.196 . . . . 0.0 111.912 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 116.57 -142.81 17.75 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 63.4 ttt180 -105.05 145.58 30.29 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.76 0.314 . . . . 0.0 110.583 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.664 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 0.1 OUTLIER -121.37 153.43 37.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.641 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.97 94.74 43.41 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.76 -179.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -47.39 129.99 16.97 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 122.025 1.817 . . . . 0.0 111.895 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 64.9 tttt -147.56 149.87 33.41 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.035 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 85.8 mtp -127.0 139.34 53.1 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 pp -139.27 175.4 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.761 0.315 . . . . 0.0 110.695 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 110.7 -12.96 29.97 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -178.62 -175.59 45.82 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.77 -29.99 41.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.947 0.404 . . . . 0.0 110.195 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.68 -7.84 25.26 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 78.71 130.94 0.66 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -107.56 7.7 28.87 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.823 0.344 . . . . 0.0 111.382 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.7 tt -151.45 147.46 15.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 178.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 78.0 tttt -104.28 117.37 34.06 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.677 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 23.1 m -128.33 163.6 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.292 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -104.36 136.75 43.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.681 -179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -105.42 123.49 47.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.097 -179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -113.18 126.7 55.72 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.607 179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.641 ' OD1' HG23 ' A' ' 74' ' ' THR . 83.3 m-20 -128.81 171.26 12.42 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.891 -179.523 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 67.21 29.71 7.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.357 179.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.882 HD11 ' CG1' ' A' ' 75' ' ' VAL . 32.5 pt -124.36 161.84 26.83 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-O 120.992 0.425 . . . . 0.0 110.904 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.909 HD13 ' H ' ' A' ' 63' ' ' ILE . 0.1 OUTLIER -110.89 141.86 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.265 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.548 HG23 ' HB3' ' A' ' 71' ' ' ALA . 14.1 tt -125.4 136.98 59.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.513 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -97.47 112.72 24.44 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.65 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 1.006 HG22 ' H ' ' A' ' 67' ' ' ALA . 27.6 mt -86.45 -156.97 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 1.006 ' H ' HG22 ' A' ' 66' ' ' ILE . . . -57.18 71.61 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.634 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.637 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . 73.54 23.82 76.15 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.431 ' CE1' ' O ' ' A' ' 70' ' ' LYS . 54.2 t-80 -134.6 143.7 47.49 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.299 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.431 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 93.4 mttt -86.9 150.1 24.34 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.199 179.473 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB3' HG23 ' A' ' 64' ' ' ILE . . . -154.75 139.95 17.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.218 179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.667 HG12 HG22 ' A' ' 63' ' ' ILE . 46.5 mt -123.27 128.23 74.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.168 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 172.09 -173.45 45.18 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 119.96 -1.114 . . . . 0.0 112.548 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.641 HG23 ' OD1' ' A' ' 60' ' ' ASP . 43.5 m -76.26 137.69 40.09 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.075 -0.562 . . . . 0.0 111.226 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.882 ' CG1' HD11 ' A' ' 62' ' ' ILE . 3.0 p -143.07 106.33 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.316 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.667 179.3 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.824 ' H ' HD12 ' A' ' 76' ' ' LEU . 4.0 mp -72.01 127.55 32.91 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.114 0.483 . . . . 0.0 111.565 -178.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 38' ' ' LEU . 42.4 t -109.36 130.8 61.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.865 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -147.5 173.02 27.76 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -63.05 -20.32 71.13 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 123.092 2.528 . . . . 0.0 112.818 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 80' ' ' THR . 1.7 t -40.13 116.97 1.27 Allowed Pre-proline 0 CA--C 1.536 0.433 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.86 -179.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.448 ' C ' HG23 ' A' ' 82' ' ' VAL . 51.6 Cg_exo -47.6 155.67 1.36 Allowed 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.25 1.966 . . . . 0.0 112.542 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.456 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 46.55 -163.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.173 179.516 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.456 ' OD1' ' O ' ' A' ' 82' ' ' VAL . 70.0 m-20 -137.15 147.08 45.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.65 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.457 HG22 HG22 ' A' ' 32' ' ' VAL . 7.5 tt -130.78 141.36 46.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 109.991 179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.485 ' O ' ' N ' ' A' ' 25' ' ' ASP . 65.5 mt -108.19 130.96 59.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 CA-C-O 120.952 0.406 . . . . 0.0 111.166 -179.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' A' ' 31' ' ' THR . . . -85.93 170.07 43.14 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.426 ' CG ' ' OD2' ' A' ' 25' ' ' ASP . 81.7 mtm180 -63.39 -22.73 67.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.701 0.286 . . . . 0.0 111.041 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -57.92 -47.2 83.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.902 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 92' ' ' GLN . 80.6 mt -75.73 -41.66 52.77 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.853 -0.339 . . . . 0.0 110.889 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 76.6 mt -61.85 -38.84 89.74 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.715 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 87' ' ' ARG . 52.9 m -61.28 -39.07 89.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.779 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 89' ' ' LEU . 51.0 tt0 -100.25 125.75 46.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.297 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.795 HG23 ' O ' ' A' ' 93' ' ' ILE . 20.3 tt -159.03 64.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.803 0.335 . . . . 0.0 110.601 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.98 21.04 61.89 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.52 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.484 0.957 0 N-CA-C 109.736 -0.909 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -56.94 -37.81 72.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -117.66 135.11 59.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.892 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 41.1 p -123.23 158.73 30.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.277 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.449 HD23 ' N ' ' A' ' 5' ' ' LEU . 0.2 OUTLIER -131.25 123.51 28.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.63 179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -61.41 -39.43 90.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.511 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.2 mttp -128.25 147.52 50.59 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.759 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.8 mtt180 -71.48 146.4 91.54 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.175 179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -64.16 -35.81 50.62 Favored 'Trans proline' 0 N--CA 1.495 1.58 0 C-N-CA 122.437 2.091 . . . . 0.0 112.706 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 41.6 mt -90.74 143.06 27.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.94 0.4 . . . . 0.0 110.89 -179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.65 146.94 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.176 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.0 p -121.75 152.96 38.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.617 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.6 pt -130.13 164.01 34.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.772 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 79.9 tttt -122.47 117.08 25.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.64 179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.514 HG23 ' O ' ' A' ' 15' ' ' ILE . 14.9 tt -135.13 123.87 40.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.347 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.9 8.34 52.9 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 179.013 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.07 2.37 59.32 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.734 -0.947 . . . . 0.0 110.734 -179.654 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -112.99 149.32 33.46 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 110.175 -0.305 . . . . 0.0 110.175 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 1.1 mp -95.79 128.07 42.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.744 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -132.23 158.55 41.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -109.26 140.23 43.16 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.497 179.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -142.05 153.62 44.35 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.461 -0.495 . . . . 0.0 111.276 -179.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 63.3 mt -103.13 144.49 31.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.368 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.788 ' N ' HD12 ' A' ' 24' ' ' LEU . 3.9 mp -90.05 138.44 31.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.812 0.339 . . . . 0.0 110.761 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -145.28 97.79 3.05 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.553 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.1 m -63.79 -19.49 65.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.384 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -93.92 -15.36 49.21 Favored Glycine 0 CA--C 1.527 0.802 0 C-N-CA 120.94 -0.648 . . . . 0.0 111.935 -179.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' C ' ' H ' ' A' ' 30' ' ' ASP . . . -59.17 -41.5 88.57 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.871 -0.332 . . . . 0.0 111.078 -179.342 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 34.8 t0 70.9 -39.46 0.45 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.166 0.507 . . . . 0.0 109.831 -179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.541 ' H ' ' C ' ' A' ' 28' ' ' ALA . 90.1 m-20 -103.08 158.31 16.39 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.084 -179.562 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.443 ' OG1' HD13 ' A' ' 89' ' ' LEU . 94.0 m -127.31 132.04 50.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.832 179.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.596 HG22 HG22 ' A' ' 84' ' ' ILE . 2.8 m -141.52 153.54 19.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 C-N-CA 120.244 -0.582 . . . . 0.0 111.683 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.709 HG23 ' ND2' ' A' ' 83' ' ' ASN . 71.9 mt -120.61 135.84 59.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.203 179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.458 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 84.6 tt0 -55.14 147.06 16.99 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.488 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -68.52 139.05 55.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.966 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 2.5 mmm 176.8 -65.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.244 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 p -97.71 -149.12 0.33 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.307 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER 53.51 71.01 1.51 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.235 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.491 ' O ' ' O ' ' A' ' 40' ' ' GLY . 90.4 Cg_endo -78.05 -100.46 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.686 0 C-N-CA 122.758 2.306 . . . . 0.0 112.117 179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.491 ' O ' ' O ' ' A' ' 39' ' ' PRO . . . -36.23 160.18 0.01 OUTLIER Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 72.95 102.67 0.07 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.293 -179.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.54 ' CZ2' ' CZ ' ' A' ' 57' ' ' ARG . 3.0 m95 -127.17 117.01 21.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.403 -179.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -122.15 81.31 44.19 Favored Pre-proline 0 C--N 1.33 -0.276 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -51.31 139.44 44.72 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 123.016 2.477 . . . . 0.0 113.051 -178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -137.26 145.36 43.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.597 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 86.5 mtp -93.44 119.38 32.47 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.66 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 47' ' ' ILE . 10.9 tp -137.42 154.34 29.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.682 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 129.51 -33.11 3.07 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 87.38 -165.51 35.65 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 78.5 mt -59.75 -33.99 54.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.676 0.274 . . . . 0.0 110.894 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -52.66 -32.05 38.78 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 167.16 156.37 9.75 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.4 129.32 55.79 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.837 -0.345 . . . . 0.0 110.663 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 65.5 mt -116.89 144.59 24.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 37.2 tttp -86.36 117.64 25.28 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.536 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 t -120.33 149.13 23.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.568 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.54 ' CZ ' ' CZ2' ' A' ' 42' ' ' TRP . 0.0 OUTLIER -99.57 130.13 45.78 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.69 -179.507 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -107.41 127.95 54.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.854 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -108.29 123.09 48.27 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.193 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -109.44 159.17 17.25 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.224 -179.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.2 mt-30 59.72 40.3 19.93 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.679 179.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 13.8 tt -111.84 146.82 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.925 0.393 . . . . 0.0 110.514 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 19.0 tt -113.25 136.68 48.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.513 -179.556 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 19.4 tt -128.36 146.75 33.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.519 -179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 76.8 mm-40 -102.99 119.66 39.24 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.155 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 72.0 mt -127.81 127.03 67.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.83 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.417 ' O ' ' ND1' ' A' ' 69' ' ' HIS . . . 45.98 42.1 8.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.81 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.21 14.61 71.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.676 -0.569 . . . . 0.0 111.676 179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.417 ' ND1' ' O ' ' A' ' 67' ' ' ALA . 74.2 m80 -116.77 138.23 51.63 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.948 -179.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -83.35 147.28 28.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.602 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.23 134.32 14.07 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.384 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 70.8 mt -125.84 128.38 72.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.87 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 179.15 -179.68 48.85 Favored Glycine 0 CA--C 1.525 0.701 0 C-N-CA 120.548 -0.834 . . . . 0.0 111.802 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 82.7 m -75.31 139.69 42.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.719 0.295 . . . . 0.0 110.563 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.9 t -142.24 107.39 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 C-N-CA 120.649 -0.42 . . . . 0.0 111.537 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 76' ' ' LEU . 3.5 mp -71.58 127.92 34.13 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.872 -179.22 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.511 HG13 ' O ' ' A' ' 33' ' ' ILE . 32.0 t -112.18 134.35 54.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.836 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.602 ' N ' ' CD ' ' A' ' 79' ' ' PRO . . . 118.21 -35.18 4.13 Favored Glycine 0 CA--C 1.532 1.126 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.631 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.602 ' CD ' ' N ' ' A' ' 78' ' ' GLY . 57.9 Cg_exo -40.33 -107.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.352 2.035 . . . . 0.0 113.161 -179.048 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.582 HG22 HG21 ' A' ' 32' ' ' VAL . 8.4 t -89.54 146.67 36.22 Favored Pre-proline 0 CA--C 1.534 0.332 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.343 -179.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.424 ' C ' HG23 ' A' ' 82' ' ' VAL . 53.2 Cg_exo -46.97 172.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.49 1.295 0 C-N-CA 121.983 1.788 . . . . 0.0 111.645 178.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.426 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.2 OUTLIER 47.35 -162.12 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.687 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.709 ' ND2' HG23 ' A' ' 33' ' ' ILE . 39.9 m-20 -127.35 138.7 53.09 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.974 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.596 HG22 HG22 ' A' ' 32' ' ' VAL . 21.3 tt -127.82 143.93 39.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.862 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 59.0 mt -110.23 131.01 62.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.82 0.343 . . . . 0.0 110.404 -179.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -95.68 171.42 28.99 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -64.34 -21.05 66.49 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.812 0.339 . . . . 0.0 110.52 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.0 t30 -57.7 -46.28 84.56 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.501 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.536 HD12 ' N ' ' A' ' 89' ' ' LEU . 10.7 mp -73.94 -40.85 62.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.369 179.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 57.9 mt -62.83 -38.08 89.34 Favored 'General case' 0 C--N 1.331 -0.199 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.273 179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 45.6 m -62.25 -37.63 86.18 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.536 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -94.44 122.91 37.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.554 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 18.8 tt -174.32 -10.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.036 0.446 . . . . 0.0 110.389 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.634 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -115.82 -43.32 0.68 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.634 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.6 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . 0.462 ' O ' ' O ' ' A' ' 2' ' ' GLN . 14.3 Cg_exo . . . . . 0 N--CA 1.484 0.945 0 N-CA-C 109.491 -1.004 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.462 ' O ' ' O ' ' A' ' 1' ' ' PRO . 46.5 tt0 43.65 97.67 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.651 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 66.9 mt -114.12 128.95 70.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.186 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.9 p -115.91 -4.3 12.08 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 120.816 -0.353 . . . . 0.0 111.563 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.457 ' H ' HD12 ' A' ' 5' ' ' LEU . 0.2 OUTLIER -133.15 108.85 9.07 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.745 179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.2 m-90 -64.51 -40.36 95.49 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -99.59 141.21 32.68 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.664 HH11 ' CG ' ' A' ' 8' ' ' ARG . 0.0 OUTLIER -89.82 112.9 54.74 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.631 179.933 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -49.86 -12.9 0.45 Allowed 'Trans proline' 0 N--CA 1.494 1.516 0 C-N-CA 122.098 1.865 . . . . 0.0 112.111 179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 29.9 tp -87.09 135.46 33.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.422 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t -108.95 140.05 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.838 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 18.9 p -121.96 156.21 33.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.293 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 pt -126.33 162.82 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.025 0.441 . . . . 0.0 111.354 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 56.9 tttp -129.92 122.02 27.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.873 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.0 mt -134.5 120.8 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.905 0.383 . . . . 0.0 111.245 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.1 42.23 80.72 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.121 178.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.04 2.03 70.48 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.844 -0.694 . . . . 0.0 111.741 179.05 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -110.17 143.83 39.7 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.88 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 57.3 mt -102.5 133.55 47.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.292 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.6 mttm -132.75 156.96 46.12 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.619 -179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -110.81 140.03 45.59 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.18 153.37 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.228 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' N ' HD12 ' A' ' 23' ' ' LEU . 5.5 mp -103.76 146.18 28.99 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.449 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.881 HD22 ' N ' ' A' ' 24' ' ' LEU . 1.4 mm? -92.11 134.58 34.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.259 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.592 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 14.3 t70 -101.81 145.82 28.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.611 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 51.6 m -66.23 -27.64 68.13 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.18 55.39 0.07 OUTLIER Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.592 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -65.81 -27.34 68.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.777 0.322 . . . . 0.0 110.857 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.496 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 59.2 t0 59.7 20.01 8.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.063 0.459 . . . . 0.0 109.834 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.496 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 68.6 m-20 -161.32 142.67 11.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.397 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.953 HG22 ' H ' ' A' ' 86' ' ' GLY . 6.6 p -123.68 134.84 53.67 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.129 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 41.1 t -132.31 132.45 60.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.537 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 74.0 mt -122.9 132.27 71.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.716 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 24.2 pt-20 -57.96 157.17 8.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.574 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -90.91 136.12 33.28 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.552 179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.572 ' O ' ' CB ' ' A' ' 37' ' ' SER . 94.3 mmm -146.99 12.23 1.09 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.161 179.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.572 ' CB ' ' O ' ' A' ' 36' ' ' MET . 3.3 t 96.77 60.03 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.292 0 O-C-N 123.819 0.699 . . . . 0.0 109.415 -178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.76 ' H ' ' CD ' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -118.27 -43.59 0.05 OUTLIER Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.886 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.76 ' CD ' ' H ' ' A' ' 38' ' ' LEU . 5.2 Cg_exo -74.61 120.95 6.4 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 123.041 2.494 . . . . 0.0 111.946 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -85.7 -78.02 1.19 Allowed Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.524 -1.031 . . . . 0.0 110.524 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.615 ' O ' ' CG ' ' A' ' 42' ' ' TRP . 64.9 ttt180 -85.59 -42.2 14.57 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.678 ' CH2' ' NH1' ' A' ' 57' ' ' ARG . 69.6 p-90 46.55 168.76 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.177 -0.919 . . . . 0.0 112.191 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -131.78 139.55 35.51 Favored Pre-proline 0 CA--C 1.533 0.325 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.838 179.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.62 135.06 27.52 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.473 2.115 . . . . 0.0 113.001 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -139.56 144.06 37.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.974 179.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -110.03 138.17 46.79 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.685 -0.406 . . . . 0.0 110.371 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.0 pt -140.71 163.77 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.877 179.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 106.69 -22.24 30.67 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 50.82 -128.58 29.61 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.502 ' C ' ' H ' ' A' ' 52' ' ' GLY . 18.9 tt -61.33 -27.84 42.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.758 0.313 . . . . 0.0 110.907 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -72.32 17.81 1.37 Allowed Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.502 ' H ' ' C ' ' A' ' 50' ' ' ILE . . . 100.22 148.95 23.16 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -110.17 126.19 53.83 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.184 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 11.3 tt -125.0 143.21 39.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -82.82 119.59 24.56 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.996 0.427 . . . . 0.0 110.692 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.79 137.15 52.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.467 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.678 ' NH1' ' CH2' ' A' ' 42' ' ' TRP . 23.2 mtt-85 -90.03 134.35 34.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.356 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -123.27 142.79 50.56 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.908 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' HD11 ' A' ' 62' ' ' ILE . 1.1 t80 -128.08 143.17 51.05 Favored 'General case' 0 C--N 1.332 -0.168 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.541 179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.738 ' OD1' HG23 ' A' ' 74' ' ' THR . 81.5 m-20 -119.6 169.66 9.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.077 0.465 . . . . 0.0 111.291 -179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 61.45 39.46 15.01 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.738 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.402 HD11 ' CD1' ' A' ' 59' ' ' TYR . 32.5 mm -113.05 140.37 33.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.846 0.355 . . . . 0.0 110.331 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.461 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.4 pt -111.31 143.28 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.784 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 27.2 pt -133.05 159.61 43.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.647 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -110.18 122.09 46.81 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.823 -0.351 . . . . 0.0 110.568 179.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 68' ' ' GLY . 77.4 mt -127.68 126.56 67.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.576 179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.28 -68.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.866 0.365 . . . . 0.0 110.314 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.59 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.86 19.8 0.06 OUTLIER Glycine 0 CA--C 1.525 0.707 0 N-CA-C 111.567 -0.613 . . . . 0.0 111.567 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -131.34 143.16 50.29 Favored 'General case' 0 C--N 1.332 -0.158 0 C-N-CA 120.824 -0.351 . . . . 0.0 110.68 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 25.7 mtmt -93.09 136.62 33.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.729 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -132.64 143.12 49.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.258 179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.461 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.4 tt -124.87 134.59 66.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.033 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 177.82 -176.39 48.0 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.399 -0.68 . . . . 0.0 111.399 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.738 HG23 ' OD1' ' A' ' 60' ' ' ASP . 90.4 m -72.01 136.46 46.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.812 0.339 . . . . 0.0 110.58 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.731 HG23 ' O ' ' A' ' 75' ' ' VAL . 27.9 m -130.78 98.02 3.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.158 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 36.8 tp -62.74 128.36 35.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.048 -0.523 . . . . 0.0 111.294 -178.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 57' ' ' ARG . 39.9 t -107.83 131.0 59.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.409 179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -132.04 162.88 23.94 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.542 -0.623 . . . . 0.0 111.542 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.74 -21.29 38.85 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 123.237 2.625 . . . . 0.0 113.068 -179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.82 138.83 93.62 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.233 -179.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.01 35.48 0.57 Allowed 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 122.687 2.258 . . . . 0.0 112.171 179.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.458 HG12 ' N ' ' A' ' 83' ' ' ASN . 45.1 t -125.23 154.56 33.59 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-O 121.368 0.604 . . . . 0.0 112.086 -178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.458 ' N ' HG12 ' A' ' 82' ' ' VAL . 72.2 m-20 -130.08 118.87 22.18 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.918 179.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.4 tt -129.29 141.77 45.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.822 0.344 . . . . 0.0 110.647 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.8 mt -112.33 130.12 66.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.528 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.953 ' H ' HG22 ' A' ' 31' ' ' THR . . . -93.03 179.29 39.48 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 -179.623 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.671 ' CG ' HH11 ' A' ' 87' ' ' ARG . 0.0 OUTLIER -63.47 -21.12 66.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.618 0.247 . . . . 0.0 111.18 -179.876 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -55.66 -45.49 77.7 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.476 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.473 ' O ' ' O ' ' A' ' 92' ' ' GLN . 10.3 mp -79.38 -42.94 24.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.059 179.628 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 58.3 mt -60.74 -41.14 94.79 Favored 'General case' 0 C--N 1.332 -0.171 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.426 -179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 43.7 m -61.05 -38.91 87.86 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.366 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.473 ' O ' ' O ' ' A' ' 89' ' ' LEU . 63.6 tt0 -96.97 118.46 33.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.11 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.422 HD12 ' HA ' ' A' ' 93' ' ' ILE . 11.1 tp -171.22 -23.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.887 0.375 . . . . 0.0 110.381 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.712 ' O ' ' HB3' ' A' ' 95' ' ' ALA . . . -55.0 -33.47 57.27 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.712 ' HB3' ' O ' ' A' ' 94' ' ' GLY . . . . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.5 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo . . . . . 0 N--CA 1.484 0.921 0 N-CA-C 109.554 -0.979 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -119.32 164.23 15.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.092 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 21.6 mm -98.79 144.52 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.953 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 m -59.94 138.29 57.87 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.895 0.379 . . . . 0.0 110.682 -179.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.498 ' H ' HD23 ' A' ' 5' ' ' LEU . 0.1 OUTLIER -79.55 149.97 31.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.856 -179.564 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -88.87 131.94 34.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.548 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.9 tttp -105.12 -28.03 11.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.029 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.492 ' N ' ' CD ' ' A' ' 9' ' ' PRO . 1.2 ttt180 -50.02 -48.43 78.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.291 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' CD ' ' N ' ' A' ' 8' ' ' ARG . 32.5 Cg_exo -55.65 -17.52 17.84 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 122.411 2.074 . . . . 0.0 112.053 -179.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 44.6 tp -89.9 128.12 36.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.562 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.1 144.56 36.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.376 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 26.6 p -120.91 154.86 35.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.49 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.7 pt -123.43 162.45 24.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.936 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 73.8 tttt -128.04 121.79 30.6 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.735 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 79.6 mt -135.73 120.47 27.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.287 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 72.97 -0.3 46.83 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 178.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.86 14.32 21.44 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.956 -0.857 . . . . 0.0 110.956 -179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.483 ' C ' HD22 ' A' ' 19' ' ' LEU . 92.7 mt-30 -117.5 146.4 43.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.731 0.3 . . . . 0.0 110.263 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.698 HD22 ' N ' ' A' ' 19' ' ' LEU . 3.0 mm? -93.9 135.61 35.06 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.953 0.406 . . . . 0.0 110.893 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -133.9 159.3 41.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.672 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -102.75 140.35 37.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 0.0 109.941 179.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -146.6 147.84 31.5 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.065 0.46 . . . . 0.0 111.462 -179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 67.8 mt -111.83 148.71 33.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.436 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 65.5 mt -94.42 134.19 37.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.554 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.603 ' OD1' ' N ' ' A' ' 28' ' ' ALA . 16.3 t70 -100.99 151.19 22.08 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.527 179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.573 ' O ' ' NH2' ' A' ' 87' ' ' ARG . 48.5 m -67.74 -30.42 69.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.067 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 178.66 49.1 0.07 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.603 ' N ' ' OD1' ' A' ' 25' ' ' ASP . . . -64.72 -29.57 70.56 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.887 0.375 . . . . 0.0 110.305 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.493 ' O ' ' OD1' ' A' ' 30' ' ' ASP . 82.1 m-20 57.14 37.37 28.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.367 -179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' O ' ' A' ' 29' ' ' ASP . 70.8 m-20 -160.95 138.77 9.44 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.352 179.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.38 113.74 20.32 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.427 179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.643 ' HB ' HG21 ' A' ' 80' ' ' THR . 23.0 m -135.76 144.65 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.556 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.57 ' HB ' HG22 ' A' ' 77' ' ' VAL . 35.7 mm -117.12 138.77 46.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.101 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.491 ' OE1' ' O ' ' A' ' 80' ' ' THR . 49.0 tp10 -55.16 148.29 14.53 Favored 'General case' 0 C--N 1.333 -0.133 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -71.49 123.06 21.58 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.553 -0.459 . . . . 0.0 109.923 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.559 ' O ' ' CB ' ' A' ' 37' ' ' SER . 9.1 tpp -134.27 9.35 3.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.65 -179.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.559 ' CB ' ' O ' ' A' ' 36' ' ' MET . 1.2 t 88.77 89.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.865 179.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.57 ' O ' ' CZ ' ' A' ' 59' ' ' TYR . 1.2 tp -144.71 53.04 1.93 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.597 179.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.467 ' HB3' HH12 ' A' ' 57' ' ' ARG . 73.8 Cg_endo -76.81 95.24 1.06 Allowed 'Trans proline' 0 N--CA 1.493 1.495 0 C-N-CA 122.685 2.256 . . . . 0.0 113.124 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -113.92 -48.25 0.58 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 109.631 -1.387 . . . . 0.0 109.631 178.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -128.07 150.96 49.72 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 73.4 t-105 -106.42 87.24 2.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.65 -0.42 . . . . 0.0 111.721 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.63 80.52 66.22 Favored Pre-proline 0 C--N 1.331 -0.213 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -50.97 138.99 42.47 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.009 2.473 . . . . 0.0 113.073 -179.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.61 150.68 45.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.112 179.394 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 65.1 mtt -111.08 131.64 54.91 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.909 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.412 ' HA ' HD13 ' A' ' 47' ' ' ILE . 0.3 OUTLIER -136.02 150.2 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.698 179.828 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 134.71 -10.96 4.58 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.91 -169.17 40.97 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 17.6 tt -56.54 -31.23 33.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.92 0.39 . . . . 0.0 110.027 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.0 -1.14 30.16 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.04 120.06 0.01 OUTLIER Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -96.74 4.63 51.69 Favored 'General case' 0 C--N 1.333 -0.115 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -178.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.411 HG23 HG13 ' A' ' 56' ' ' VAL . 4.6 tt -133.7 154.02 37.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 69.4 mttt -102.82 123.75 47.06 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.924 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.411 HG13 HG23 ' A' ' 54' ' ' ILE . 33.0 m -129.38 161.19 39.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.735 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.467 HH12 ' HB3' ' A' ' 39' ' ' PRO . 79.2 mtm180 -100.64 142.6 31.89 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 32.6 tt0 -117.52 130.92 56.73 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.669 -0.412 . . . . 0.0 111.928 -178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.57 ' CZ ' ' O ' ' A' ' 38' ' ' LEU . 74.7 m-85 -112.54 125.75 54.59 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.956 -0.566 . . . . 0.0 109.576 178.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -102.2 156.99 17.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.14 0.495 . . . . 0.0 111.885 -178.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 62.31 41.48 10.25 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.726 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 3.8 tp -105.62 150.67 8.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 13.9 tt -112.23 132.87 59.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.135 0.493 . . . . 0.0 111.267 -179.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 16.9 tt -121.96 140.69 45.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.847 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -113.82 127.41 55.99 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.665 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.545 ' O ' ' N ' ' A' ' 68' ' ' GLY . 70.9 mt -125.29 124.29 66.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.603 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.411 ' HB3' ' O ' ' A' ' 66' ' ' ILE . . . 63.97 -63.01 0.15 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.533 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.545 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -178.05 22.79 0.05 OUTLIER Glycine 0 CA--C 1.526 0.732 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.61 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -121.03 136.34 55.0 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.851 0.357 . . . . 0.0 110.548 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -93.22 135.65 34.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.397 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -144.89 146.59 32.1 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.933 0.396 . . . . 0.0 110.839 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.6 mt -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.524 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.02 -178.04 47.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.0 m -77.89 144.02 37.25 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 58.6 t -142.85 109.86 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.24 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.718 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.681 HD12 ' N ' ' A' ' 76' ' ' LEU . 5.0 mp -84.18 121.57 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.881 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.57 HG22 ' HB ' ' A' ' 33' ' ' ILE . 49.1 t -115.75 139.5 41.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.172 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -176.12 -160.62 23.83 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.408 ' O ' ' C ' ' A' ' 80' ' ' THR . 33.3 Cg_exo -56.22 -15.19 13.83 Favored 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.092 2.528 . . . . 0.0 112.61 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.643 HG21 ' HB ' ' A' ' 32' ' ' VAL . 1.4 t -39.51 109.58 0.56 Allowed Pre-proline 0 CA--C 1.533 0.319 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 -179.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.434 ' O ' ' C ' ' A' ' 82' ' ' VAL . 76.7 Cg_exo -45.95 143.09 7.38 Favored 'Trans proline' 0 N--CA 1.491 1.375 0 C-N-CA 122.227 1.951 . . . . 0.0 112.478 -179.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.479 HG12 ' H ' ' A' ' 83' ' ' ASN . 0.6 OUTLIER 35.69 -149.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.901 179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.496 ' ND2' HG23 ' A' ' 33' ' ' ILE . 78.8 m-20 -129.05 134.19 48.01 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.523 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.8 tt -126.74 136.34 61.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.187 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 75.0 mt -112.9 133.01 60.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.876 -179.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -108.64 -173.4 21.46 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.538 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.573 ' NH2' ' O ' ' A' ' 26' ' ' THR . 40.7 mtt-85 -58.57 -23.72 59.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.582 -0.309 . . . . 0.0 111.53 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 47.7 t30 -54.56 -45.38 73.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.552 -179.106 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.493 ' O ' ' O ' ' A' ' 92' ' ' GLN . 4.1 mp -85.29 -39.11 18.07 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.773 -0.371 . . . . 0.0 111.54 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 72.2 mt -59.42 -41.86 90.5 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.614 -179.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 44.9 m -62.69 -37.93 88.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.874 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . 0.493 ' O ' ' O ' ' A' ' 89' ' ' LEU . 66.8 tp60 -97.82 127.08 43.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.604 -179.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 16.8 tt -159.25 6.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.971 0.415 . . . . 0.0 110.467 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -83.1 179.1 52.94 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.984 -1.008 . . . . 0.0 110.635 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo . . . . . 0 N--CA 1.482 0.826 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -58.86 -36.91 75.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.538 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.0 tt -60.81 -26.92 39.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.4 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.4 m -87.89 137.45 32.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.809 -179.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.77 141.97 46.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.35 179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m-90 -62.12 137.7 58.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.876 0.37 . . . . 0.0 110.411 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 19.8 mttp -61.0 -37.9 84.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.856 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 12.1 mmt180 -91.27 111.1 46.97 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -80.18 157.49 23.15 Favored 'Trans proline' 0 N--CA 1.489 1.252 0 C-N-CA 122.159 1.906 . . . . 0.0 111.787 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 45.6 mt -87.02 136.05 33.06 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.378 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.8 t -125.29 141.17 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.464 -179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 t -127.1 156.54 41.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.387 179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 41.7 pt -126.7 161.49 33.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.402 ' O ' ' OE1' ' A' ' 65' ' ' GLU . 16.6 mtpp -107.95 120.27 41.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.358 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 15' ' ' ILE . 17.2 tt -140.16 117.72 10.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.967 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 52.09 50.4 45.72 Favored Glycine 0 CA--C 1.527 0.799 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.699 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.9 7.91 14.13 Favored Glycine 0 CA--C 1.526 0.762 0 C-N-CA 121.11 -0.567 . . . . 0.0 111.722 179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.55 ' OE1' ' SD ' ' A' ' 36' ' ' MET . 94.0 mt-30 -113.42 145.98 40.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.924 0.392 . . . . 0.0 110.579 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 25.7 mt -99.54 131.64 45.4 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.294 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HZ3' ' CG2' ' A' ' 33' ' ' ILE . 47.5 tttt -130.1 156.78 43.98 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -112.75 135.48 53.44 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.31 156.38 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.971 0.415 . . . . 0.0 111.156 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 46.6 mt -99.19 147.94 24.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.383 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.53 ' O ' ' C ' ' A' ' 25' ' ' ASP . 5.1 mp -87.62 130.39 34.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.895 -179.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.585 ' OD2' ' NE ' ' A' ' 87' ' ' ARG . 59.0 t0 13.34 104.4 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 O-C-N 123.876 0.735 . . . . 0.0 111.968 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . 0.558 HG22 ' N ' ' A' ' 27' ' ' GLY . 9.9 m -92.0 -82.31 0.32 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.057 0.456 . . . . 0.0 110.184 178.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.558 ' N ' HG22 ' A' ' 26' ' ' THR . . . -140.25 23.76 2.7 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.03 153.77 48.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.852 0.358 . . . . 0.0 111.016 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 86.8 m-20 -96.19 -11.9 25.45 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.119 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -86.65 157.82 19.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.462 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.658 HG23 ' HA ' ' A' ' 85' ' ' ILE . 60.5 m -114.54 127.43 55.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.221 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 60.7 t -132.59 127.15 55.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.483 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.584 ' CG2' ' HZ3' ' A' ' 20' ' ' LYS . 72.3 mt -125.04 140.05 49.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.673 179.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.538 ' H ' HD22 ' A' ' 83' ' ' ASN . 11.5 pt-20 -67.39 172.02 5.37 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.564 ' OE2' ' NH2' ' A' ' 57' ' ' ARG . 45.3 mt-10 -84.82 132.35 34.42 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.684 179.752 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . 0.564 ' O ' ' CB ' ' A' ' 37' ' ' SER . 32.2 ttm -113.22 -2.4 14.09 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.36 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.564 ' CB ' ' O ' ' A' ' 36' ' ' MET . 0.8 OUTLIER 89.77 86.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.433 179.847 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -162.04 60.11 1.07 Allowed Pre-proline 0 C--N 1.326 -0.433 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.083 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.08 104.53 1.86 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.703 2.269 . . . . 0.0 112.447 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -128.12 -64.5 0.13 Allowed Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . . . . . . . . . 84.9 mtm180 -144.14 132.03 21.47 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.472 ' CD1' ' N ' ' A' ' 42' ' ' TRP . 9.7 p-90 -145.19 160.41 41.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.21 0.528 . . . . 0.0 111.801 -179.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 5.7 mttm -128.77 113.63 19.06 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.013 179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -46.96 129.15 14.54 Favored 'Trans proline' 0 N--CA 1.492 1.387 0 C-N-CA 121.855 1.704 . . . . 0.0 112.206 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 54.1 tttm -141.3 146.75 37.14 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.333 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 63.6 mtt -128.89 144.91 51.31 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.911 -0.316 . . . . 0.0 110.453 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 18.8 tt -129.45 143.83 39.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.852 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.74 171.41 37.41 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . -151.63 -111.7 0.51 Allowed Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 80.7 mt -57.86 -37.38 60.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.886 0.374 . . . . 0.0 110.196 179.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -87.0 -71.04 1.3 Allowed Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.391 -1.083 . . . . 0.0 110.391 179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 49' ' ' GLY . . . -84.15 -177.07 51.33 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.455 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . 0.624 ' CG ' ' O ' ' A' ' 53' ' ' PHE . 3.5 t80 163.76 77.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.048 0.452 . . . . 0.0 110.444 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 18.8 tt -130.89 149.61 33.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -100.28 123.15 44.15 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.664 -179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -127.86 165.77 26.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.453 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.564 ' NH2' ' OE2' ' A' ' 35' ' ' GLU . 78.3 mtm180 -110.54 138.71 46.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 110.669 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 31.5 tt0 -104.49 123.31 47.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.568 -179.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.457 ' OH ' ' CZ ' ' A' ' 57' ' ' ARG . 75.8 m-85 -108.83 121.31 44.82 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.415 ' O ' ' CB ' ' A' ' 61' ' ' GLN . 83.8 m-20 -109.46 155.49 21.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.274 -179.343 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . 0.415 ' CB ' ' O ' ' A' ' 60' ' ' ASP . 35.8 tp60 77.09 28.18 0.65 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.733 179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.6 mm -108.46 136.95 42.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.981 0.42 . . . . 0.0 110.789 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.598 HG22 ' HB ' ' A' ' 72' ' ' ILE . 28.6 pt -117.08 147.87 20.18 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.557 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.4 HD11 HD23 ' A' ' 89' ' ' LEU . 29.3 pt -135.19 161.19 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.649 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.402 ' OE1' ' O ' ' A' ' 14' ' ' LYS . 57.8 mp0 -117.72 127.56 54.04 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.198 179.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 68' ' ' GLY . 69.9 mt -127.37 127.72 69.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.501 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.81 -68.04 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.809 0.338 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.27 20.42 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.408 -0.677 . . . . 0.0 111.408 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -128.23 139.94 52.17 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.829 0.347 . . . . 0.0 110.556 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.4 pttm -99.0 145.1 27.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.619 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.2 150.13 34.3 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.829 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.598 ' HB ' HG22 ' A' ' 63' ' ' ILE . 14.1 tt -124.43 136.83 59.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.489 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 178.99 -176.76 48.18 Favored Glycine 0 CA--C 1.524 0.652 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.781 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 32.3 m -72.6 135.86 45.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.555 -0.323 . . . . 0.0 110.245 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.469 ' CG1' HD12 ' A' ' 33' ' ' ILE . 46.8 t -131.88 100.64 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.091 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 11.3 mt -73.44 129.82 38.8 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.99 0.424 . . . . 0.0 110.628 -178.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 61.6 t -104.88 134.3 46.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.5 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -124.4 160.19 19.0 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -67.06 -20.78 50.11 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 123.112 2.542 . . . . 0.0 112.933 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.462 ' H ' HG22 ' A' ' 80' ' ' THR . 0.0 OUTLIER -59.45 137.0 89.16 Favored Pre-proline 0 CA--C 1.537 0.452 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.102 -179.177 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.419 ' C ' ' OE1' ' A' ' 34' ' ' GLU . 78.4 Cg_endo -78.53 31.61 0.45 Allowed 'Trans proline' 0 N--CA 1.493 1.499 0 C-N-CA 122.427 2.085 . . . . 0.0 112.132 179.373 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 83' ' ' ASN . 31.0 t -124.31 153.16 30.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.305 0 CA-C-O 121.191 0.52 . . . . 0.0 111.728 -178.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.538 HD22 ' H ' ' A' ' 34' ' ' GLU . 3.2 m120 -120.94 113.46 20.13 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.1 179.548 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.408 HD11 ' HB ' ' A' ' 26' ' ' THR . 15.8 tt -129.46 139.37 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.78 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.658 ' HA ' HG23 ' A' ' 31' ' ' THR . 36.8 pt -118.43 142.9 30.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.885 0.374 . . . . 0.0 110.796 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -99.5 -175.2 31.22 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -179.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.585 ' NE ' ' OD2' ' A' ' 25' ' ' ASP . 30.1 mmt180 -64.41 -18.01 64.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.664 -0.268 . . . . 0.0 111.021 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -54.69 -44.02 73.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.224 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.411 ' N ' HD12 ' A' ' 89' ' ' LEU . 11.0 mp -102.05 -43.85 5.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.138 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 93' ' ' ILE . 7.4 tt -54.49 -40.72 68.78 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.929 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 55.8 m -64.58 -37.61 88.16 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.896 0.379 . . . . 0.0 110.785 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 62.6 tt0 -55.57 -35.41 65.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.616 -179.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.741 HG22 ' O ' ' A' ' 90' ' ' LEU . 13.4 tt -57.49 -25.28 23.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.756 -179.172 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.5 -165.88 37.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.963 -1.018 . . . . 0.0 110.684 -179.916 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.003 0 N-CA-C 109.667 -0.936 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 51.27 60.73 3.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.505 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.6 tt -58.59 -24.73 26.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.677 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 23.8 p -80.22 160.44 25.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.537 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.89 43.84 2.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.641 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -105.34 129.25 53.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.438 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 56.1 tttp -99.25 -72.89 0.64 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.748 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -89.98 149.73 42.27 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.678 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -43.53 95.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.314 -1.277 0 C-N-CA 122.114 1.876 . . . . 0.0 111.659 179.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.718 HD13 ' N ' ' A' ' 11' ' ' VAL . 0.2 OUTLIER -90.6 128.37 36.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.248 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.718 ' N ' HD13 ' A' ' 10' ' ' LEU . 47.8 t -109.02 133.49 54.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.139 179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.0 m -114.14 143.35 44.94 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.786 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.7 pt -123.18 158.13 28.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.081 179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.556 ' NZ ' ' OE1' ' A' ' 65' ' ' GLU . 5.4 pttp -141.97 131.41 23.76 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.985 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.497 HG12 HG23 ' A' ' 64' ' ' ILE . 77.6 mt -128.15 116.59 42.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.67 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.79 9.87 83.18 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.38 4.78 58.24 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 92.0 mt-30 -97.03 142.29 29.16 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 72.0 mt -93.68 123.23 36.86 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.93 0.395 . . . . 0.0 111.172 -179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 31.2 mttp -135.48 157.08 47.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.115 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 56.8 mp0 -112.24 145.07 40.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.572 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.97 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.505 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 5.1 mp -106.2 146.5 30.2 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.527 179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 47.3 mt -86.98 139.1 30.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.414 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -142.89 104.71 4.37 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.136 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.4 m -61.99 -19.27 62.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.635 179.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.17 40.06 2.94 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -141.15 101.37 4.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.805 0.336 . . . . 0.0 110.592 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -59.77 -37.29 78.63 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.638 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -120.52 -176.87 3.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.482 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.4 t -127.99 147.3 50.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.972 0.415 . . . . 0.0 110.882 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.6 m -142.55 152.07 17.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.445 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.616 HD11 HG22 ' A' ' 77' ' ' VAL . 37.2 pt -125.98 153.38 34.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.748 179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -65.38 165.2 12.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.353 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 47.1 tp10 -71.05 133.0 45.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.988 0.423 . . . . 0.0 110.807 -179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' MET . . . . . . . . . . . . . 79.2 mtp -150.99 156.09 40.43 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.815 179.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 47.2 t -61.48 124.76 21.55 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.672 -0.411 . . . . 0.0 110.334 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.1 mt -142.55 82.96 12.23 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.501 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -48.44 154.7 2.53 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 122.723 2.282 . . . . 0.0 112.283 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.45 -133.73 10.25 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ARG . . . . . 0.491 ' HG2' HH11 ' A' ' 41' ' ' ARG . 30.0 ttt-85 -123.46 147.25 47.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.983 0.42 . . . . 0.0 110.972 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 57.0 p-90 -131.93 158.32 41.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.322 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.0 mttm -114.9 131.51 23.44 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.72 -179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -69.19 127.27 14.8 Favored 'Trans proline' 0 N--CA 1.494 1.532 0 C-N-CA 121.848 1.699 . . . . 0.0 111.855 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 31.0 tptt -137.71 143.52 41.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.491 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . . . . . . . . . 64.1 mtt -121.71 141.05 51.55 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 33.1 pt -138.57 166.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 120.918 -0.313 . . . . 0.0 110.423 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -152.58 27.92 0.85 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 120.396 -0.907 . . . . 0.0 112.123 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -57.28 -41.66 93.08 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 120.707 -0.759 . . . . 0.0 111.224 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.0 mm -65.57 -40.87 89.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.866 0.365 . . . . 0.0 110.939 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 156.08 -64.02 0.32 Allowed Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -78.81 175.2 55.1 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 178.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -110.03 127.05 54.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 117.278 0.539 . . . . 0.0 111.179 -179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.38 155.34 38.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.597 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 17.0 mttp -88.33 114.04 24.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -114.92 147.05 18.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.219 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.531 HH11 ' CG ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -106.78 135.74 47.8 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.647 -179.83 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -112.32 137.54 50.31 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.004 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.495 ' CD1' HD11 ' A' ' 62' ' ' ILE . 2.0 t80 -118.48 130.38 55.91 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.409 ' OD1' HG23 ' A' ' 74' ' ' THR . 78.6 m-20 -114.85 171.47 7.63 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.28 0.562 . . . . 0.0 112.199 -178.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 65.52 39.09 5.21 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.612 179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.495 HD11 ' CD1' ' A' ' 59' ' ' TYR . 84.9 mt -112.94 144.95 19.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.443 179.336 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 46.8 pt -107.23 139.77 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.251 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . 0.497 HG23 HG12 ' A' ' 15' ' ' ILE . 71.8 mt -121.76 139.68 48.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.635 -179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.556 ' OE1' ' NZ ' ' A' ' 14' ' ' LYS . 96.2 mt-10 -114.71 128.57 56.38 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.002 0.43 . . . . 0.0 110.188 179.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.572 ' O ' ' N ' ' A' ' 68' ' ' GLY . 67.3 mt -127.29 125.5 66.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.556 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.42 -62.82 0.11 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.803 179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 66' ' ' ILE . . . -172.63 18.49 0.06 OUTLIER Glycine 0 CA--C 1.527 0.815 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.936 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 66.0 m80 -125.37 139.39 53.72 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 117.065 0.433 . . . . 0.0 110.725 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 13.3 ptpt -99.65 145.59 27.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.829 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.87 149.87 33.07 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.382 179.734 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 17.2 tt -122.61 136.82 58.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.937 0.398 . . . . 0.0 110.796 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -178.64 -176.68 46.72 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.406 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.409 HG23 ' OD1' ' A' ' 60' ' ' ASP . 87.6 m -73.7 138.78 44.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.788 0.328 . . . . 0.0 110.988 -179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.0 t -135.27 99.31 2.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.49 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.569 ' H ' HD12 ' A' ' 76' ' ' LEU . 5.5 mp -71.71 130.15 40.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.342 -178.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.616 HG22 HD11 ' A' ' 33' ' ' ILE . 41.0 t -111.32 126.86 68.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.033 179.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -154.53 175.1 32.79 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.503 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -62.04 -12.18 25.06 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 123.22 2.613 . . . . 0.0 113.123 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.8 t -39.61 145.8 0.41 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.723 -0.217 . . . . 0.0 110.632 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 82' ' ' VAL . 30.8 Cg_endo -66.0 146.81 83.51 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.531 2.154 . . . . 0.0 112.755 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 81' ' ' PRO . 0.2 OUTLIER 29.43 -151.13 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.468 179.496 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 71.9 m-20 -123.35 137.38 54.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.807 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 tt -125.41 136.67 60.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.417 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 67.8 mt -110.76 129.63 65.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.761 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -101.08 -178.79 29.0 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.603 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 59.2 mtp180 -56.47 -21.79 28.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.65 0.262 . . . . 0.0 111.387 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 54.9 t-20 -53.62 -42.69 68.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.723 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 66.8 mt -102.44 -37.95 7.79 Favored 'General case' 0 C--N 1.33 -0.278 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 5.0 tp -53.99 -40.29 66.8 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.774 0.321 . . . . 0.0 110.824 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -76.47 -29.86 57.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.101 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 -54.56 -40.13 68.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.015 -179.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . . . . . . . . . 9.8 mt -67.63 -35.77 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.897 0.38 . . . . 0.0 110.517 179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -59.12 -35.05 82.39 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.685 -179.889 . . . . . . . . 0 0 . 1 stop_ save_